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Most HIV vaccines currently in development aim to protect people from infection or 
disease by eliciting strong anti-HIV cytotoxic T lymphocyte (CTL) responses.   Evolved 
evasion mutations that undermine host immune responses pose a major challenge to the 
development of such vaccines.  Understanding the mechanisms that selectively favour the 
emergence of CTL evasion mutations in vivo and the impact of these mutations on both 
disease progression and long-term HIV evolution will not only contribute to our 
understanding of HIV pathogenesis, but will also inform vaccine design strategies.  This 
study aimed at investigating CTL escape mutations in HIV-1 Gag and Nef, during the 
acute and early phases of infection and the impact of these mutations on subsequent 
disease progression in a cohort of recently HIV-1 subtype C infected females. 
 
Of 36 women recruited into the study within 12 weeks of infection (median 6 weeks) and 
followed for six months, 32 were infected with single viruses.  Two participants were 
infected with epidemiologically unlinked viruses (dual infection), and in a further two 
individuals the viruses were highly divergent suggestive of dual infection and/or 
recombination.  These individuals were excluded from further analysis as it was difficult 
to predict CTL escape due to high degrees of diversity between sequences.  In the 
remaining 32 study participants, there was a high frequency of CTL escape with putative 
escape mutations identified in 21 of 32 individuals (66%). Twelve of these 21 (33%) 
harboured viruses which developed escape mutations in Gag, and 17 (53%) developed 
escape mutations in Nef.  In the conserved structural protein, p24, potential reversion 
mutations were more frequent than potential escape mutations. During the first six 
months of infection whereas potential reversion mutations occurred at low entropy sites, 
potential escape mutations occurred at high entropy sites.  Although there was no 
detectable association between the timing of escape mutations and disease progression, 
there was an association between the degree of deviation of the p24 sequence from the 
subtype-C population consensus (a measure of escape mutation load) and CD4+ counts. 
 
Analysis of the earliest sampled viruses from HLA-B*57/B*5801 negative study 











polymorphisms, A146X (n = 9) and T242N (n =6), that were associated with improved 
viral control.  The polymorphisms are well-known escape mutations in HLA-
B*57/B*5801 restricted epitopes.  This suggested transmission of these variants from 
individuals carrying these alleles.  Further evidence that viruses carrying the T242N 
and/or A146X mutations had been previously passaged through B*57/B*5801 positive 
individuals came from the fact that the observed T242N mutations reverted to wild type 
during follow-up.   There was no significant change in viral load and CD4+ counts upon 
reversion of the T242N mutations.   In vitro replication assays using chimeric viruses 
containing gag sequences from one of participants showed that the virus harbouring the 
T242N mutation was fitter than that carrying the reversion mutation.  These viruses 
harboured other T242N associated compensatory mutations suggesting that these 
compensatory mutations may themselves carry a fitness cost in the absence of the T242N 
mutation.  This suggests that there possibly exist networks of B*57/B*5801 associated 
mutations and that reversion of some of these mutations in isolation does not necessarily 
restore viral fitness.   
 
Lastly, the kinetics of CTL escape in HLA-B*5801 positive participants (n = 6) and the 
impact of escape on disease progression was investigated.  CTL escape within B *5801 
positive individuals was found to predominantly occur within the TW10 in Gag (n = 4) 
and KAF9 in Nef (n = 6) epitopes.  The emergence of the T242N mutation in TW10 was 
always preceded by mutations elsewhere in the epitope and was associated with the 
occurrence of previously described compensatory mutation upstream of the epitope.  The 
targeting of TW10 and the emergence of T242N escape mutations were associated with 
higher CD4+ counts at 12 months postinfection in the B*5801 positive individuals (p = 
0.0231 and p = 0.0282, respectively).  Independent of host HLA genotypes, the presence 
of the A146X and T242X mutations was associated with higher CD4+ counts (p = 
0.0495). 
 
This study provides some useful insights into HIV-1 subtype C pathogenesis.  The notion 
that CTL escape mutations do not invariably result in less fit viruses is evidenced by the 
observation that escape was not obviously associated with disease progression in this 











in particular, was associated with improved viral control.  There is therefore evidently a 
complex interaction between escape and compensatory mutations and further work is 
required to identify the impact of compensatory mutations on viral fitness.  Overall, this 
study provides further evidence that vaccines need to elicit responses that specifically 
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Human immunodeficiency virus (HIV) is responsible for what is undoubtedly the most 
devastating epidemic humankind has ever faced.  During the period 2003 – 2007 HIV 
inflicted an annual global death toll of over two million (www.unaids.org, 2008).  The 
sub-Saharan regions of Africa remains the worst affected, containing 67% of all people 
living with HIV and accounting for 72% of AIDS deaths in 2007.   In this same year an 
estimated 33 million people world-wide were living with the virus (Figure 1.1).  Despite 
this dire situation global statistics describing the growth of the HIV epidemic have greatly 
improved since the late 1990s.  For example the number of new infections per year has 
decreased from 3 million in 2001 to 2.7 million in 2007.   In South Africa, the prevalence 
of HIV among pregnant women who access antenatal services from the public health 
sector has shown a tendency towards stabilisation since 2004 (www.doh.gov.za). 
Nevertheless an unacceptable number of people are continuing to get infected each year. 
 




Figure 1.1: Global overview of the population-wide incidence of HIV infections in 2007 (from 

















HIV belongs to the genus Lentivirus within the family Retroviridae. This genus includes 
the diverse array of distinct primate infecting close relatives of HIV known collectively as 
the simian immunodeficiency viruses (SIVs) as well as more distant relatives such as, 
Visna virus, Feline immunodeficiency virus and equine infectious anemia virus (Turner 
and Summers, 1999).  There are two major HIV lineages named HIV-Type 1 (HIV-1) and 
HIV-Type 2 (HIV-2) with the global epidemic being almost entirely attributable to HIV-1 
infections.  HIV-2 is rare and is largely restricted to West Africa and is also less 
pathogenic than HIV-1 (Levy et al., 1995).   
 
There are three main groups of HIV-1: group M (major), group O (outlier), and group N 
(non-M/ non-O; Robertson et al., 2000).  Recently, a new group that is distinct from the 
other HIV-1 groups and is closely related to gorilla simian immunodeficiency virus 
(SIVgor) has been identified and named group P (Plantier et al., 2009).  HIV-1 M 
infections account for over 95% of HIV infections worldwide (McCutchan et al., 2000) 
and Group M has been further sub-divided into 9 genetic subtypes named sybtypes A, B, 
C, D, E, F, G, H, J and K.  Subtypes A and F are further divided into sub-subtype 
respectively referred to as A1 and A2, and F1 and F2.  Besides these “pure” subtypes at 
least thirty-four different circulating recombinant forms(CRFs) comprising a mixture of 
genome regions inherited from viruses in different subtypes (e.g., CRF01_AE, 
CRF02_AG, CRF03_AB, CRF04_cpx, CRF05_FD, CRF06_cpx, CRF07_BC, 
CRF08_BC, and CRF09_cpx) are known to exist (Robertson et al., 2000; Passaes et al., 
2009; Sawadogo et al., 2003).  CRFs have been identified as the dominant viruses in 
some geographical regions.  For example, CRF02_AE dominates the epidemic in South 
East Asia, whereas CRF02_AG accounts for a substantial proportion of HIV infections in 
West Africa (Passaes et al., 2009; Sawadogo et al., 2003; McCutchan et al., 2004). 
 
HIV-1 Group O and Group N viruses are genetically distinct from group HIV-1 M 
viruses and, like HIV-2, are mainly restricted to West Africa (Simon et al., 1998; 
Mauclere et al., 1997; Peeters et al., 1997).  A few cases of HIV-1 O infections have, 


















1.1 Worldwide Subtype Distribution 
 
HIV-1 subtype C is the predominant HIV-1 lineage driving the global epidemic.  For 
example, in 2004 it accounted for approximately 50% of all infections (Figure 1.2; 
Hemelaar et al., 2006).  The next most prevalent subtypes are A, B, G and, D which are 
responsible for 12, 10, 6 and 3% of all infections, respectively.  CRF01_AE and 
CRF02_AG each account for 5% of infections whereas subtypes F, H, J, and K together 
caused about 0.94% of infections.  All other recombinant forms collectively account for 














Figure 1.2: The relative contributions of different subtypes and CRFs to the global HIV-1M epidemic as 
estimated by Hemelaar et al., 2004.  Subtype C accounts for approximately 50% of all infections globally.  
 
Geographically, subtype C is predominantly found throughout Southern Africa, Ethiopia 
and India (van Harmelen et al., 2001; Abebe et al., 1997; Hussein et al., 2000; Dowling 
et al., 2003).  Subtype A is distributed accross Eastern Europe, Central Asia (Hemelaar et 















Europe and East Asia.  Subtype D is most prevalent in North Africa and the Middle East 
but is also fairly common (although not most prevalent) throughout East and Central 
Africa.  Subtype G infections in West Africa account for 89% of the global infections by 
this subtype but it is also quite commonly found in Central Africa.  The global HIV-1 




Figure 1.3: Worldwide HIV-1 subtype distribution (from Woodman and Williamson, 2009) 
 
1.2 HIV-1 Genome and Structure 
 
The HIV-1 genome is approximately 9.8 kb long and encodes 9 proteins (Muesing et al., 
1985).  These include the three major structural proteins, Gag, Pol and Env, the 




















Figure 1.4: The genome organisation of HIV-1.  The genome encodes 9 proteins and is flanked by so-
called long-terminal repeats (LTRs) (from www.virologyj.com).   
 




The Gag gene encodes a polyprotein precursor which is expressed from an unspliced 
mRNA and has a molecular weight of ~55 kD. It is, therefore also known as the Pr55
Gag
 
(Wills and Craven, 1991).  Following viral budding from the host cell, Pr55
Gag
 is cleaved 
by the viral protease (a product of the pol gene) into p17 (the matrix protein), p24 (the 
capsid protein), p9 (the nucleocapsid protein) and p6 (Wiegers et al., 1998). 
 
The myristylated N-terminal end of Pr55
Gag
 comprises of the p17 matrix protein.  Matrix 
molecules remain associated with the inner surface of the viral membrane, conferring 
stability to the viral particle.  The matrix protein contains a nuclear localization signal 
(NLS) which is required for the nuclear importation of viral genomes (Gallay et al., 
1995).  The nuclear transport of nucleoprotein complexes enables HIV-1 to infect non-
dividing cells (Lewis et al., 1992) and involves other viral proteins such as Vpr (Nitahara-
Kasahara et al., 2007).  The matrix protein has also been implicated in the incorporation 
of the Env glycoprotein into virions (Yu et al., 1992; Dorfman et al., 1994; Freed and 
Martin, 1995; Gallay et al., 1995). 
 
The p24 capsid protein forms the core of the viral particle surrounding the viral genomic 
RNA and its associated proteins (reviewed in Freed, 1998).  It is composed of two 















145) and the C-terminal region also known as the ‘dimerization’ domain (amino acid 
residues 151-231).  The ‘core’ domain is essential for virion maturation (von Schwedler 
et al., 1998) and the incorporation of cyclophilin A (Cyp A) into HIV particles (Franke et 
al., 1994).  Gag interactions with Cyp A have been demonstrated to be essential for viral 
replication (Franke and Luban, 1996).  The ‘dimerization’ domain is involved in Gag-
Gag interactions (Jowett et al., 1992; Zhang et al., 1996).  The capsid protein is also 
required for the incorporation of the Gag-Pol precursor into virions (Smith et al., 1993).  
This process is important for the recruitment of reverse transcriptases, intergrases and 
proteases into viral particles. 
 
The Gag NC domain is responsible for recognition of the HIV packaging signal (Harrison 
and Lever, 1992).  The nucleocapsid consists of two Cys-X2-Cys-X4His-X4-Cys (CCHC) 
domains commonly found in DNA binding proteins (Summers et al., 1990; 1992).  The 
two CCHC domains (zinc-finger motifs) mediate interactions between the nucleocapsid 
and the packaging signal.  Nucleocapsid also takes part in the initiation of reverse 
transcription (Lapadat-Tapolsky, et al., 1993). 
 
The p6 polypeptide is a proline-rich protein located at the C-terminus of Gag.  It is 
involved in incorporation of the accessory protein Vpr into the HIV virion by mediating 
interactions between Pr55
Gag
 and Vpr (Paxton et al., 1993).  The late domain of p6, 




HIV enzymes are encoded by the pol gene.  However, they are translated as part of a 160-
kDa Gag-Pol polyprotein (Pr160
gag-pol
), which consists of the gag gene products and the 
pol-encoded enzyme products.  The Pol protein is cleaved to yield protease, reverse 
transcriptase and integrase.  The translation of a Gag-Pol fusion protein occurs as a result 
of a -1 ribosomal frameshift which occurs during 5% of translation events.  This 
frequency is essential for the maintenance of the Gag:Gag-Pol ratio which is important 
















The HIV protease is a homodimeric aspartyl protease (Navia et al., 1989; Davies, 1990).  
Its subunits are made up of 99 amino acids and the dimer is stabilized by a four-stranded 
antiparallel β-sheet formed by N- and C-terminal β-strands (reviewed Turner and 
Summers, 1999).  The enzyme’s active site is between identical subunits and contains the 
Asp-Thr-Gly triad (Asp25-Thr26-Gly27), which is characteristic of aspartic proteases.    
  
One of the first steps following viral entry into the host cell is the reverse transcription by 
the viral reverse transcriptase of the HIV-1 RNA genome into a double-stranded DNA 
copy (Turner and Summers, 1999).  This occurs in the cytosol and the mechanism of this 
process is not well-understood and is thought to involve a complex consisting of several 
viral proteins including matrix protein, nucleocapsid protein, Nef and Vif (Schwartz et 
al., 1995; Goncalves et al., 1996; Sova and Volsky, 1993; Purohit et al., 2005; 
Goldschmidt et al., 2006).  Several cis-acting elements on the viral RNA play an 
important role in the synthesis of DNA. Among these is the TAR element which contains 
the binding site for Tat that is required for the enhancement of reverse transcription 
(Harrich et al., 1996).  Reverse transcriptase lacks proof-reading capability and is 
primarily responsible for HIV’s high mutation rate.  Reverse transcriptase is packaged 
into HIV-1 virions within the Gag-Pol precursor which is then cleaved into a homodimer 
of two p66 molecules (Turner and Summers, 1999).  A p66 molecule consists of two 
domains: a polymerase and an RNase H.  The RNase H functions by removing the RNA 
strand from the first DNA strand during the first steps of reverse transcription, thereby 
allowing the synthesis of the second DNA strand (Zack et al., 1990).  p66 is then further 
cleaved into the mature p66-51 heterodimer by the removal of the RNase H domain from 
one of the subunits.   
 
The integrase protein mediates the integration of viral DNA into the host genomic DNA 
(Bushman et al., 1990; Heuer and Brown, 1997).  The integration process starts with the 
recognition by integrase of the long terminal repeat (LTR) sequences at the 5΄ and 3΄ ends 
of the HIV genome.  Two to three bases are cleaved from the 3΄ end of viral genomic 















enzymes then complete the integration process by repairing the unligated 3΄ ends of the 
host genomic DNA to fill the gaps.  Integrase consists of three domains, an N-terminal 
zinc binding domain, a central catalytic domain and a C-terminal DNA binding domain 




The HIV-1 envelope (Env) is a 160-kD protein which is expressed by the env gene 
(Capon et al., 1991).  The Env protein is synthesised on the rough endoplasmic reticulum 
(RER) where it is glycosylated.  Terminal glycosylation occurs in the Golgi apparatus.  
Glycosylation takes place at asparagine residues (NXS/T motifs) to which 25-30 N-linked 
carbohydrate side chains are added.  It is thought that glycosylation is important for viral 
infectivity and humoral immune evasion (Quakkelaar et al, 2007; Wei et al, 2003).  
Proteolytic cleavage of gp160 by a cellular protease generates the transmembrane protein 
gp41 and the surface protein gp120 (Bernstein et al., 1995). 
 
Infection of the host cell is mediated by interactions between gp120 and the CD4 receptor 
(Hwang et al., 1991).  The gp120 protein is highly glycosylated and contains five 
hypervariable regions (V1-V5) interspersed by conserved regions (C1-C5) (Leonard et 
al., 1990; Hwang et al., 1991).  The V3 loop determines whether viruses bind to CCR5 
and/or CXCR4 co-receptors and thus determines the tropism of the virus (Feng et al., 
1996; Deng et al., 1996).  Gp120 also interacts with the cell surface protein DC-SIGN 
which enhances viral infectivity (Geijtenbeek, 2000) and it has been suggested that this 
interaction might play an important role in trans-infection of T cells during transmission 
(Sewell & Price, 2001; Wilkinson & Cunningham, 2006).  
 
The transmembrane protein gp41 comprises of an N-terminal domain, a transmembrane 
domain and a C-terminal domain which interacts with the matrix protein (Turner and 
Summers, 1999).  The N-terminal domain mediates fusion of viral and cellular 




















The transcriptional transactivator protein (Tat) is encoded from multiply spliced RNA 
(Jeang et al., 1999).  Tat functions to enhance transcriptional elongation by binding to the 
trans-activating response element (TAR) site on the genomic RNA transcript (Alonso et 
al., 1992).  Cellular proteins take part in the binding of Tat to TAR and in so doing 
increase viral transcription rates at least 1000-fold (Roy et al., 1990).  Phosphorylation of 
the C-terminal region of RNA polymerase II by a kinase, CDK9, activates transcription 
elongation in a process initiated by the binding of CDK9 to Tat (Southgate and Green, 
1991).  A cellular co-factor, cyclin T1, is required for recognition of the TAR loop by Tat 
(Wei et al., 1998; Bres et al., 2002).  Recent studies have shown that Tat is regulated by 
lysine methylation for its transcriptional activity and that it interacts with a histone 





Rev takes part in the transportation of unspliced viral mRNAs from the nucleus to the 
cytoplasm (Ohno et al., 1998).  It is a 13-kD protein which is encoded by two exons and 
binds to the Rev-responsive element (RRE) sequence within the env gene (Daly et al., 
1989; Malim et al., 1990).  Rev induces a transition from the early to the late phase of the 
viral life cycle (Kim et al., 1989).  Following the binding of Rev to the RRE, unspliced 
and incompletely spliced RNA molecules are exported from the nucleus to the cytoplasm 
(Felber et al., 1990; Cullen et al., 2003).  Rev consists of a basic arginine-rich domain 
(Arg35 to Arg50) which is important for both its nuclear localisation and mediating its 
interaction with the RRE (Kjems et al., 1992; Malim and Cullen, 1991).  An effector 





















The HIV-1 negative factor (Nef) is the first protein which accumulates to high levels 
following infection (Kim et al., 1989; Goldsmith et al., 1995).  It is a 27-kD 
myristoylated regulatory factor which is essential for achieving and maintaining high 
levels of viremia.  Nef has multiple functions including enhancing viral replication, 
down-regulation of CD4 receptors on infected cells, and down-regulation of MHC I 
expression (Garcia and Miller, 1992; Goldsmith et al., 1995; Schwartz et al., 1996).  
Down-regulation of CD4 occurs through interaction with amino acid residues in the 
cytoplasmic tail of the CD4 receptor followed by endocytosis and lysosomal degradation 
(Aiken et al., 1994; Salghetti et al., 1995).  CD4 down-regulation is important for both 
preventing superinfection of cells and ensuring that CD4 on the cell surface does not 
interfere with Env incorporation and viral budding (Mangasarian and Trono, 1997; Ross 
et al., 1999).  Nef also enhances viral infectivity in a process that likely involves 
interactions between Nef and the Src family of kinases (Miller et al., 1994; Saksela et al., 
1995).  An SH3 binding motif (Pro-X-X-Pro) on the Nef protein is required for binding to 
the Src tyrosine kinases.  Progression to AIDS has been found to be significantly slowed 
when Nef is not expressed (Kestler et al., 1991; Churchill et al., 2006).  Nef may also 





Vpr is a 96 amino acid protein, the expression of which is Rev-dependent (Schwartz et 
al., 1991).  Interactions between Vpr and the carboxy-terminal domain of p55gag 
(corresponding to p6) mediate the incorporation of Vpr into virions (Lu et al., 1993; 
Kondo et al., 1995; Zack et al., 1990). The Vpr protein is localised to the nucleus of non-
dividing cells and plays a role in their infection by facilitating nuclear import of the 















nuclear localisation signal of Vpr is within the C-terminus of the protein (amino acids 77-
96) and consists of seven arginine residues (Lu et al., 1993). 
 
Within monocytes and macrophages Vpr also plays an unknown role in the virus life-
cycle as it is required after replication has completed but before transcription begins 
(Ogawa et al., 1989; Connor et al., 1995).  This role is, however, likely to be subserved 
by cellular proteins in established T cells because viruses infecting these cells can 
replicate independently of Vpr espression.  In vitro studies have also shown that cells 
expressing Vpr stall at the G2 phase of the cell cycle and are unable to proceed through 
mitosis (Rogel et al., 1995; Jowett et al., 1995). 
 
Other functions of Vpr involve both interactions with cellular proteins such as uracil-
DNA glycosylase (Bouhamdan et al., 1996) and the induction or facilitation of cell death 
(Rogel et al., 1995).  Cells expressing intact Vpr are aparently unable to sustain chronic 
HIV infections and in vitro studies have indicated that long-term cultures tend to lose Vpr 
function (Stevenson et al., 1990; Popovic et al., 1984).  However, loss of Vpr function 
alone is unlikely to affect disease outcome as macaques infected with Vpr(-) SIVs still 




The Vpu gene is found exclusively in HIV-1 and not HIV-2 or SIV (Strebel et al., 1988; 
Deora et al., 2001).  It is a 16-kD integral membrane phosphoprotein which is expressed 
by the mRNA containing the downstream Env ORF (Schwartz et al., 1990).  The main 
functions of Vpu are the down-regulation of CD4 receptor expression and the regulation 
of viral particle release (Schubert et al., 1996; Klimkait et al., 1990; Strebel et al., 1989; 
Terwilliger et al., 1989).  Recent studies have shown that Vpu mediates viral particle 
release by counteracting the host restriction factors tetherin and interferon-α (Neil et al., 



















The virus infectivity factor (Vif) is a 23-kD protein that is essential for the replication of 
HIV (Strebel et al., 1987).  In most HIV replication permissive cells, the virus replicates 
in the absence of Vif (Gaddis et al., 2003; Simon et al., 1998).  Vif defective HIV virions 
are still capable of infecting non-permissive cells but they encounter an early block in 
replication before integration of the viral genome into the host genome (Strebel et al., 
1987; Strebel, 2003).  This suggests that Vif functions are host-dependent.  Vif has been 
shown to counter the mutagenic influences of the host anti-viral hypermutation factor, 
APOBEC3G, by preventing it from accessing the virus particle (Sheehy et al., 2002).  Vif 
mediated inhibition of APOBEG3G is species specific.  For example, Vif proteins from 
HIV efficiently inhibit human APOBEG3G whereas Vifs from SIV do not (Gaddis et al., 
2004). 
 
1.3 The Viral Cycle 
 
The entry of HIV-1 into a host cell is initiated by binding of its gp120 protein to a cell 
surface CD4 receptor (Wyatt and Sodroski, 1998; Figure 1.5).  CD4 receptors are 
expressed on the surfaces of T lymphocytes, dendritic cells, macrophages and microglia 
where they normally function in immune recognition.  Interactions between gp120 and 
the amino-terminal immunoglobulin domain of CD4 mediate the binding of HIV to cells.  
In addition to the CD4 receptor, HIV requires a second co-receptor for entry (Kwong et 
al., 1998).  Although several co-receptors belonging to the G-protein-coupled receptor 
family can be utilised, HIV primarily uses the CCR5 (CC chemokine receptor 5) and the 
CXCR4 (CXC chemokine receptor) receptors in vivo.  Viruses that utilise CCR5 and 
CXCR4 co-receptors are respectively referred to as R5 and X4 viruses.  Some HIV 
variants are capable of utilising both receptors and these are therefore known as R5X4 
viruses (Berger, 1998). 
 
The binding of gp120 to both CD4 and a co-receptor molecule induces a conformational 















and Sodroski, 1998).  This enables release of the viral core into the host cell interior 
(Chan and Kim, 1998).  Following uncoating of the viral core, the genomic viral RNA 
dimer and reverse transcription complex is then released into the cytoplasm of the host 
cell (Karageorgos et al., 1993).  The viral RNA is then reverse transcribed into double 
stranded DNA (dsDNA) through the activity of reverse transcriptase.  The accessory 
protein Vif and the viral nucleocapsid are thought to facilitate the initial stages of reverse 
transcription. 
 
The dsDNA is then transported to the nucleus as part of a pre-integration complex which 
includes the viral integrase, matrix protein, reverse transcriptase and Vpr as well as the 
host cellular protein HMG-I (Y), which belongs to the high-mobility group I protein 
family (Miller et al., 1997).  The nuclear localisation signal of the matrix protein 
facilitates movement of the pre-integration complex to the nucleus (Bukrinsky et al. 
1993; von Schwedler et al., 1994) but Vpr is thought to connect the pre-integration 
complex to the cellular nuclear import machinery (Fouchier et al., 1997).  After its 
transportation to the nucleus, integrase ensures the integration of the viral genome into 
the host genome.  It has been suggested that the HIV genomes preferentially integrate into 
actively expressing genes (Schroder et al., 2002). 
 
Following integration, viral mRNA is synthesised by RNA polymerase II using the host’s 
normal transcription machinery. Transcription is initiated by a single promoter in the 5΄ 
LTR (Schwartz et al., 1990).  Completely spliced transcripts encoding Rev, Tat and Nef 
are intitially transported out of the nucleus.  Translation of Rev and Tat in the cytoplasm 
and their importation into the nucleus increases transcription and allows unspliced and 
partially spliced mRNAs to be transported out of the nucleus (Herrman and Rice, 1995; 
Wei et al., 1998).  Differential splicing enables the synthesis of Gag and Gag-Pol from 
unspliced mRNA molecules (Saltarelli et al., 1996).  Unspliced mRNAs are retained in 
the nucleus where they are either spliced or degraded. Rev mediates the transportation of 
unspliced mRNAs to the cytoplasm, thereby functioning as a switch between gene 
expression from the early spliced mRNAs (Tat, Rev and Nef) and that from either the late 















mRNAs.  The Env precursor (gp160) is synthesised on the RER whereas Pr55
Gag
 is 
synthesised in the cytoplamic ribosomes (Chan et al., 1997; Bennett et al., 1993).  The 
myristoylated N-terminal domain of the matrix protein directs binding of Gag and Gag-
Pol proteins to the cell membrane and it interacts with the cytoplasmic tail of gp41 
(Bennett et al., 1993; Freed and Martin, 1995; Dorfman et al., 1994).  About 1200 to 
2000 copies of Gag bud to form the immature viral particle, recruiting two copies of 
unspliced genomic viral RNA (Freed, 1998).  Proteolytic cleavage of the polyproteins by 
protease occurs subsequent to budding and results in the production of independent 
enzymes (integrase, reverse transcriptase, protease and RNase H) and structural proteins, 
(matrix, capsid and nucleocapsid proteins).  Maturation of the viral particle produces an 
infectious virus (Wiegers et al., 1998).  The cellular protein cyclophilin A, which is 
required for viral infectivity, is packaged into the viral particle.  Newly formed viral 
partiles bud from cholesterol and glycolipid-enriched membrane lipid rafts (Nguyen and 
Hildreth, 2000; Ono et al, 2000). 
  
Figure 1.5: The general features of the viral life cycle (from Turner and Summers, 1999). The early phase 
(upper portion of the diagram) begins with CD4 recognition and involves events up to and including 
integration of the proviral DNA. The late phase includes all events from transcription of the integrated 















1.4 Natural History of HIV infection 
 
HIV infections can be classified into three phases (Bonhoeffer et al., 2003; Wei et al., 
1995).  The first stage known as acute or primary infection is characterised by rapidly 
rising viral loads which then decline to a steady state.  Acute infection normally refers to 
the first three months of infection.  The viral load steady state attained at the end of acute 
infection, also known as the set-point, and the CD4+ count are predictors of disease 
progression (Lyles et al., 2000; Mellors et al., 1997).  The second stage is the chronic or 
asymptomatic phase.  During this period the viral load remains relatively stable due to 
equilibrium between virus production and clearance by CTL and possibly neutralising 
antibody responses.  The final stage, AIDS, is the clinical phase which is characterised by 
a decline in CD4+ T cells and sharp increase in viral load (Levy, 1993).  
 
1.5 Host Factors Influencing Infection and Disease Progression 
 
Several host factors have been reported to moderate viral replication (O’brien and Nelson, 
2004; Fauci, 2003; O’brien and Moore, 2000; Carrington and O’brien, 2003).  These host 
factors influence the risk of infection in those exposed to the virus and the rate of disease 
progression in those infected with the virus.  Human genes that have an influence on the 
outcome of HIV exposure or infection have been described as AIDS restriction genes 
(ARGs; O’Brien and Dean, 1997; O’brien, 1998).  These genes include CCR5, CCR2, 
CCl5, CXCL12, CCL2-CCL7-CCL11, IL10, IFNγ, HLA, and KIR3DS1 (Dean et. al, 
1996; Dean et al., 1999; Martin et al., 1998; Smith et al., 1997; Anzala et al., 1998; An et 
al., 2002; Winkler et al., 1998; Duggal et al., 2003; Modi et al., 2003; Shin et al., 2000; 
An et al., 2003; Carrington et al., 1999; Tang et al., 1999; Carrington and O’Brien, 2003; 
Gao et al., 2001).  A recent study by Fellay et al. using a genome-wide approach has 
identified several host determinants associated with host control of HIV (Fellay et al., 
2007).  The most significant of these was a polymorphism located in the HLA complex 
P5 (HCP5) gene (Single Nucleotide polymorphism database number rs2395029).  The 

















Other host factors associated with HIV infection include APOBEC3G (apolipoprotein B 
mRNA-editing enzyme catalytic, polypeptide-like 3G), a member of a family of cytidine 
deaminases (Sheehy et al., 2002).  APOBEC3G acts as a post-entry HIV restriction factor 
(Chiu et al., 2005).  APOBEC3G triggers G-to-A hypermutations in HIV during reverse 
transcription, thereby impairing viral replication.  It exists in stimulated CD4+ T cells as a 
high molecular weight inactive ribonucleoprotein which is activated to a low molecular 
weight active form by RNase treatment (Chiu et al., 2005).  The low molecular weight 
form predominates in unstimulated CD4+ T cells where it blocks HIV replication.  The 
inhibitory effect of APOBEG3G on HIV replication is countered by the viral protein Vif 
(Sheehy et al., 2002).  Vif functions by preventing the incorporation of APOBEG3G into 
virions through inducing its unbiquitination and proteasomal degradation (Xu et al., 
2004).  Vif resistant forms of APOBEG3G have been identified to have a single mutation, 
D128K that interferes with its binding to HIV-1 Vif (Xu et al., 2004). 
 
The natural chemokine ligands for CCR5 are the ‘regulated on activation normal T cell 
expressed and secreted’ (RANTES), and the ‘macrophage inflammatory proteins’ (MIP)-
1α and MIP-1β (Coffey et al., 1997).  The ligand for CXCR4 is the stromal-derived 
factor-1 SDF1 (Marechal et al., 1999).  These ligands physically block infection by R5 
and X4 tropic viruses by covering their entry co-receptors (Weiss, 2003; Berger et al., 
1999).  Elevated circulating levels of RANTES have been associated with slow disease 
progression and prevention of infection (Gallo et al., 1999).  Reduction in the levels of 
RANTES in infected individuals leads to rapid disease progression (An et al., 2002).  
Although neither MIP-1α nor MIP-1β expression has any significant impact on viral 
replication on their own in the presence of RANTES they result in notably decreased 
rates of viral replication (Coffey et al., 1997). 
 
TRIM5α belongs to the TRIM (tripartite motif) family of proteins (Reddy et al., 1992).  
TRIM5α acts soon after viral entry by recognising motifs on the capsid protein and 
accelerates viral uncoating such that reverse transcription is inhibited and transportation 















al., 2004; Stremlau et al., 2006).  HIV-1 successfully counters the viral restriction 
properties of TRIM5α by accumulating mutations within capsid protein residues that are 
required for recognition by TRIM5α (Perez-Caballero et al., 2005).  A recent study by 
Sewram et al. found expression levels of TRIM5α were inversely associated with 
susceptibility to HIV-1 infection (Sewram et al., 2009). 
 
Tetherin, a recently identified host restriction factor, prevents viral particle release from 
the surface of producer cells (Neil et al., 2008; Van Damme et al., 2008).  Tetherin is a 
transmembrane protein consisting of an N-terminal cytoplasmic tail, a single membrane-
spanning helix, an extracellular coiled-coil domain, and a C-terminal 
glycosylphosphotidylinositol membrane anchor (Kupzig et al., 2003; Rollason et al., 
2007).  The mechanisms through which tetherin adheres virions to the extracellular 
membrane are not yet known (Wolf and Goff, 2008). 
 
1.6 Immune Responses to HIV-1 
 
Disease progression within HIV-1 infected individuals is associated with increasing viral 
loads and decreasing CD4
+
 T cell counts (Edwards et al., 2002).  Host immune responses 
play a crucial role in determining the outcome of HIV infections.  Neutralising antibodies 
(Nab) represent the primary component of an effective defence against many pathogens 
(Moog et al., 1997; Kostrikis et al., 1996; Moore et al., 1996).  However, following HIV 
infection, the emergence of virus-neutralising antibodies only occurs after the initial drop 
of the peak viremia, raising questions about their role in viral control during the acute 
phase of infection (Montefiori et al., 2001; Richman et al., 2003; Aasa-Chapman et al., 
2004; Gray et al., 2007).  Primate model studies have shown that HIV infections can be 
prevented by passive administration of neutralising antibodies (Mascola, 2003).  
However, there is lack of cross-reactivity between antibodies raised to one HIV variant 
and tested on another variant, probably due to neutralising antibodies targeting the most 
variable regions of the envelop glycoprotein such as V1V2, V3, V4 and V5 (Moore et al., 
2008).  This poses a challenge for vaccine development as vaccines would have to elicit 
















Conversely, cellular immune responses to HIV, mediated by cytotoxic T lymphocytes 
(CTL) appear to play a crucial role in viral control (McMichael and Rowland-Jones, 
2001; Walker et al., 1987; Kiepiela et al., 2004; Kiepiela et al., 2007; Altfeld et al., 
2006).  CD8+ T cells suppress viral replication by both directly killing infected cells and 
through their secretion of soluble factors such as RANTES, MIP-1α and MIP-1β that 
appear to reduce rates of viral replication (Gulzar and Copeland, 2004).  Following 
infection by HIV-1, strong virus-specific immune responses are stimulated in infected 
individuals (Walker et al., 1987; Plata et al., 1987).  During an acute infection, CTL 
responses track an initial rise in viral load following which levels of viremia drop as the 
immune response peaks (Ogg et al., 1998; Figure 1.6).  The important role of CTL in the 
control of viral replication is supported by findings from both CD8 depletion experiments 
in the monkey model, and studies on “HIV resistant” female sex-workers and long term 
non-progressors (Matano et al., 1998; Rowland-Jones et al., 1998; Schmitz et al., 1999).  
The importance of T cell responses in HIV-1 infection is further supported by recent 
studies which found that the viral setpoint and disease progression is influenced by the 
responses in acute infection (Streeck et al., 2009; Altfeld et al., 2006).  The evidence of 
CTL responses in HIV-exposed commercial sex-workers in Kenya who remained 
seronegative suggests that CTLs may protect them against HIV infection (Kaul et al., 
2001).  In long-term non-progressors, strong CTL activity is generally associated with 
suppression of viral replication in primary infection and long-term control (Harrer et al., 
1996; Rinaldo et al., 1995).  Recent findings suggest an association between the quality 
of CTL responses, as defined by either the presence of polyfunctional responses, or the 
absence of negative immunoregulatory molecules such as Programmed Death-1 (PD-1), 
and disease progression (Emu et al., 2008; Peretz et al., 2007; Betts et al., 2006; Emu et 
al., 2005).  The specificity of CTL responses has been shown to influence disease 
outcome, with Gag specific T cell responses being associated with better viral control 
(Kiepiela et al., 2004; Rolland et al., 2008).  Elite controllers have been shown to 
preferentially target Gag (Pereyra et al., 2009).  On the other hand, responses targeting 

















           
Figure 1.6: The natural history of an HIV-1 infection (from Sewell et al., 2000). The initial drop in peak 
viremia coincides with the peak in CTL responses. Antibody responses appear a few weeks later. CD4+ T 
cells gradually decline during the course of infection. 
 
1.7 HLA Alleles and disease progression 
 
There is an association between human leucocyte antigen (HLA) class I and II expression 
and HIV-1 disease progression (Kaslow et al., 1996; Keet et al., 1999; Migueles et al., 
2000; Fellay et al., 2007; Kiepiela et al., 2004).  HLA molecules bind and present 
peptides to CTLs (Lamas et al., 1998).  Polymorphisms in HLA-alleles determine their 
peptide specificities by modulating the structural conformations of their antigen binding 
pockets (Garrett et al., 1989).  HLAs are grouped into subfamilies of closely related 
variants (Parham et al., 1995).  Polymorphisms in HLAs are mostly located in their 
peptide binding sites where they influence both peptide and T-cell receptor (TCR) 
interactions (Lopez de Castro, 1995).  CTLs are able to distinguish between the closely 
related HLA allelic variants (Lopez et al., 1994).  In class I HLA, polymorphism within 















binding capacities and affinities (Lamas et al., 1998).  These differences have a large 
effect on the immunogenicity of peptides. 
 
As a result of polymorphic HLA molecules, different individuals will respond to different 
HIV-1 epitopes according to the HLA alleles that they carry.  Whereas the HLA class I 
alleles HLA-B35, HLA-cω4, HLA-A29 and HLA-B22 are associated with rapid disease 
progression (Tomiyama et al., 1997; Jeannet et al., 1989; Hendel et al., 1999) the alleles 
HLA-B14, HLA-C8, HLA-B*57, HLA-B*5801 and HLA-B*27 are associated with long-
term non-progression (Hendel et al., 1999; Goulder et al., 1996; Kaslow et al., 1996; 
Klein et al., 1998; Kiepiela et al., 2004; Kiepiela et al. 2007). In addition, HLA-DRB*01 
has been associated with resistance to HIV-1 infection (MacDonald et al., 2000). 
Heterozygosity at HLA class I loci has been shown to be more protective than 
homozygostity at these loci (Carrington et al., 1999; Tang et al., 1999; Keet et al., 1999).  
For example, an association has been detected between the absence of HLA-B*35 and/ or 
heterozygosity at all HLA class I loci and slower disease progression (Carrington et al., 
1999).   
 
Several studies have attempted to determine the factors underlying the strong influences 
that certain HLA alleles have on disease progression but in many cases these are still 
unknown.  For example, whereas accelerated progression to AIDS in patients carrying the 
HLA-B*35 allele is thought to be caused by poor CTL responses, accelerated disease 
progression in individuals that are homozygous at multiple HLA class I loci is thought to 
be caused by the inability of these individuals to recognise a broad enough range of HIV 
epitopes (Carrington et al., 1999; Tang et al., 1999).  Although this latter notion has been 
supported by recent discoveries indicating that broader based immune responses 
generally achieve better control of virus proliferation (Kiepiela et al., 2004; Kiepiela et 
al., 2007), some patients that progress rapidly to AIDS have very broad anti-HIV CTL 
responses while some long-term non-progressors have narrowly focused CTL responses 
(Hay et al., 1999; Draenert et al., 2004; Goulder et al., 1997; Feeney et al., 2004).  Such 















associated viral control is largely due to CTLs with varying specificities and efficacies 
(Turner and Summers, 2004). 
 
The exact viral protein targeted by a host immune response may also be important in 
determining rates of disease progression.  Whereas HLA class I alleles recognising 
epitopes in Gag (specifically the the capsid protein, p24) tend to be associated with more 
effective virus control (Kiepiela et al., 2004; Kiepiela et al., 2007; Borghans et al., 2007; 
Wang et al., 2009; Rolland et al., 2009), those targeting Env and Nef are possibly 
associated with more rapid disease progression (Borghans et al., 2007; Kiepiela et al., 
2007).  The importance of targeting Gag is further supported by studies on elite 
controllers which reported that viral control in these individuals is mainly due to targeting 
of this region (Miura et al., 2009; Pereyra et al., 2009).  There is also an association 
between responses targeted by HLA-B and viral control (Kiepiela et al., 2004).   
 
1.8 CTL Escape 
 
One of the biggest challenges facing vaccine designers is how to deal with the emergence 
of viral escape mutants capable of evading vaccine-induced immunity (Barouch and 
Letvin, 2002).  The occurrence of so-called CTL escape mutants during an infection is 
generally associated with decreased control of viral replication and increased rates of 
disease progression (Peyerl et al., 2004).  Viral mutants that avoid CTL mediated immune 
responses will in many cases have a significant replicative advantage over those that do 
not (Smith, 2004).  However, some CTL escape mutations may carry a fitness cost to 
viral replication, resulting in slow progression (Peyerl et al., 2004). 
 
CTL escape can occur by so-called mutational or constitutive pathways (Sewell et al., 
2000).  Mutational CTL escape (Figure 1.7) generally involves the occurrence of single or 
multiple nucleotide substitutions either within the epitopes themselves, or in amino acid 
residues flanking the epitopes that are involved with their processing and presentation as 
peptides on cellular surfaces (Draenert et al., 2004; Borrow et al., 1997; Allen et al., 















Price et al., 1997).  Mutational escape can result in non-binding of class I HLA 
molecules, altered antigen processing, or non-recognition by the T cell receptor (reviewed 
by Sewell et al., 2000; Figure 1.7).  Following infection, peptides will be processed and 
presented on the cell’s surface by class I HLA molecules.  If these peptides are 
recognised by HIV-specific CTLs the infected cell will be lysed.  The time-frame for this 
recognition, from initial peptide presentation to killing is generally within five hours 
(Yang et al., 1996).  There therefore exists a tremendously powerful selection pressure 
for viruses to avoid detection by CTLs. Those viruses that avoid detection, even if they 
incur a slight loss of maximum replication rate in the process, will therefore generally 
have an over-all replicative advantage over those that are recognised and killed by CTLs 




Figure 1.7: Mechanisms of mutational CTL escape (Sewell et al., 2000). 
 
Constitutive CTL escape is a non-mutational process that could involve viral mediated 
down-regulation of MHC class I molecules and viral latency (Ploegh, 1998; Stevens and 
Cook, 1971; Jones and Sun, 1997) (Figure 1.8).  The down-regulation of MHC class I 
expression that is mediated by Nef involves Nef re-routing newly synthesised MHC 















al., 1998; Le Gall et al., 1998; McMichael and Rowland-Jones, 2001).  This Nef-
mediated down-regulation of MHC class I molecules only affects HLA-A and HLA-B 
molecules as they contain a specific sequence motif in the cytoplasmic tail which is 




Figure 1.8: Mechanisms of constitutive avoidance of CTL recognition (from Sewell et al., 2000). 
 
1.9 The Consequences of CTL Escape 
 
HIV genotypes containing CTL escape mutations are frequently found to dominate viral 
populations within infected individuals, due, presumably, to CTL responses exerting 
selective pressures that favour the proliferation of escape mutants (Goulder et al., 1997; 
Barouch and Letvin, 2002; Klenerman et al., 2002).  In vitro analyses employing the 
SIVmac model (specifically SIVmac239) have indicated that escape mutants often 
display reduced replication rates (Friedrich et al., 2004).  Fitness costs associated with 
CTL escape probably play a large part in determining both which viral mutants will 
emerge as dominant genotypes within infected individuals and which genotypes will have 















virus’ perspective, the frequency and success of CTL escape will depend on the 
conflicting demands of replicative fitness on one hand and immune evasion on the other. 
 
CTL responses that target functionally important, and therefore structurally constrained, 
epitopes within key domains of HIV proteins tend to be associated with long-term non-
progression (Wang et al., 2009; Altfeld et al., 2006; Kiepiela et al., 2004; Rolland et al., 
2008; Miura et al., 2009).  Conversely, CTL responses that target less-conserved, 
probably less functionally constrained, regions of the HIV proteome tend to be associated 
with more rapid disease progression (Borghans et al., 2007; Kiepiela et al., 2007; Evans 
et al., 1999).  
 
 Some CTL epitopes within the HIV proteome are recognised by multiple different HLA 
class I alleles (Iversen et al., 2006) and are therefore likely to be subject to multiple 
simultaneous selective pressures in patients possessing the appropriate HLA alleles.  It 
may be difficult for viruses to escape such multi-pronged attacks since escape mutations 
that mask the epitopes from one HLA allele will not necessarily mask them from any 
others.   
 
The associations between the two HLA alleles, HLA-B*57 and HLA-B*5801, and rates 
of disease progression are particularly informative in this regard (Leslie et al., 2004).  
These alleles both restrict a specific CTL epitope, called TW10, in the HIV-1 Gag p24 
protein.  HIV infected individuals carrying either of these HLA alleles will generally 
mount a CTL response that selects for escape mutations in this epitope.  The specific 
mutations associated with escape from such responses will almost always result in the 
substitution at position 242 of the Gag protein of a threonine residue for an asparagine 
residue – a mutation commonly referred to as T242N.  Upon transmission to individuals 
that do not carry these alleles, the escape mutations will revert at high frequency to yield 
the wild-type aminio acid residue at Gag position 242.  Such observations and in vitro 
mutational studies strongly suggest that the T242N immune evasion mutation has a potent 
negative effect on viral fitness in the absence of associated host HLA-B*57 or HLA-
















Secondary mutations within or outside CTL epitopes have been reported to restore viral 
fitness losses incurred by escape mutations (Leslie et al., 2004; Martinez-Picado et al., 
2006; Brockman et al., 2007; Schneidewind et al., 2007).  These mutations are known as 
‘compensatory mutations’.  Again the T242N HLA-B*57/ HLA-B*5801 escape mutation 
serves to illustrate this point.  This escape mutation is associated with several 
compensatory mutations that usually arise after the emergence of the T242N mutation, 
which have been shown to partially restore viral replicative fitness (Leslie et al., 2004; 
Martinez-Picado et al., 2006; Brockman et al., 2007).   
 
The HLA-B*57 and B*5801 alleles also restrict other conserved epitopes, called ISW9 
and KF11, within the p24 (the capsid protein) region of Gag, (Crawford et al., 2007; 
Kiepiela et al., 2007; Draenert et al., 2004).  Responses to these epitopes are strong and 
contribute to the viral control observed in individuals carrying these alleles.  The A163G 
and S165N amino acid substitutions in KF11 are escape mutations that arise in response 
to targeting by HLA-B*57 and B*5801  alleles (Kiepiela et al., 2007; Crawford et al., 
2007).  The A146P substitution flanking the ISW9 epitope is also an escape mutation that 
arises in response to host HLA-B*57 and B*5801 alleles but rather than directly altering 
recognition of the epitope by these alleles, it alters the processing of the epitope such that 
it is not presented at the cell surface for recognition  (Draenert et al., 2004).  The A163G 
mutation has been shown to carry a replicative fitness cost in vitro (Crawford et al., 
2007).  On the other hand, the A146X mutation has been shown in some cases to have no 
impact on viral replication (Draenert et al., 2004) while other studies have shown that its 
presence in combination with other HLA-B*57/B*5801 associated escape mutations 
results in reduced viral replication (Crawford et al., 2009; Boutwell et al., 2009). 
 
There also appears to be a distinct pattern of shifting immunodominance in HIV-1 
subtype B infected individuals carrying the B*57/B*5801 HLA alleles (Goulder and 
Watkins, 2004).  In acute infections, the dominant CTL response is targeted at the TW10 
epitope (Altfeld et al., 2003; Figure 1.9), but early escape mediated by the T242N 















responses then further shifts immunodominance to targeting of the KF11 epitope 
(Goulder and Watkins, 2004).   
 
Recent observations by Crawford et al., have pointed to a different pattern of shifting 
immunodominance during subtype C infections involving individuals carrying the HLA-
B*57 allele (Crawford et al., 2009).  The immunodominant epitope during acute subtype 
C infections in such individuals appears to be ISW9 since escape mutations generally 
occur in this epitope before those in TW10.  This then suggests that the dynamics of HIV-
1 infection vary from subtype to subtype.  Nevertheless it remains clear that individuals 
carrying the HLA-B*57 and B*5801 alleles control viral replication due to strong 
immune responses which target multiple functionally and structurally constrained 
epitopes.  A recent study by Miura et al. reported that HLA-B*57/B*5801 positive elite 
controllers select for rare CTL escape variants in the TW10 epitope and these mutations 
are associated with severe defects in viral replication (Miura et al., 2009). 
 
In contrast to early and vigorous responses elicited by HLA-B*57 and B*5801 alleles, 
certain other HLA alleles such as HLA-A*0201 apparently only elicit immune responses 
late during infections (Goulder et al., 1997; Goulder et al., 2001; Goulder and Watkins, 
2004).  HLA-A*0201 mediated responses target the SL9 epitope in Gag, p17 (the matrix 
protein) and are not generally detectable until the chronic phases of infections (Figure 
1.9).  Unlike immune responses during acute infection which often have a strong impact 
on viral steady state, later responses, such as those mediated by HLA-A*0201,  tend not 
to have any substantial impact on rates of disease progression.   
 
Immune escape at the SL9 epitope occurs in a complicated manner depending on the 
host’s HLA genotype (Iversen et al., 2006).  SL9-reactive CTLs are highly susceptible to 
cytokine induced apoptosis (Kan-Mitchell et al., 2004) and it is therefore possible that the 
scarcity of HLA-A*0201 mediated responses during acute infections is the result of 
intense innate immune activation leading to cytokine-induced apoptosis of SL9-reactive 
















Figure 1.9: The timing of HIV CTL escape in relation to the emergence of different HLA-B*57B*5801 
and HLA-A2-restricted CTL responses (from Goulder and Watkins, 2004). 
 
The mutational pathways leading to CTL evasion in individuals carrying the highly 
protective HLA-B*27 allele is quite different from HLA-B*57B*5801-driven escape in 
the TW10 epitope.  Control of viral replication by individuals carrying this allele is 
attributable to strong immune responses targeting the immunodominant epitope, KK10, in 
p24 Gag (Altfeld et al., 2006; Goulder et al., 1997; Kelleher et al., 2001).  Relative to 
HLA-B*57B*5801-mediated viral suppression, that mediated by HLA-B*27 is 
apparently more durable with respect to the time it takes for viral escape mutants to 
emerge, usually between 9-12 years (Goulder et al., 1997).   Ultimately, however, late 
escape from HLA-B*27 mediated immune responses following R264K substitutions in 
the KK10 epitope result in rapid rates of disease progression (Goulder et al., 1997).  
Although the R264K mutation incurs a severe replicative fitness cost, a compensatory 
mutation upstream of the KK10 epitope fully restores viral replication (Schneidewind et 
al., 2007; 2008).    It is the long period of time the viruses need to successfully 
accumulate these mutations that affords HLA-B*27 carrying individuals long-term 
















CTL escape involving amino acid sites within the HIV proteome that have relatively few 
functional constraints may lead to stable mutants which do not revert in the absence of 
CTL pressure (Leslie et al., 2005).  In this case, escape mutations could accumulate and 
become stably fixed within populations.  Examples of such mutations are the Nef glycine-
83 residue within the KF9 epitope (a HLA-B*57B*5801 escape mutation) and mutations 
in the SIV Tat SL8 epitope (a macaque Mamu-A*01 escape mutation) that do not have 
replicative fitness costs and, therefore, do not revert following the removal of immune 
pressures (Friedrich et al., 2004) (Figure 1.10).  The increase in prevalence of an escape 
mutation to the point where it becomes the most frequent polymorphism in a population 
is known as a ‘negative association’ (Leslie et al., 2005).  Negative associations may 
result in the loss of epitopes as immune targets.  Recent studies have shown that the 
frequencies of HLA-associated escape mutations in individuals not carrying the 
respective alleles is positively correlated with the HLA frequency of the alleles selecting 
for the mutations (Kawashima et al., 2009).  
 
Figure 1.10: The joint effects of CTL efficacy and the viral replicative fitness costs of CTL escape (from 
Goulder and Watkins, 2004).  More effective CTLs exert stronger selection pressures on the virus than less 
effective CTLs.  However, some epitopes are more tolerant to escape mutations than others, resulting in 


















1.10 Study rationale 
 
HIV-1 subtype C is the major cause of AIDS in sub-Saharan Africa and accounts for over 
95% of infections in southern Africa (van Harmelen et al., 2001; Bredell et al., 2007; 
Novitsky et al., 2009).  However, while several studies have focused on subtype C 
chronic infection (Kiepiela et al., 2004; Kiepiela et al., 2007), we were interested in acute 
infection as events during this phase of infection impact subsequent disease progression 
and are important for vaccine design.     
 
This study focuses on the identification and characterisation of CTL escape in acute and 
early HIV-1 subtype C infected female sex workers in the KwaZulu Natal region of South 
Africa.  The research seeks to address the question of whether there is an association 
between CTL escape in acute infection and disease progression. The work presented 
forms part of the Centre for AIDS Program of Research in South Africa (CAPRISA) 002 
study.  CAPRISA 002 focuses on investigating the role of viral and immunologic factors 
during acute and early subtype C infections.  The cohort includes high risk HIV negative 
women monitored for recent HIV-1 infections who become enrolled into the study upon 
HIV infection (within 3 months of infection). 
 
This study focuses on the Gag and Nef regions of the virus for two main reasons; 1) Gag 
and Nef have been shown to be the immunodominant regions of the HIV-1 proteome 
(Gray et al., 2009; Kiepiela et al., 2007) and 2) Targeting of the Gag protein has been 
shown to be associated with better disease outcome (Kiepiela et al., 2007; Rolland et al., 
2008; Miura et al., 2009; Schneidewind et al., 2007).. 
 
The specific objectives of the project were: 
1) To investigate the timing and frequency of CTL escape and reversion in acute 
infection and its association with disease progression. 
2) To characterise CTL escape mutations in recently transmitted viruses that arose in 
former hosts and investigate their association with either viral control or rapid 















3) To determine if CTL escape mutations affect viral replication. 
4) To elucidate the mechanisms of differential viral control in individuals carrying 
specific HLA alleles  
 
Development of an effective CTL-based vaccine may depend on our achieving an 
appreciably more detailed understanding of HIV pathogenesis than we currently possess.  
Most studies on HIV-1 pathogenesis have focused on subtype B infections and 
observations made from those cannot always be extrapolated to other subtypes.  The 
overarching aim of this study was therefore the elucidation of factors associated with HIV 
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Abstract 
 
The timing of escape from CTL pressure and its consequences on HIV disease 
progression are not well defined in subtype C infection.  Although CTL escape mutations 
can provide viruses with substantial survival benefits they can also incur a replicative 
fitness cost.  In order to identify CTL escape mutations and their frequency in subtype C 
infection, gag and nef sequences were generated from 36 individuals at ~1.5, 3 and 6 
months postinfection.  For 32 of these study participants, viral sequences from each 
individual clustered together within phylogenetic trees, and were therefore indicative of 
single infections.  The sequences from the remaining four study participants were highly 
diverse, either clustering on indirectly linked branches of phylogenetic trees or were not 
bootstrap supported, indicative of infections with two epidemiologically unlinked viruses 
(dual infection).  For the 32 participants who had single infections, there were high 
frequencies of putative CTL escape mutations in Gag and Nef (33% and 53% of the 
participants, respectively).  The overall frequency of escape in Nef and Gag was 66%, 
suggesting that CTLs exert considerable selection pressure in these immunodominant 
regions soon after infection.  Although there was no obvious association between the 
presence of CTL escape mutations and disease progression, an association was detected 
between disease progression and mutations away from subtype C consensus p24 Gag 
amino acid states. Reversions in the Gag p24 region were more frequent than escape 
mutations suggesting that early viral evolution of this conserved protein predominatly 
favours the reversion of defunct immune escape mutations that had a negative impact on 






















 - 34 - 
2.0 Introduction 
 
Viral evolution during acute HIV-1 infections is dominated by HLA-associated mutations 
(Li et al., 2007; Goepfert et al., 2008; Goonetilleke et al., 2009; Crawford et al., 2009; 
Wang et al., 2009).  These mutations are either immune evasion mutations which 
generally involve amino acid substitutions away from population consensus amino acid 
states, or reversion mutations generally involving substitutions towards consensus states.  
Usually the latter occurs as a result of defunct CTL escape mutations that had been 
selectively favoured in former hosts reverting to wild type or consensus amino acid states 
that confer a replicational fitness advantage.   
 
CTL escape mutations have been associated with increased viral loads and more rapid 
disease progression (Borrow et al., 1997; Koenig et al., 1995; Goulder et al., 1997; 
Barouch et al., 2002).  However, mutations associated with CTL evasion can also incur 
significant viral replicative fitness costs and some escape mutations have therefore been 
associated with decreased viral loads (Crawford et al., 2009; Miura et al., 2009; 
Brockman et al., 2007; Schneidewind et al., 2009).    In the macaque model, for example, 
in vitro replication of SIVmac239 variants carrying certain CTL escape mutations is 
impaired relative to SIVmac239 without the mutations (Friedrich et al., 2004; Peyerl et 
al., 2004).  Fitness costs associated with CTL escape have also been demonstrated in 
HIV-1 infected humans carrying either the B*57 or B*5801 HLA alleles. CTL escape 
mutations that frequently arise in these individuals, such as the T242N mutation in the 
Gag TW10 epitope and the A163X (X = G, N, D or S) mutation in the KF11 epitope, 
have been found to compromise viral replicative capacity (Martinez-Picado et al., 2006; 
Crawford et al., 2007; Crawford et al., 2009; Boutwell et al., 2009).  A recent study by 
Miura et al., reported that in elite controllers, selection of rare escape variants by HLA-
B*57 resulted in severely compromised viral replication (Miura et al., 2009). 
 
HIV-1 epitopes targeted by the protective HLA types occur within functionally important 
protein domains and escape mutations in these domains tend to decrease viral replicative 
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et al., 2009). Therefore decreased rates of disease progression in people carrying the 
B*57, B*5801 and B*27 alleles is at least partially driven by HLA associated virus 
attenuation.  Evidence that certain escape mutations carry a fitness cost on viral 
replication comes from the observation that some mutations rapidly revert to population 
consensus following transmission to HLA-mismatched recipients (Goepfert et al., 2008; 
Schneidewind et al., 2009; Leslie et al., 2004).  Whenever CTL-escape mutations do not 
revert following transmission to such hosts, it is generally assumed either that the fitness 
costs of the mutations are negligible (Leslie et al., 2004; Draenert et al., 2004), or that the 
replicative fitness of escape mutants has been effectively restored by compensatory 
mutations (Kelleher et al., 2001; Draenert et al., 2004; Crawford et al., 2007). 
 
This study focused on the immunodominant regions of HIV-1, Gag and Nef.  Several 
studies have shown that Gag responses are associated with better viral control while there 
is no association between T cell responses targeting Nef and disease progression 
(Kiepiela et al., 2004; Kiepiela et al., 2007; Rolland et al., 2008; Pereyra et al., 2007).  
The frequency of CTL escape in Gag and Nef in the first 6 months postinfection was 
investigated.  The association between escape and prognostic markers of disease 
progression at 12 months postinfection was analysed.  A comparison of escape and 
reversion in the functionally constrained p24 Gag region was carried out to determine 
their contribution to viral evolution and disease progression during the early phases of 
infection. 
 
2.1 Materials and Methods 
 
2.1.1 Study subjects 
 
Participants in this study are part of the CAPRISA 002 cohort investigating the role of 
viral and immunological factors in acute and early HIV-1 infections (van Loggerenberg et 
al., 2008).  The cohort includes high risk HIV negative women monitored monthly for 
recent HIV-1 infection using two HIV-1 rapid antibody tests and PCR (Roche Amplicor 
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Women were enrolled in the present study within 3 months of infection from both the 
HIV negative cohort, and other seroincidence cohorts in Durban, South Africa.  The 
timing of infection was estimated to be either at the midpoint between the last HIV-1 
negative test and the first antibody positive test, or as 14 days where individuals were 
PCR positive - antibody negative.  Samples were collected at enrolment, weekly for three 
weeks, fortnightly until 3 months, monthly until a year and quarterly thereafter.  CD4+ T 
cell counts were assessed using a FACSCalibur flow cytometer and viral loads were 
measured using a COBAS AMPLICOR
TM
 HIV-1 Monitor Test v1.5 (Roche Diagnostics). 
Plasma collected in EDTA was stored at -70
o
C until use. Written informed consent was 
obtained from all participants. This study received ethical approval from the University of 
KwaZulu-Natal, University of the Witwatersrand and University of Cape Town.  Clinical 
data was provided by K. Mlisana, University of KwaZulu-Natal, South Africa (UKZN). 
 
2.1.2 RNA isolation, RT-PCR and viral sequencing 
 
Plasma samples were obtained from the study participants at the closest available time to 
infection, three and six months postinfection.  RNA was isolated from plasma samples 
using the Magna-Pure Compact Nucleic Extractor (Roche).  The RNA was reverse 
transcribed using the Invitrogen Thermoscript Reverse transcription kit (Invitrogen) and 
Gag D reverse primer 5'-AAT TCC TCC TAT CAT TTT TGG-3' (HXB pos 2382-2402).  
Limiting dilution nested PCRs were carried out by serial dilution of cDNAs until end-
points were reached.  First round PCR primers; Gag D forward 5'-TCT CTA GCA GTG 
GCG CCC G-3' (HXB pos 626-644) and Gag D reverse 5'-AAT TCC TCC TAT CAT 
TTT TGG-3' (HXB pos 2382-2402), second round PCR primers; Gag A forward 5'-CTC 
TCG ACG CAG GAC TCG GCT T-3' (HXB pos 683-704) and Gag C reverse 5'-TCT 
TCT AAT ACT GTA TCA TCT GC-3' (HXB pos 2334-2356).  PCR products were 
directly sequenced using the ABI PRISM dye terminator cycle-sequencing kit (Applied 
Biosysytems) and the primers Gag A forward, Gag A reverse 5'-ACA TGG GTA TCA 
CTT CTG GGC T-3' (HXB pos 1282-1303), Gag B forward 5'-CCA TAT CAC CTA 
GAA CTT TGA AT-3' (HXB pos 1226-1246), Gag B reverse 5'-CTC CCT GAC ATG 
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AAA ATG CGA-3' (HXB pos 1748-1768) and Gag C reverse.  Sequences were 
assembled using the CAPRISA Assembly Pipeline tool (http://tools.caprisa.org) and 
aligned using the Bioedit ClustalW (default settings, Thompson et al., 1994).   
 
2.1.3 HLA typing 
 
High resolution (four digit) HLA typing was performed on all participants. DNA was 
extracted from either PBMCs or granulocytes using the Pel-Freez DNA Isolation kit (Pel-
Freez). HLA-A, -B and -C typing was performed by sequencing of exons 2, 3 and 4 using 
Atria AlleleSeqr kits (Abbott) and Assign-SBT 3.5 (Conexio Genomics). Any 
ambiguities resulting from either polymorphisms outside the sequenced exons or identical 
heterozygote combinations were resolved using sequence-specific primers.  HLA data 
was provided by C. Gray, National Institute of Communicable Diseases, Johannesburg, 
South Africa (NICD).   
 
2.1.4 Phylogenetic analyses 
 
Neighbour-joining phylogenetic trees were constructed using MEGA 4.0 (Tamura et al., 
2007).   
 
2.1.5 Identification of CTL escape and determination of entropy 
 
Putative CTL epitopes were identified using the list of published epitopes 
(www.hiv.lanl.gov).  Additionally, previously reported HLA-associated polymorphisms 
from studies involving a large subtype C chronic infection cohort were also taken into 
consideration (Goepfert et al., 2008; Matthews et al., 2008; Rousseau et al., 2008).  CTL 
escape was defined as non-synonymous changes within or flanking putative epitope(s) 
restricted by participant HLA alleles or at sites where previous HLA associated 
polymorphisms have been identified.  The amino acid frequencies at each site were 
determined using 413 Gag and 586 Nef subtype C sequences obtained from the HIV 
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each site, CTL escape was classified as substitutions resulting in the replacement of high 
frequency amino acid states with low frequency amino acid states.  The entropy of p24 
Gag was determined using the same 413 Gag sequences and the Entropy-One tool on the 
Los Alamos HIV database (www.hiv.lanl.gov).  
 
2.1.6 Statistical Analyses 
 
Mann-Whitney U test was used to test for differences in the median viral loads and CD4+ 
counts at 12 months postinfection between individuals showing CTL escape and those 
whose viruses did not escape.  Fisher’s exact test was used to test the association between 
expression of HLA-B*5801 and escape in p24 Gag.  Pearson’s correlation was used to 
test for an association between deviation from population-wide consensus amino acid 
states in the earliest sampled viruses and CD4+ counts 12 months postinfection.  The 





In order to identify early CTL escape mutations and their frequency during subtype C 
infections, gag and nef sequences from a total of 36 individuals were generated from 
plasma samples obtained as close as possible to first infection and at three and six months 
postinfection.  The median time postinfection for the earliest sequenced sample was 1.5 
months.  The median log viral load and CD4+ count for the 32 participants included in 
this study at 12 months postinfection was 4.56 copies.ml
-1
 and 422 cells.µl
-1
, respectively.   
 
All 36 participants were infected with HIV-1 subtype C (Figure 2.1).  Gag and nef 
phylogenetic trees constructed to determine the clustering of longitudinal sequences from 
the study participants showed sequences from 32 individuals obtained over time clustered 
together with high bootstrap support:  A phylogenetic pattern indicative of these viruses 
having been sampled from single infections (i.e. infections initiated from a single source).  
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with divergent, potentially epidemiologically unlinked, viruses (dual infection) either due 
to transmission (co-infection) or through superinfection.  The two study participants, 
CAP137 and CAP256 (respectively red and green in Figure 2.1), who were infected with 
viruses that clustered on independent branches of the gag and/or nef trees were almost 
certainly dual infections.  Divergent sequences from CAP037 and CAP084 (respectively 
pink and blue in Figure 2.1) were still loosely associated with one another within the 
phylogenetic trees.  The high degree of sequence diversity observed in their infections 
could be explained by one or both of the divergent sequence lineages being recombinants 
of epidemiologically unlinked viruses brought together through dual infection.  These 
study participants were excluded from further analyses as the viruses they were infected 
with were too diverse to be used productively for identifying CTL escape. 






































































































































































Figure 2.1: Neighbour-joining phylogenetic trees of longitudinal (enrolment to 6 months postinfection) 
full-length gag (A) and nef (B) sequences from the CAPRISA cohort and reference sequences from the HIV 
database (www.hiv.lanl.gov).  The triangles (▲) denote viruses from the 32 CAPRISA participants which 
clustered together with strong bootstrap support and were therefore indicative of single infections.  Groups 
of sequences from study participants which did not group together (CAP137 and Cap256) or, when they did  
together grouped with only low degrees (<70x%) of bootstrap support (CAP037 and CAP084) are shown in 
colour-coded solid circles as follows; blue (●) – CAP037, pink (●) – CAP084, red (●) – CAP137, and green 
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2.2.1 High frequencies of CTL escape in Gag and Nef during acute/early infection 
 
Analysis of inferred viral Nef and Gag amino acid sequences sampled from the 32 study 
participants indicated that putative escape mutations in at least one epitope in Gag and/or 
Nef arose in 21 (66%) of the participants during the first six months of infection (Table 
2.1).  Whereas viruses infecting twelve (33%) of the participants carried potential escape 
mutations in Gag (six in p17, six in p24 and none in p7p6), those infecting seventeen 
(53%) participants carried potential  escape mutations in Nef (Figure 2.2A and B; Table 
2.1).  The total number of different epitopes experiencing putative escape mutations was 
seven for Gag (4 in p17 and 3 in p24) and twelve for Nef (Figure 2.2C and D).  Whereas 
none of the examined sequences displayed evidence of escape mutations occurring in 
more than one Gag epitope, sequences from three individuals carried potential escape 
mutations in more than one Nef epitope (Table 2.2 and 2.3).  Detailed summaries of 
possible CTL escape mutations in Gag and Nef are shown in Appendix D.  It is important 
to stress that the CTL escape mutations described here are ‘putative’ as they remain 
unconfirmed by supporting immunological data. 
 
Table 2.1: Summary of CTL Escape in Gag and Nef in the first six months postinfection 
 
Region No. of individuals
a
 %  
Gag 12 33% 
p17 6 19% 
p24 6 19% 
p7p6 0 0% 
Nef 17 53% 
a
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Figure 2.2: A) Frequency of putative CTL escape in the Gag and Nef genes in the first six months 
postinfection; B) frequency of potential escape mutations in p17, p24, and p7p6 Gag regions; C) number of 
epitopes experiencing potential escape mutations in Gag and Nef; D) number of experiencing potential 
escape mutations in the p17, p24, and p7p6 Gag regions. 
 
The timing of CTL escape within the first six months of infection was investigated by 
classifying potential escape mutations into those occurring during the acute (0 to ~3 
months) and early (~3 to ~6 months) phases of infection.  Analysis of the timing of 
escape in Gag revealed that escape mutations arose in seven participants (22%) during the 
acute phase whereas five (16%) arose during the early phase (Table 2.2).  In Nef, escape 
mutations arose in seven (22%) individuals during the acute phase and in fourteen (44%) 
individuals during the early phase (Table 2.3).  The high frequency of acute and early 
escape suggests that CTLs exert considerable pressure on the virus and drive diversity 
during this phase of infection.  
 
Analysis of CTL escape with respect to HLA class I expression revealed that in both the 
Gag and Nef proteins, escape in the first six months of infection was predominantly 
driven by HLA-B alleles (Tables 2.2 and 2.3).  In Gag, four of the epitopes that 
experienced escape mutations were restricted by HLA-A, eight by HLA-B and none by 
HLA-C (Table 2.2).  In Nef, one epitope that experienced escape mutations was restricted 
by HLA-A, seven by HLA-B and five by HLA-C (Table 2.3).  In total, five epitopes 
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showed escape driven by HLA-A, fifteen by HLA-B and five by HLA-C.  These data 
support previous findings that have supported the dominant influence of HLA-B in 
driving HIV epitope evolution (Kiepiela et al., 2004).  Of the Gag and Nef potential 
escape mutations detected in acute/early infection, 7/12 and 10/21 have previously been 
reported to be HLA-associated during chronic infection (Goepfert et al., 2008; Matthews 
et al., 2008; Rousseau et al., 2008).  The fact that some of the mutations have not been 
previously detected may be due to the fact that in acute infection CTL escape 
intermediates may precede the fixed escape mutations frequently observed in chronic 
infection.  Another possible explanation is that the immune responses may shift to other 
epitopes resulting in reversion of the escape mutations. 
 
Previous studies have identified specific viral polymorphisms arising during chronic 
subtype C infections that are significantly associated with the expression of specific host 
HLA class I alleles (Goepfert et al., 2008; Matthews et al., 2008; Rousseau et al., 2008).  
Comparison of the epitopes and/or peptides where these HLA-associations occur and the 
putative escape mutations identified in this study revealed that for eight of the twelve 
(67%) individual epitopes in which potential escape mutations were observed in Gag, 
there have been previously reported HLA-associations, with seven of the identified 
polymorphisms being located at the same sites as those previously identified (Table 2.2; 
Goepfert et al., 2008; Matthews et al., 2008; Rousseau et al., 2008)  In Nef, 17 of the 21 
(81%) individual epitopes have known HLA-associations, with 13 of the identified 
potential CTL escape mutations been detected at the same sites as those reported 
previously (Table 2.3; Goepfert et al., 2008; Matthews et al., 2008; Rousseau et al., 
2008).  The occurrence of mutations outside of previously identified HLA-associated 
sites but within epitopes could be due to amino acid toggling that occurs in acute 
infection prior to the fixation of specific amino acid states that is characteristically 
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Table 2.2:  Summary of potential CTL escape mutations in Gag showing their timing, HLA associations 





b Timing Log VL 
CD4+ 
count 
CAP008 KHYMLKHLVWA A*2301 - Acute 4.59 332 
CAP040 IRLRPGGKKHYM B*4201 + Acute 4.04 321 
CAP061 IRLRPGGKKHYM B*4201 + Early 2.62 412 
CAP069 DYVDRFFKTLR B*1503 - Early 6.09 202 
CAP129 ISPRTLNAWVKVI B*8101 +
c Early 5.16 634 
CAP174 TLYCVHEKIEVRDT* A*7401 + Early 4.53 303 
CAP217 TTSTLQEQIAWM B*5801 + Acute 4.63 533 
CAP229 TTSTLQEQIAWM B*5801 + Acute 4.35 680 
CAP239 TTSTLQEQIAWM B*5801 + Acute 5.19 793 
CAP244 KHYMLKHLVWA A*2301 - Early 4.16 303 
CAP248 QIIKQLQPALQ A*2902  - Acute 4.81 313 
CAP274 TTSTLQEQIAWM B*5801 + Acute 5.57 452 
Median     4.59 332 
*No known epitope 
aEpitope with respect to consensus subtype C 
b(+): presence of HLA-association, (-): absence of previously identified HLA association (Goepfert et al., 2008; 
Matthews et al., 2008; Roussease et al., 2008) 
cVariation observed at different site from published HLA-associated site 
Underlining denotes the CTL epitope in the peptide sequence 
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Table 2.3:  Summary of potential CTL escape mutations arising in Nef showing their timing, HLA 
association, and 12 month viral loads.  
 
PID Epitopea Restricting HLA HLA-Associatedb Timing Log VL 
CD4+ 
count 
CAP008 FFLKEKGGLEG B*0801 - Early 4.59 332 
 IYSKKRQEILDLWVYH Cw*0701 +
c Acute   
CAP030 EEEVGFPVRPQVP B*4501 +
 c Acute 5.31 573 
CAP045 VLKWKFDSHLA Cw*0601 - Acute 2.75 1030 
CAP061 ATNNADCAWLEA* B*1401/Cw*0802 + Early 2.62 412 
CAP088 EEEVGFPVRPQVP B*4501 +
 c Early 4.59 499 
CAP129 KKRQEILDLWVYH B*1801 + Early 5.16 634 
CAP174 KKRQEILDLWVYH Cw*0701 +
c Acute 4.53 303 
CAP217 YKAAFDLSFFL B*5801 + Acute 4.63 533 
 IYSKKRQEILD Cw*0602/B*1503
e,c + Early   
 NYTPGPGVRYP B*5801 - Early   
CAP229 YKAAFDLSFFL B*5801 +
 c Early 4.35 680 
CAP239 YKAAFDLSFFL B*5801 + Early 5.19 793 
CAP244 KKRQEILDLWVYH B*4403 +
d Acute 4.16 303 
CAP255 KKRQEILDLWVYH B*1801 + Acute 4.26 397 
CAP257 KKRQEILDLWVYH B*4403 +
 d Early 4 470 
CAP258 VRYPLTFGWCFK A*2301 +
 c Early 5.03 228 
CAP262 VRPQVPLRPMT B*8101 + Early 3.55 432 
CAP268 GFPVRPQVPLR B*0705 +
 d Early 4.09 474 
CAP270 GWPAVRERIR B*0801 - Early 6.23 255 
 YKAAFDLSFFL B*5801 +
 c Early   
Median     4.53 470 
*No known epitope 
aEpitope with respect to consensus subtype C 
b(+): presence of HLA-association, (-): absence of previously identified HLA association (Goepfert et al., 2008; 
Matthews et al., 2008; Roussease et al., 2008) 
cVariation observed at different site from published HLA-associated site 
dPredicted epitope with an HLA-associated polymorphism 
eHLA associated with the polymorphism but no known or predicted epitope 
Underlining denotes the CTL epitope in the peptide sequence 
Bold residues indicate the positions where escape was observed 
 
 
2.2.2 There is no association between acute/early CTL escape and disease 
progression 
 
To determine the effect of acute/early CTL escape on disease progression, viral loads and 
CD4+ counts were compared between study participants infected with viruses that either 
did or did not experience possible escape mutations (Figure 2.3).  There was no 
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and disease progression (Figure 2.3A and B).  However, participants infected with viruses 
that had potential escape mutations in the Gag p24 had slightly higher than median CD4+ 
counts while those infected with viruses carrying potential  escape mutations in p17 had 
slightly lower CD4+ counts (Figure 2.3D).  Interestingly, the same participants infected 
with viruses that escaped in p24 also had higher viral loads, suggesting there was no 
association between escape and disease progression. 
 
Immune responses elicited by HLA-B alleles are associated with better viral control 
(Kiepiela et al., 2004).  Analysis of escape mutation dynamics during acute/early 
infections in the context of different HLA classes failed to detect any associations 
between escape from particular HLA classes and viral loads 12 months postinfection in 
either Gag or Nef (Figure 2.3E).  However, individuals infected with viruses that 
experienced escape mutations in HLA-B restricted epitopes had slightly higher CD4+ 
counts while those infected with viruses carrying mutations in HLA-A restricted epitopes 
had lower than median CD4+ counts (Figure 2.3F).  Despite there being no significant 
association between disease progression and Nef and Gag escape mutations arising within 
the first 6 months of infection, the high frequency of escape mutations arising during this 
infection phase may, as suggested by other studies, be contributing to control of the initial 































































































































































































































































































































































































Figure 2.3: An absence of associations between CTL escape and disease progression.  Comparison of viral 
loads (A) and CD4+ counts (B) at 12 months postinfection for the participants infected with viruses 
showing no escape, those infected with viruses carrying escape mutations in either Gag or Nef, and those 
infected with viruses carrying mutations in both genes. Comparison of viral loads (C) and CD4+ counts (D) 
for participants showing infected with viruses showing no escape, those infected with viruses carrying 
escape mutations in p17 Gag, p24 Gag, and Nef. Comparison of viral loads (E) and CD4+ counts (F) for 
participants infected with viruses carrying no escape mutations and those carrying escape mutations in 
HLA-A, HLA-B and HLA-C restricted epitopes.  The dotted blue line indicates the median log viral load or 
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2.2.3 Deviation of p24 sequences from the population consensus is associated with 
better control of viral replication 
 
An analysis was performed on p24 as several studies have shown that functional 
constraints within this region might reduce the tolerability of CTL escape mutations 
therein (Schneidewind et al., 2008; Niefield et al., 1995; Peyerl et al., 2003).  Protective 
HLA alleles selectively favour the emergence of escape mutations at conserved amino 
acid sites (Wang et al., 2009).  In particular, CTL responses targeting the p24 Gag protein 
are associated with better viral control (Dyer et al., 2008; Martinez-Picardo et al., 2006; 
Kiepiela et al., 2004).   
 
The degree of conservation at amino acid sites where potential escape mutations were 
observed in p24 during the first 6 months of infection was assessed using entropy values 
calculated for each p24 residue using 413 subtype C reference sequences 
(www.hiv.lanl.gov).  The mean entropy across the p24 was 0.115 (Figure 2.4A-C).  
Whereas sites with lower than mean entropy were categorised as low entropy sites, those 
with higher than mean entropy were categorised as high entropy sites.   
 
The degree of deviation from the population-wide subtype C consensus was assessed for 
the earliest sampled viruses (Figure 2.4A and B).  It is likely that many (if not most) 
deviations from the consensus sequence observed in sequences sampled at the earliest 
time-points are either escape mutations transmitted from the donor host or early escape 
mutations.  In the viruses from the 32 participants, deviations from the consensus 
sequence were detected at 56 sites (Figure 2.5A and B; Appendix E), with seventeen sites 
(30%) located at low entropy positions and 39 (70%) at high entropy positions.   
 
All the 56 sites in the earliest sampled viruses that showed deviations from the consensus 
sequence were within previously described CTL epitopes (Appendix E).  This strengthens 
the notion that viruses already carrying these mutations either occurred in response to 
CTL pressures operating very early during the infection, or were transmitted from donors 
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The impact of these possible CTL escape mutations on disease progression was assessed.  
Although there was no detectable association between degrees of deviation of the earliest 
viruses from the consensus sequence and viral loads at 12 months postinfection (data not 
shown), the degree of deviation from the consensus in these viruses was marginally 
associated with CD4+ counts (p = 0.0661; Pearson’s test; Figure 2.4A).  There was also a 
highly significant positive correlation between the frequency of mutations in the earliest 
sampled viruses and the entropy of the sites at which the mutations occurred (Figure 
2.4B).  This suggests a possible association between the fitness costs of escape mutations 
and their population-wide frequency.  Mutations in the more constrained regions revert 
rapidly following transmission while those in the less constrained regions remain, 
resulting in high variation at the sites. 
 
































































Figure 2.4:  A) An association between CD4+ counts at 12 months postinfection and degrees of deviation 
of infecting viruses from the population-wide consensus in the Gag p24.region B) An association between 
the frequency of mutations (deviation from consensus) in the earliest sampled viruses and the entropy 
scores at the respective sites within the HIV subtype C population (www.hiv.lanl.gov). 
 
2.2.4 Reversion mutations occur during acute/early infection within the more 
conserved p24 sites as compared to escape mutations 
 
As in section 2.2.3 above, the mutations in p24 Gag were analysed in this section as this 
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Peyerl et al., 2003). Sequence analysis showed that, during the first six months of 
infection, potential reversion mutations occurred at 18 sites in 20 participants (Figure 
2.5A) and potential escape mutations occurred at four sites in six participants (Figure 
2.5B).  Of the apparent reversion mutations, seven (39%) were located at low entropy 
sites and eleven (61%) were at high entropy sites.  Interestingly, three of the four (75%) 
sites at which escape mutations were inferred were categorised as having high entropies.  
Four sites within epitopes where escape mutations were inferred also showed transient 
mutations of which three were at low entropy sites (Figure 2.5B and D).  Comparison of 
the sites at which potential reversion and escape mutations occurred in p24 during the 
first 6 months of infection (Figure 2.5C and D) indicated that whereas the potential 
reversion mutations predominantly occurred at low entropy positions, the potential escape 
mutations occurred at high entropy positions.  These findings suggest that whereas the 
virus may persistently explore escape mutations at less functionally constrained sites 
during the acute and early infection phases, reversion mutations predominate (as 
compared to escape mutations) as HIV-1 attempts to recoup replicative fitness losses 
incurred by CTL escape mutations at functionally constrained sites within former hosts.  
 
Of the six participants infected with viruses carrying escape mutations in p24, four were 
HLA-B*5801 positive.  In fact, the HLA-B*5801 allele in this study was significantly 
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Figure 2.5: A) Entropy at sites in p24 Gag showing reversion and the sites which showed deviation from 
consensus at the earliest sampling timepoint. B) Entropy at sites in p24 Gag showing escape and transient 
mutations within potential CTL epitopes and the sites which showed deviation from consensus at the 
earliest sampling timepoint. C) Comparison of entropy values for sites experiencing potential escape and 
reversion mutations. D) Comparison of entropy values for sites experiencing transient mutations and 




The association between CTL escape in individuals carrying certain HLA alleles such as 
B*57, B*5801 and B*27 and disease progression has been well studied (Leslie et al., 
2004; Martinez-Picardo et al., 2006; Crawford et al., 2009; Brockman et al., 2007; 
Dranert et al., 2004; Goulder et al., 1997; Schneidewind et al., 2007).  However, the 
association between CTL escape and disease progression at a population level is not well 
established.  This study examined the frequency of CTL escape mutations within the Gag 
and Nef regions of HIV-1 during the first 6 months of infection and sought to associate 
these with disease progression using viral loads and CD4+ counts at 12 months 
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A high percentage of individuals were infected with viruses carrying potential CTL 
escape mutations in both Gag and Nef (33% and 53%, respectively; Table 2.1).  These 
mutations were either within or flanking epitopes known to restricted by the participants’ 
HLA alleles.  Only known epitopes and sites where previous HLA-associated 
polymorphisms have been identified were considered in this analysis, and therefore the 
escape mutation frequency measured here is probably an underestimation of the actual 
frequency of Nef and Gag escape mutations occurring within the first six months of 
infection.  Although the status of the potential CTL escape mutations would need to be 
confirmed using immunological assays, the high frequency is nevertheless indicative of 
the evolutionary pressures exerted on HIV by CTLs during acute infections.  The 
frequency of potential escape mutations being higher in Nef than in Gag suggests that 
amino acid substitutes within the structurally constrained Gag proteins may be less 
tolerable than those in the more variable Nef protein.   
 
There was no association detected between the timing of potential CTL escape mutations 
and disease progression (Figure 2.3).  This is probably due to the fact that the fitness 
benefits of CTL escape mutations can be quite complex and larger sample sizes might be 
necessary to detect more subtle associations between early CTL escape mutations and 
disease progression.  Another possibility is that immune responses targeting regions of 
the virus genome besides Nef and Gag were not considered here.  The timing of these 
other responses and the escape mutations they elicit might have a much stronger influence 
on disease progression than those occurring in Gag and Nef    
 
Despite failing to detect an association between the timing of escape mutations and 
disease progression, the high frequencies of potential CTL escape mutations observed in 
Gag and Nef suggest that CTL responses exert considerable selection pressures on HIV 
and that these pressures, along with the escape mutations they induce, might contribute to 
the effective control of peak viremia during acute infections.  This is supported by a 
recent study which showed that viral escape mutants were rapidly selected for as viral 
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Analysis of amino acid sequence evolution in the Gag p24 region over six months 
showed that, during the initial infection phases at least, reversion mutations are probably 
more common than CTL escape mutations (18 sites in 20 individuals vs. four sites in six 
individuals, respectively).  The high frequencies of potential reversion mutations suggests 
that viral evolution during the early phases of an infection may be driven primarily by 
selection favouring the restoration of replicative fitness. 
 
There was a marginal but positive association between degrees of deviation from the 
population consensus p24 sequence amongst the earliest sequence samples and CD4+ 
counts at 12 months postinfection (r = 0.3266, p = 0.0681).  All p24 sites showing some 
degree of deviation from the population consensus were located in known epitopes, 
strongly suggesting that the observed deviations were the result of CTL imposed 
selection.  It remains unknown, however, whether the CTL driven selection indicated by 
these deviant sites occurred in the donor host or during the earlier pre-sampling phases of 
the studied infections.   
 
Of the 56 sites where amino acid states deviated from the consensus, reversion mutations 
were observed at 18 during the first six months of infection.  The observed positive 
association between degrees of p24 sequence deviation from the consensus and CD4+ 
counts could be due in part to the cumulative fitness costs of both defunct and presently 
useful CTL escape mutations within this region.  Several studies have associated CTL 
escape mutations in p24 Gag with slow disease progression as a result of the fitness costs 
frequently incurred by these mutations (Schneidewind et al., 2009; Brockman et al., 
2007; Miura et al., 2009).   
 
This study illustrates that CTL responses in both current and former hosts most likely 
strongly influence viral evolution during the acute phase of HIV-1 infections.  It provides 
some indication that vaccines inducing robust responses that target the constrained p24 
region may be difficult for viruses to overcome without their suffering substantial fitness 
losses.  Vaccines that target conserved epitopes could have a broad impact on the long 
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Abstract 
 
This study investigated the relationship between amino acid polymorphisms in recently 
transmitted viruses and disease progression in 21 individuals who did not have the HLA-
B*57/B*5801 alleles that are generally associated with virological control during HIV 
infections.   Nine individuals were infected with viral variants that contained CTL escape 
mutations in the HLA-B*57/B*5801 restricted Gag immunodominant epitopes, TW10 
and/or ISW9.  Relative to people infected with viruses that did not carry these mutations 
at three and twelve months postinfection those carrying the mutations had both 
significantly lower viral loads (p = 0.0077 and 0.0276, respectively) and significantly 
higher CD4+ counts (p = 0.0129 and 0.0173, respectively).  Sequence analysis over time 
indicated that the T242N escape mutation in the TW10 epitope reverted to wild type in 
5/6 participants whereas the A146X processing escape mutation adjacent to the ISW9 
epitope only reverted in 2/9 participants.  Analysis of In vitro replication kinetics using 
chimeric viruses carrying gag fragments from one of the study participants showed that 
the revertant form was less replicationally fit than the escape variant.  The presence of 
compensatory mutations in the absence of the T242N escape mutation may be responsible 
for the observed reduction in viral fitness.  This, however, remains to be proven through 
further studies.  It may, however, explain why the individuals infected with viruses 
carrying HLA-B*57/B*5801 associated CTL escape mutations have better disease 
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3.0 Introduction 
 
CTL responses exert selective pressures such that viral genomes carrying mutations that 
make CTL targeted epitopes less recognisable (i.e., CTL escape mutations) will be 
favoured (Friedrich et al., 2004; Borrow et al., 1997; Price et al., 1997).  In the macaque 
model in vitro replication of infectious SIVmac239 variants containing certain CTL 
escape mutations was impaired, suggesting that despite the fitness advantages provided 
by escape mutations, some mutations incur a significant cost in terms of replicative 
fitness (Friedrich et al., 2004).  Given a population of immune escape mutants, replicative 
fitness should be a significant determinant of which immune escape variants both emerge 
as the dominant strain in infected individuals and are able to survive following 
transmission to new hosts.   
 
Because of the fitness costs associated with CTL escape mutations, specific HLA allelic 
backgrounds of HIV infected individuals have an influence on rates of disease 
progression. For example, HIV-infected individuals possessing the B*57, B*5801 and 
B*27 HLA-alleles tend to take significantly longer to progress to AIDS than individuals 
without these alleles (Goulder et al., 1996; Kaslow et al., 1996; Klein et al., 1998; 
Kiepiela et al., 2007; Miura et al., 2009).  HIV-1 epitopes targeted by these HLA types 
occur within functionally important protein domains and escape mutations in these 
domains tend to decrease viral replicative fitness (Martinez-Picardo et al., 2006; 
Crawford et al., 2007; Schneidewind et al., 2007; Peyerl et al., 2004).  Secondary 
mutations have been reported that are associated with partial or full restoration of viral 
fitness incurred by escape mutations (Leslie et al., 2004; Brockman et al., 2007; 
Schneidewind et al., 2007; Miura et al., 2009; Crawford et al., 2007). 
 
Most studies to date have focused on host factors such as HLA genotypes to understand 
the high variation in HIV-1 disease progression (reviewed by O’brien and Nelson, 2004; 
Fauci, 2003; O’brien and Moore, 2000; Carrington and O’brien, 2003).  This study 
investigates the presence of markers on recently transmitted viruses which influence 
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infection as prognostic markers.  The impact of these markers on viral replication fitness 
were also investigates.  Part of this study was published in Chopera et al., 2008.   
 
3.1 Materials and Methods 
 
3.1.1 Study subjects 
 
The study participants that were involved are part of the CAPRISA 002 cohort 
investigating the role of viral and immunological factors in acute and early HIV-1 
infections (van Loggerenberg et al., 2008; Chapter 2).  Clinical data was provided by K. 
Mlisana, UKZN. 
 
3.1.2 RNA isolation, RT-PCR and viral sequencing 
 
RNA isolation, RT-PCR and viral sequencing were carried as described in section 2.1.2.  
For the participants whose infecting viruses were identified to carry polymorphisms 
associated with better disease progression (n = 9), sequencing was done on samples up to 
at least one year postinfection.  Cloning was carried out for the study participants whose 
infecting viruses carried the T242N mutation (n = 6).  The PCR amplicons were cloned 
into the pGEM-T Easy cloning system according to the manufacturer’s instructions 
(Promega, USA).  Positive clones were sequenced as outlined in section 2.1.2. 
 
3.1.3 HLA typing 
 
High resolution (four digit) HLA typing was performed as described in section 2.1.3.  
HLA data was provided by C. Gray, NICD.   
 
3.1.4 IFN-γ ELISpot assay 
 
PBMC were prepared and HIV-1 specific T cell responses were quantified by gamma 
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(15- to 18-mer peptides overlapping by 10 amino acids) spanning the entire HIV-1 clade 
C Gag protein corresponding to the HIV-1 consensus C were used in the assay. T cell 
responses were determined using either a deconvoluted pool matrix approach or 
confirmed using individual peptides. The epitopes within peptides showing responses 
were delineated using published epitopes sequences in the Los Alamos HIV database 
(www.hiv.lanl.gov).  Immunology data was provided by C. Gray, NICD.   
 
3.1.5 Phylogenetic and recombination analyses 
 
Phylogenetic trees were constructed using the maximum likelihood method implemented 
in PHYML (Guindon and Gascuel, 2003) (100 full maximum likelihood bootstrap 
replicates, HKY model+gamma with four substitution rates and transition:transversion 
ratio determined from the data). Seven different recombination analysis methods 
implemented in RDP3 (Martin et. al., 2005) were used, with default settings, to test for 
the presence of recombination amongst the 21 acute infection sequences and an additional 
102 publicly available gag sequences sampled from a matched cohort. Evidence of 
phylogenetic clustering of viruses carrying particular Gag polymphisms was assessed 
using a permutation test (with 10000 iterations) implemented in RDP3 that is similar to 
that described in Poss et al. (1998).  The phylogenetic analysis was carried out by D. 
Martin, University of Cape Town, South Africa (UCT). 
 
3.1.6 Statistical analyses 
 
Wilcoxon rank-sum tests were used to identify amino acid sites (encoded by the earliest 
gag sequences determined postinfection) that were associated with low viral loads and 
high CD4+ counts at 12 months postinfection. These tests compared the median viral 
loads and CD4+ counts between groups of viruses with the consensus or an alternative 
amino acid at each site independently (without correction for multiple testing). Fisher’s 
exact test was used to test; 1) each HLA allele for enrichment among individuals with 
either the A146X or T242N mutations and to test for associations between Gag ELIspot 
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association between the presence of HLA-B*57/B*5801 escape mutations in Gag, A146X 
and T242N, and Nef, A83G and S88G. The rates of infectivity of viral constructs 
generated before and after reversion pairs were compared using a Student t test for paired 
samples. Changes in viral loads and those in viral spread were tested using the Wilcoxon 
matched pairs test. Statistical tests were implemented in either the R statistical computing 
environment (R Development Core Team, 2005) or in GraphPad Prism 4.0 (GraphPad 
Software, Inc.). 
 
3.1.7 Viral replication assay 
 
3.1.7.1 pBR246-F10 and NL4-3 constructs 
 
Clonal gag sequences in the pGEM-T Easy vector (Promega, USA) from two timepoints 
(1.9 and 29.7 months postinfection) were aligned using the ClustalW program 
implemented in Bioedit (Thompson et al., 1994).  The gag clone representing the 
dominant virus at 1.9 months postinfection was selected and one representing reversions 
at T242N, A146P and I147L mutations was selected for 29.7 months postinfection.  The 
subtype C backbone was provided by G. Shaw (University of Alabama at Birmigham) 
and subtype B backbone was provided by T. Allen (Partners AIDS Research Centre and 
Harvard Medical School).  Site directed mutagenesis was carried out to insert cloning 
sites BssHII and XhoI (by silent mutations) at the beginning of the gag gene (second and 
third amino acids) and just after the end of the gag open reading frame (~60 nucleotides 
downstream of the gag stop codon) for the pBR246-F10 subtype C backbone (Appendix 
F). For the NL4-3 subtype B backbone, a unique BssHII site was present about 80 bp 
upstream of the gag start codon.     A XhoI site was inserted at the same position as for 
the pBR246-F10 backbone and an existing XhoI site in NL4-3 was deleted.  Gag genes 
were ligated to the cloning sites using standard techniques.  E. coli OneShot Stbl3 
(Invitrogen) cells were transformed to propagate full-length proviral plasmids and stocks 
were prepared by using a Qiagen Plasmid Midi Kit (Qiagen, Valencia, CA). Sequences of 
the BssHII-XhoI inserts were verified by using previously described primers (section 
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subtype C backbone (MJ4) containing the consensus p24 fragment (provided by C. 
Boutwell, Harvard University) and cloned in the same way as the CAP061 clones.  
 
3.1.7.2 Viral stocks 
 
Viral stocks were generated by transfection of HEK293T cells with 7.5 µg of plasmid 
DNA in Dulbecco modified Eagle medium (Gibco) supplemented with 10% fetal bovine 
serum (Atlantic Biologicals) using Lipofectamine 2000 (Invitrogen). Supernatants were 
harvested 48 h after transfection for the NL4-3 viruses and after 72 h for the pBR-246-
F10 viruses and aliquots were stored at -80°C. Capsid concentration of the viral stocks 
was quantified by p24 enzyme-linked immunosorbent assay using the Vironostika HIV-1 
Antigen Microelisa system (Biomerieux, Netherlands). 
 
3.1.7.3 Viral replication assays 
 
PBMC isolated from 4 healthy HIV-negative donors were stimulated in RPMI 1640 
supplemented with 20% FBS, 5 mg.mL
-1
 of phytohemagglutinin (Sigma, St. Louis, Mo., 
USA), and 20 U.mL
-1
 of interleukin-2 (Becton Dickinson Labware, Bedford, Mass., 
USA) for 72 h prior to infection. After 72 h, the PBMC were washed with 1x phosphate-
buffered saline (PBS) supplemented with 1% (vol/vol) FBS (Wash media). 5.0x10
5
 
PBMC were inoculated with viral stocks (20 ng p24) in 1 mL of RPMI 1640 
supplemented with 20% FBS and 20 U of interleukin-2 (Growth media). After 24 h, the 
growth medium was removed and the PBMC were washed with Wash media and fresh 
growth medium was added. Two hundred and fifty microlitres of supernatant were taken 
for p24 analysis and replaced with an equal volume of growth medium on days 2, 5, 7, 




At the time of this study, twenty-four individuals in the study cohort had reached one year 
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progress slowly to AIDS (Goulder et al., 1996; Kiepiela et al., 2007; Kaslow et al., 1996; 
Klein et al., 1998) and since the aim of this study was to identify markers on transmitted 
viruses that are associated with disease progression, three individuals carrying these HLA 
alleles were excluded from the analyses.  The 21 remaining HLA-B*57, -B*5801 and -
B*27 negative women recently infected with HIV-1 subtype C had a median log viral 
load setpoint of 4.59 RNA copies.mL
-1
 (range 2.60 to 6.09) and a median CD4+ count of 
367 cells.µL
-1
 (range 202 to 1030) at 12 months postinfection.  The participants were 
estimated to be between 22 and 62 days postinfection (median = 42 days) at the time of 
their enrolment.  These individuals were followed-up for a period of at least 12 months.  
For each participant, complete gag and nef genes were amplified and sequenced from the 
earliest available HIV positive sample, and samples taken at 3 and 6 months 
postinfection. 
 
3.2.1 Identification of sites associated with low VL and high CD4+ counts 
independent of HLA genotype   
 
As there were participants with viral loads more than 10-fold lower than the median viral 
setpoint, it was hypothesized that these viruses might share common characteristics that 
contribute to lower viremia during acute infection. To test this hypothesis, the association 
between amino acid variation at specific sites (in Gag and Nef) and either lower viral 
loads or higher CD4+ counts at 12 months postinfection was investigated using the 
Wilcoxon rank-sum test (Mann-Whitney U).  Amino acid polymorphisms at two sites in 
Gag, at HXB positions 146 (n =9) and 242 (n = 6), were significantly associated with 
high CD4 counts at 12 months postinfection (p=0.0172 and p=0.0175, respectively; Table 
3.1).  In addition, there was a significant association between variation at position 146 
and low viral loads at 12 months postinfection (p = 0.0275).  The association between the 
amino acid at position 242 and low viral loads at 12 months, while not as strong as that 
for position 146, showed a trend towards association (p = 0.0733).  No sites in the Nef 
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Position 146 is adjacent to the HLA-B*57B*5801 ISW9 epitope and A146X (X = P or S) 
is a well-known epitope processing escape mutation (Draenert et. al., 2004; Table 3.1), 
whereas position 242 represents a well-known CTL escape site in the HLA-B*57B*5801 
immunodominant TW10 epitope. The escape mutation at T242N, results in a less fit virus 
with compromised replicative capacity (Martinez-Picardo et al., 2006).  Therefore, this 
HLA-independent analysis identified HLA-B*57/B5801 genetic ‘footprints’ associated 




Table 3.1: The identification of sites associated with high CD4+ counts and low viral loads at 12 months 
postinfection.  
 
      Median CD4+ count
a
 Median log10 viral load
a
 
               
         
Mutation n Epitope + - p-value + - p-value 
                  
         
A146X 9 ISW9 544 348 0.0172 3.49 4.87 0.0275 
         
T242N 6 TW10 538 390 0.0175 3.26 4.69 0.0733 
                  
         
a (+) Presence of mutation       
   (-) Absence of mutation       
 
 
3.2.2 T242N and A146X mutations are consistent with transmission from 
B*57/B*5801 positive individuals 
 
If the viral variants carrying the T242N and A146X escape mutations were transmitted 
from HLA-B*57B*5801 positive donors, it was hypothesised that selection pressures 
would be evident in immunodominant HLA-B*57B*5801 specific Gag epitopes. To 
verify this suggestion, three immunodominant epitopes, TW10 (TSTLQEQIAW: HXB 
position 241-249), ISW9 (ISPRTLNAW: HXB position 147-155) and KF11, 
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al., 2006; Leslie et al., 2004; Draenert et al., 2006; Crawford et al., 2007).  Odds ratios 
for non-synonymous (i.e. amino acid changing) mutations occurring within these epitopes 
and adjacent residues with respect to the subtype C consensus nucleotide sequence were 
calculated using the SNAP program (www.hiv.lanl.gov).  One flanking amino acid was 
included on either side of the epitope to include possible processing escape mutations in 
the analysis.  The data showed that the sequences from participants with variation at sites 
146 and 242 had significantly more non-synonymous mutations within the three 
B*57/B*5801 immunodominant epitopes (p = 0.0010) (Figure 3.1), suggesting that the 
variants had previously experienced immune pressure at these sites. The accumulation of 
non-synonymous mutations within these epitopes further supports the hypothesis that 
these viruses had previously undergone selection in HLA-B*57/B*5801 positive hosts.  
Interestingly, the data also identified a few participants that lacked the T242N and the 
A146X mutations but had high odds ratios, suggesting that these individuals may be 
infected with variants that, at some time in the past (but not necessarily in the most recent 
donor), have been exposed to CTL responses targeting these B*57/B*5801-specific 
epitopes. 
 
This analysis also revealed additional evidence of selection by B*57/B*5801 restriction 
in the viruses carrying the A146X and T242N mutations.  Apart from the potential 
immune evasion mutations at Gag positions 242 and 146, three sequences (CAP088, 
CAP228 and CAP255) also carried the well-studied A163X mutation in the HLA 
B*57/B*5801 restricted KF11 epitope (Figure 3.2) (Crawford et al., 2007; Yu et al., 
2007; Bailey et al., 2006).  Also, viruses infecting all but one of the participants 
(CAP088) carried a mutation adjacent to the A146X mutation (I147X, X = L or M; 
Figure 3.2).  Variation at this site has been previously shown to be associated with CTL 
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Figure 3.1: The accumulation of non-synonymous mutations within the three B*57/B*5801-specific 
immunodominant epitopes.  Comparison of the odds ratio of non-synonymous mutations within TW10, 
ISW9 and KF11 between those B*57/B*5801-negative participants infected with variants carrying the 
T242N and A146X mutations and those not carrying the mutations. 
 
3.2.3 B*57/B*5801 associated escape mutations revert to consensus sequence in a 
sequential order 
 
Studies by Leslie et al., (2004) suggested that the T242N escape mutation reverts to wild 
type upon transmission since the mutation was very rare in chronically infected HLA-
B*57/B*5801-negative individuals.  Following limiting cDNA dilution and amplification, 
gag sequences from the nine study participants infected with T242N/A146X mutants 
were analyzed over time to detect reversion mutations (Figure 3.2).  During the studied 
period the T242N reverted to the consensus subtype C sequence in 5/6 (83%) participants 
infected with the transmitted variant (Fig. 2).  The timing of reversion varied from patient 
to patient but the earliest had reverted by 6 months postinfection.    Reversions to wild 
type occurred in only two of the nine (22%) A146X (and adjacent I147X) mutant 
infections.  The reversions occurred at approximately 16 and 24 months postinfection.  
Sequences from the two individuals infected with viruses carrying the A163X mutation in 
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finding by Leslie et al., (2004) that the T242N reverts earlier than the other escape 
mutations and that the A146X and other mutations remain as “footprints” of prior 
exposure to the HLA-B*57/B*5801 allele.  As it has been shown that the T242N 
mutation reverts upon transmission to B*57/B*5801-negative recipients, it is possible that 
some of the viruses carrying only the A146X mutation had undergone reversion 
mutations at position 242 before enrollment into the study such that the slower to revert 
A146X mutation remained as a footprint of past B*57/B*5801 pressure.  
 
 
Figure 3.2:  Sequence alignment of ISW9, KF11 and TW10 epitopes. Sequence changes in B*57/B*5801-
specific immunodominant epitopes over time for the 9 participants infected with virus variants carrying the 
T242N and A146X mutations. One flanking amino acid residue was included on either side of the epitope.  
   PID    Mo. PI    ISW9 (147 – 155)     KF11 (162 – 172)        TW10 (241 – 249) 
 
                AISPRTLNAWV  EKAFSPEVIPMFT  TTSTLQEQIAWM 
CAP045  0.5     PM.........  ............I  ...........I 
CAP045  1.2     PM.........  .............  ...........I 
CAP045  2.8     PM.........  .............  ...........I 
CAP045  21.7    PL.........  .............  ...........I 
CAP061  1.9     PL.........  .............  ...N........ 
CAP061  2.6     P..........  .............  ...N........ 
CAP061  5.9     PL.........  .............  ...N........ 
CAP061  7.8     PL.........  .............  ...N........ 
CAP061  11.9    PL.........  .............  ...N........ 
CAP061  23.9    ...........  .............  ............ 
CAP061  29.7    ...........  .............  ............ 
CAP065  1.4     SL.........  .............  ............ 
CAP065  2.6     SL.........  .............  ............ 
CAP065  4.0     SL.........  .............  ............ 
CAP065  16.6    ...........  .............  ............ 
CAP085  1.2     PL.........  .............  ...N........ 
CAP085  3.1     PL.........  .............  ...N........ 
CAP085  6.8     PL.........  .............  ............ 
CAP085  12.9    PL.........  .............  ............ 
CAP085  19.0    PL.........  .............  ............ 
CAP085  25.0    PL.........  .............  ............ 
CAP088  1.2     P..........  ..G..........  ...N........ 
CAP088  3.0     P..........  ..G..........  ...N.....V.. 
CAP088  6.1     P..........  ..G..........  ...N........ 
CAP088  12.6    P..........  ..G..........  ...N........ 
CAP088  18.9    P..........  ..G..........  ............ 
CAP200  1.4     PL.........  ............I  ...N........ 
CAP200  3.3     PL.........  ............I  ...N........ 
CAP200  5.9     PL.........  ............I  ...N........ 
CAP200  12.7    PL.........  ............I  ............ 
CAP225  0.9     PL.........  .............  ...N........ 
CAP225  2.8     PL.........  .............  ...N........ 
CAP225  5.6     PL.........  .............  ...S........ 
CAP225  11.7    PL.........  .............  ...S........ 
CAP225  14.2    PL.........  .............  ............ 
CAP228  1.8     PL.........  ..S..........  ...N........ 
CAP228  2.3     PL.........  ..S..........  ...N........ 
CAP228  6.0     PL.........  ..S..........  ...N........ 
CAP228  10.0    PL.........  ..S..........  ...N....V... 
CAP228  22.4    PL.........  ..S..........  ...N........ 
CAP255  1.8     PL.........  ..S..........  .....A.....I 
CAP255  3.0     PL.........  ..S..........  .....A...... 
CAP255  5.3     PL.........  ..S..........  .....A...... 
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To investigate the proportion of T242N and wild-type variants in the six participants 
infected with T242N mutants, bulk PCR was performed and amplicons from three time-
points were cloned (median 12 clones per participant, range 7-20) and sequenced.   The 
data showed that although there was complete replacement of the escape mutation (N242) 
by the consensus amino acid (T242) in three participants (CAP061, CAP085 and 
CAP200), in another participant (CAP228) no reversion was observed over the follow-up 
period (Figure 3.3).  In two participants (CAP088 and CAP225), a mixed viral population 
consisting of both escape mutants and wild-type variants were detected at the final time-
point assayed, indicating that complete replacement of the escape mutant with the wild-
type variant had not occurred.  In CAP225 at 14.2 months, the escape mutation was 
detected in 8/14 clones (57%), the reversion intermediate, S242 was identified in 4/14 
clones (29%), and T242 occurred in 2/14 clones (14%).  In CAP088 the T242 wild-type 
was the dominant population member at 12.6 and 18.9 months postinfection with only, 
3/11 and 4/12 of the sampled sequences at these respective time-points displaying the 
N242 polymorphism.  There was also the transient appearance of the S242 reversion 
intermediate in CAP088 detected at enrolment (1.2 months postinfection) at a frequency 
of 20% (4/20 clones).  Reversion of the A146X mutation was only observed in one 
(CAP061) of the six individuals infected with viruses carrying the T242N mutation.  
However, although the wild-type A146 polymorphism was observed in 3/10 sampled 
sequences at 11.9 months postinfection, it was not detectable amongst ten sequences 
sampled at 23.9 months postinfection (Figure 3.3). Complete reversion was observed at 
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Figure 3.3:  Proportions of HLA-B*57B*5801-associated escape mutations at different time-points in 
different study participants.  Gag bulk PCR products were cloned and sequenced at three available time-
points as indicated on the x-axis. A median of 12 sequences (range 7-20) were analyzed per participant per 
time-point.   
 
Viral load and CD4+ count dynamics were plotted over time to investigate whether 
reversion of T242N was associated with either increased viral loads or decreased CD4+ 
counts (n = 6 , Figure 3.4A and B).  Overall, there was no significant change in geometric 
mean log viral loads or CD4+ counts between either 6-12 and 12-18 months 
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pairs test) (Table 3.2). However, one of the six study participants (CAP085) had an 
increase in log viral load of 1.05 and a corresponding decrease in CD4+ count of 209 
cells.µl
-1
 between 12-18 and 18-24 months.  The T242 reversion polymorphism was 
observed in this individual at 3.1 months postinfection suggesting that the loss of viral 
control was not concomitant with reversion.  However, the early reversion observed in 
this participant may have contributed to the increase in viral load observed in this 
individual.  Of the six participants infected with viruses carrying the T242N escape 
variants, the virus infecting CAP085 showed the earliest reversion. 
 
 
Figure 3.4: a) Viral load and b) CD4+ counts over time for the 6 participants infected with viruses carrying 
T242N mutations at study enrolment. The amino acid residue at position 242 is indicated for the particular 
time-points when viruses were cloned and sequenced. Red squares indicate N242 and blue squares indicate 
T242. Where there was more than one variant, the dominant residue is shown in upper case whereas lower 
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Table 3.2: Changes in viral load and CD4+ counts for the 6 participants infected with viruses carrying the 
T242N mutations at enrolment.  Geometric means were calculated for viral loads and CD4+ counts between 
6-12 months, 12-18 months and 18-24 months postinfection and the differences in the geometric means 
over the three periods were tabulated 
 
PID ∆ log10 VL ∆ CD4+ count 
     
 6-12 and 12-18 12-18 and 18-24 6-12 and 12-18 12-18 and 18-24 
     
CAP061 -0.64 -0.1 -111 53 
CAP085 0.12 1.05 70 -209 
CAP088 -0.02 -0.62 -290 110 
CAP200 -0.08 0.09 11 77 
CAP225 0.18 0.19 -71 -96 
CAP228 -0.35 0.1 -40 4 
          
 
 
These results confirm earlier reports (Leslie et al., 2004) that the T242N mutations revert 
earlier than other HLA-B*57/ B*5801 associated escape mutations and that A146X and 
other escape mutations persist as “footprints” of prior viral exposure to HLA-
B*57/B*5801 alleles.  In addition, reversion of T242N mutations to the wild-type 
consensus sequence does not have an obvious immediate impact on viral load. 
 
3.2.4 Viruses carrying the T242N escape mutation also harbour compensatory 
mutations associated with partial restoration of viral fitness 
 
Previous studies have identified five positions at which mutations that compensate for the 
T242N mutation occur (Leslie et al., 2004; Brockman et al., 2007; Martinez-Picado et al., 
2006). These compensatory mutations at positions H219, V223, M228, A248 (G248 in 
subtype B) and S252 (N252 in subtype B) are both associated with the T242N escape 
mutation, and are known to partially recoup replicative fitness lost due to the T242N 
mutation (Brockman et. al., 2007; Martinez-Picado et al., 2006).  The occurrence of 
variations at these compensatory mutation sites was investigated to further strengthen the 
hypothesis that the viruses harbouring the T242N mutations were previously passaged 
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Similar to previous studies (Brockman et al., 2007; Schneidewind et al., 2009; Leslie et 
al., 2004), most of the viruses carrying the B*57/B*5801 associated T242N mutation also 
harboured compensatory mutations (Figure 3.5).  While reversion of the T242N mutation 
was observed in five of the six participants, most of the compensatory mutations did not 
revert to consensus.  However, reversion through a putative intermediate was observed at 
positions 223 (CAP085 and CAP228; V to A) and 252 (CAP061; H to G).  These data 
suggest that while the T242N mutation rapidly reverts to consensus following 
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Figure 3.5: Alignment of the clonal sequences from the six participants infected with viruses carrying 
T242N escape mutations showing previously described mutations.  The compensatory sites are highlighted 
in yellow and the grey highlighting indicates minority variants present at some of the time points.  The 
TW10 epitope is boxed and the Cyp A binding loop is underlined.  The sequences are aligned to the 














                                 210       220       230       240       250       260    
PID                 Mo. PI ..|....|....|....|....|....|....|....|....|....|....|....|.. Frequency 
           DTINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIAWMTSNPPIPVGDIY  
CAP061   1.9 ................Q...V....I.............N.........H.......E.. 19/19 
     11.9 ................Q...V....I.............N.........H.......E.. 10/10 
     23.9 ................Q...V..........................I.G.......E.. 9/10 
     23.9 ................Q...V...............A..........I.G.......E.. 1/10 
     29.7 ................Q...V....I.D.....................H.......E.. 8/9 
     29.7 ................Q...V....I.......................H.......E.. 1/9 
 
CAP085   1.2 ............I.......V....L.............N.........A...V...E.. 17/17 
     3.1 ............I.......V....L.............N.........A...V...E.. 6/11 
     3.1 ............T.......V....L.............N.............V...E.. 3/11 
     3.1 ............I.......V....L.............N.............V...E.. 2/11 
     18.9 ............I.......V....L...........................V...... 10/11 
     18.9 ............I.......V....L...........................V...E.. 1/11 
     26.75 ............I.......V....L...........................V...... 3/7 
     26.75 ............I.......V....I...........................V...... 1/7 
     26.75 ............I..A....V....L...........................V...... 1/7 
     26.75 ............I.......A....L...........................V...... 2/7 
 
CAP088   1.2 ....................NP.................N.........G.......... 16/20 
     1.2 ....................NP.................S.........G.......... 4/20 
     12.6 ....................NP...........................G.......... 8/11 
     12.6 ....................NP.................N.........G.......... 3/11 
     18.9 ....................NP...........................G.......... 8/12 
     18.9 ....................NP.................N.........G.......... 4/12 
 
CAP200   1.4 ....................N..................N.............V...E.. 12/12 
     5.9 ....................N..................N.............V...E.. 19/19 
     12.7 ....................N................................V...E.. 10/10 
  
CAP225   0.9 .......................................N.................... 13/17 
     0.9 .......................................N.........G...V...... 3/17 
     0.9 ...........K...........................N.................... 1/17 
     11.7 .......................................N.............V...... 7/14 
     11.7 ............................................................ 1/14 
     11.7 .......................................S.................... 5/14 
     11.7 .......................................N.....T.............. 1/14 
     14.2 .......................................N.............V...... 7/14 
     14.2 .......................................S.............V...... 2/14 
     14.2 ............................................................ 2/14 
     14.2 .......................................S.................... 2/14 
     14.2 .....................................I.N.............V...... 1/14 
 
CAP228   1.8 ....................V..................N.................... 17/17 
     22.4 ....................A..................N.................... 5/7 
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3.2.5 Evidence of selection in the Nef KAF9 HLA-B*57/B*5801 restricted epitope in 
viruses carrying T242N and A146X mutations 
 
Unlike Gag, the analysis of Nef sequences from the 21 study participants did not detect 
any polymorphisms that were significantly associated with low viremia and high CD4+ 
counts at 12 months postinfection.  However, Nef sequences were examined further for 
evidence of HLA-B*57/B*5801 associated CTL escape mutations within individuals 
infected with viruses carrying the T242N and A146X mutations.  Specifically, there are 
three well described HLA B*57/B*5801 restricted Nef epitopes:  KAF9 (KAAFDLSFF: 
HXB position 82-90), HW9 (HTQGYFPDW: HXB position 116-124), and YY8 
(YFPDWQNY: HXB position 120-127) (Figure 3.6).  Interestingly, mutations in these 
epitopes were found at high frequencies both amongst the participants infected with 
viruses carrying T242N and A146X mutations (9/9) and those infected with viruses not 
carrying the mutations (10/12).  However, in KAF9, the well documented HLA-
B*57/B*5801 escape mutation (A83X; X = G or E), was more frequent in participants 
whose infecting viruses had the T242N and A146X mutations compared to those infected 
with viruses not carrying the mutations (7/9 vs. 4/12, respectively, p = 0.0805; Fisher’s 
exact test).  Another mutation (S88G) in the KAF9 epitope was detected in participants 
infected with T242N mutants and not in the participants without these mutants (3/9 vs. 
0/12, respectively, p = 0.0632).  In the overlapping epitopes, HW9 and YY8, there was 
variation at positions 116 (H116N) and 120 (Y120X; X = F or I) but this was not different 
in the two groups (5/9 vs. 4/12; p = 0.3964 and 5/9 vs. 8/12; p = 0.6731, respectively).  
No reversion of the escape mutations was detected in the follow-up sequences which 
varied from 2.8 months to 7.8 months postinfection.   
 
This analysis therefore revealed that while there was no difference in variation within the 
HW9 and YY8 HLA-B*57/B*5801 restricted Nef epitopes between the viral variants 
with or without the T242N and A146X escape mutations, there was an appreciable 
difference in the KAF9 epitope.  The rate of reversion of these epitopes has not been 
documented and similar frequency of variation in the HW9 and YY8 epitopes could be 
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mutations in epitopes within less functionally constrained genome regions (Leslie et al., 
2005). 
 
PID        Mo. PI KAAFDLSFF  HTQGYFPDW  YFPDWQNY  
 
CAP045  1.2   .........  N...F....  F.......  
CAP061  1.9   .G....G..  ....F....  F.......  
CAP065  1.4   .........  ....F....  F.......  
CAP085  1.2   .G....G..  .........  ........  
CAP088  1.2   .G.......  N........  ........  
CAP200  1.4   .G.......  N........  ........  
CAP225  0.9   .G....G..  .........  ........  
CAP228  1.8   .E.......  N...I....  I.......  
CAP255  1.8 .G.......  N...F....  F.......  
 
CAP008  0.8   ...V.....  .........  ........  
CAP030  1.2   .G.......  ....F....  F.......  
CAP069  1.2   .........  ....F....  F.......  
CAP084  0.7   .........  .........  ........  
CAP174  0.9   .........  N...F....  F.......  
CAP206  1.8   .G.......  N...F....  F.......  
CAP210  1.2   .........  N...F....  F.......  
CAP244  1.9   .........  ....F....  F.......  
CAP248  2.1   .........  ....F....  F.......  
CAP256  1.4   .G.......  .........  .....H..  
CAP257  1.5   .G.......  N...F....  F......C  






PID        Mo. PI KAAFDLSFF 
 
CAP045  0.5 ......... 
1.2 ......... 
2.8 ......... 
CAP061  1.9 .G....G.. 
2.6 .G....G.. 
7.8 .G....G.. 
CAP065  1.4 ......... 
2.6 ......... 
4.0 ......... 
CAP085  1.2 .G....G.. 
3.1 .G....G.. 
6.8 .G....G.. 
CAP088  1.2 .G....... 
3.0 .G....... 
6.1 .G....... 
CAP200  1.4 .G....... 
3.3 .G....... 
5.9 .G....... 
CAP225  0.9 .G....G.. 
2.8 .G....G.. 
5.6 .G....G.. 
CAP228  1.8 .E....... 
2.3 .E....... 
6.0 .E....... 
CAP255  1.8 .G....... 
  3.0 .G....... 




Figure 3.6:  A) Alignment of sequences at enrolment of the three Nef HLA-B*57/B*5801 restricted 
epitopes, KAF9 (KAAFDLSFF), HW9 (HTQGYFPDW), and YY8 (YFPDWQNY). B) KAF9 epitope 
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3.2.6 Phylogenetic clustering of viruses carrying T242N and A146X mutations 
 
The combined population frequency of HLA-B*57 and B*5801 alleles in the South 
African Zulu-Xhosa population is 16.5% (Leslie et al., 2005; www.hiv.lanl.gov).  The 
38% observed frequency of participants infected with the viruses carrying the T242N and 
A146X mutations is higher than the population frequency of the alleles driving these 
mutations.  However, given a sample of 21 individuals from this population, the expected 
number of HLA-B*57/B*5801 positive individuals (95% confidence interval range) 
would be between two and eleven.  In order to test whether the observed A146X and 
T242N mutations had all arisen independently, the 21 sequences from the study was 
analysed together with 102 other sequences sampled from the same population and within 
five years of those sampled in this study (Kiepiela et al., 2007).  A maximum likelihood 
tree was constructed from the sequences after discarding potentially recombinant 
sequences and those that had codons corresponding to known HLA-B*57/B*5801 
associated escape mutations (n = 9) (Figure 3.7).  The sequences carrying the T242N and 
A146X escape mutations clustered significantly within this tree (p = 0.0157), suggesting 
that there is a degree of epidemiological linkage amongst viruses with these mutations.  
This observation supports the notion that some HLA-B*57/B*5801 associated mutations 
may persist for extended periods within circulating viruses.  The phylogenetic analysis 
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Figure 3.7:  Maximum likelihood tree of HIV-1 subtype C gag sequences sampled in Durban South Africa.  
Whereas blue symbols represent sequences carrying nucleotide sequence polymorphisms characteristic of 
immune evasion mutations that occur in HLA-B*57/B*5801 positive individuals, red symbols indicate 
sequences without these polymorphisms.  Blue bars to the right of the figure indicate clades in which 
sequences carrying the polymorphisms predominate.  Sequences denoted with triangles are those 
determined in this study.  Whereas branches labelled with filled circles have >50% bootstrap support, those 
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3.2.7 Individuals infected with putative transmitted CTL escape variants did not 
have common HLA alleles 
 
Certain HLA alleles are associated with viral control (Kiepiela et. al., 2004). In order to 
rule out the possibility that the HLA alleles of the studied individuals are responsible for 
the elevated degrees of viral control observed during acute infection, the HLA allele 
frequency of the 21 individuals were analysed using Fisher’s exact test.  There was no 
detectable enrichment of any alleles when comparing the participants infected with 
viruses carrying the putative transmitted CTL escape mutations and those without them 
(Table 3.3).  This analysis revealed that the lower viremia and increased CD4+ counts 
were not obviously associated with over-representation of any one HLA allele.  
 
3.2.8 No differences in magnitude or breadth of responses to Gag between 






Previous studies have reported that the breadth of CD8+ T cell responses to Gag are 
associated with viral control in subtype C HIV-1 infection (Kiepiela et al., 2007).  The 
lower viral loads and higher CD4+ counts observed in the participants infected with the 
T242N and A146X mutants could have been a result of T cell responses to Gag.  To 
determine whether the better viral control observed in the 9 individuals infected with 
viruses carrying the putative transmitted CTL escape mutations was associated with T 
cell responses to Gag, IFN-gamma ELIspot responses were assessed at 9-15 weeks 
postinfection (Table 3.4).  The data showed that there was no significant difference in the 
breadth and magnitude of responses to Gag between the 9 participants infected with the 
T242N and A146X mutants and the 12 participants not infected with these mutants.  Four 
out of nine individuals infected with T242N and A146X mutants had detectable responses 
to Gag with three recognizing single peptides (CAP085, 225, 228) and the fourth 
individual recognizing two peptides (CAP255).  Of the 11 individuals infected with the 
wild-type variant, five responded to Gag, with two individuals recognising single peptides 
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responses to Gag peptides overlapping with the TW10 and ISW9 epitopes were detected 
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Table 3.3: Comparison of class I HLA* frequencies between the participants infected with T242N and 
A146X mutants (T242N/A146X) and those not infected with the mutants (NON-T242N/A146X). 
 
  T242N/A146X NON-T242N/A146X COMPARISON 
HLA-A n (%) n (%) p-value 
A0101 1 (11%) 0 (0%) 0.4286 
A0201 0 (0%) 1 (8.33%) 1 
A0205 1 (11%) 1 (8.33%) 1 
A0301 1 (11%) 3 (25%) 0.603 
A2301 3 (33.33%) 5 (41.67%) 1 
A2601 1 (11%) 0 (0%) 0.4286 
A2901 0 (0%) 1 (8.33%) 1 
A2902 2 (22.22%) 4 (33.33%) 0.6594 
A3001 1 (11%) 0 (0%) 0.4286 
A3002 1 (11%) 0 (0%) 0.4286 
A3004 0 (0%) 1 (8.33%) 1 
A3201 0 (0%) 1 (8.33%) 1 
A3402 0 (0%) 1 (8.33%) 1 
A4301 1 (11%) 0 (0%) 0.4286 
A6601 1 (11%) 1 (8.33%) 1 
A6602 1 (11%) 0 (0%) 0.4286 
A6802 2 (22.22%) 1 (8.33%) 0.5534 
A7401 0 (0%) 2 (16.67%) 0.4857 
A8001 1 (11%) 0 (0%) 0.4286 
HLA-B    
B0702 0 (0%) 1 (8.33%) 1 
B0801 2 (22.22%) 1 (8.33%) 0.5534 
B1401 1 (11%) 1 (8.33%) 1 
B1503 0 (0%) 4 (33.33%) 0.1038 
B1510 3 (33.33%) 2 (16.67%) 0.6108 
B1801 1 (11%) 0 (0%) 0.4286 
B4101 1 (11%) 1 (8.33%) 1 
B4201 1 (11%) 1 (8.33%) 1 
B4202 1 (11%) 1 (8.33%) 1 
B4403 1 (11%) 4 (33.33%) 0.3383 
B4407 0 (0%) 1 (8.33%) 1 
B4501 3 (33.33%) 1 (8.33%) 0.2722 
B4901 0 (0%) 1 (8.33%) 1 
B5101 1 (11%) 0 (0%) 0.4286 
B5802 2 (22.22%) 4 (33.33%) 0.6594 
B8101 1 (11%) 0 (0%) 0.4286 
HLA-C    
C0202 1 (11%) 1 (8.33%) 1 
C0210 0 (0%) 3 (25%) 0.2286 
C0303 1 (11%) 0 (0%) 0.4286 
C0304 0 (0%) 1 (8.33%) 1 
C0401 1 (11%) 3 (25%) 0.603 
C0602 3 (33.33%) 4 (33.33%) 1 
C0701 2 (22.22%) 3 (25%) 1 
C0702 1 (11%) 1 (8.33%) 1 
C0802 1 (11%) 0 (0%) 0.4286 
C0804 1 (11%) 1 (8.33%) 1 
C1601 2 (22.22%) 2 (16.67%) 1 
C1701 3 (33.33%) 2 (16.67%) 0.6108 
C1801 1 (11%) 0 (0%) 0.4286 
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Table 3.4: ELIspot
C
 responses for the 9/21 study participants who responded to Gag*.   In bold are the 4 
individuals with the transmitted viruses carrying T242N/A146X mutations. Underlined are the known 
epitopes and their corresponding restricting HLA alleles.  
 
PID HLA Reactive peptide 
SFU x 106  
 (9-15weeks)   
    
CAP085 A3002  A3002  B0801  B4501  Cw0701 Cw1601 TGTEELRSLYNTVATLY  a138 
    
CAP225 A0101  A3001  B4202  B8101  Cw0701 Cw1801 GATPQDLNTMLNTVGGH a1058 
    
CAP228 A2301  A2601  B4403  B5101  Cw0303 Cw0701 AFSPEVIPMFTALSEGA a265 
    
CAP255 A0301  A8001  B0801  B1807  Cw0202 Cw0702 IAPGQMREPRGSDIA* b295 
 A0301  A8001  B0801  B1807  Cw0202 Cw0702 WMTSNPPVPVGDIYWKRWI   b295 
        
CAP008 A2301  A2301  B0801  B1510  Cw0701  Cw1601 GKKHYMLKHLVWASREL  a1288 
    
CAP084 A2902  A7401  B1503  B4407  Cw0210  Cw0701 TGTEELRSLYNTVATLY b183 
    
CAP210 A6802  A6802  B1510  B1510  Cw0304  Cw0304 NTMLNTVGGHQAAMQMLKDTINEEAAEWDRLHPV b70 
 A6802  A6802  B1510  B1510  Cw0304  Cw0304 GPKEPFRDYVDRFFKTLRAEQATQDVKNWMTDTL a153 
    
CAP256 A2902  A6601  B1503  B5802  Cw0401  Cw0602 PRTLNAWVKVIEEKAF b58 
 A2902  A6601  B1503  B5802  Cw0401  Cw0602 GATPQDLNTMLNTVGGHQAAMQMLK b58 
    
CAP257 A2301  A2902  B4202  B4403  Cw1701  Cw1701 GKKHYMLKHLVWASREL a775 
 A2301  A2902  B4202  B4403  Cw1701  Cw1701 MREPRGSDIAGTTSTL* b115 
        
    
* No predicted epitope within the peptide matches the 
participant's HLA   
a Derived from deconvoluting the pool matrix ELIspot response and subsequently confirming with single peptides  
b Derived from deconvoluting the pool matrix ELIspot response only  
CELISpot data provided by C. Gray (NICD)  
   
 
3.2.9 HLA-B*57/B5801-negative study participants infected with variants carrying 
the escape mutations T242N and A146X have lower viremia during acute infection 
 
The T242N and A146X sites were detected by a naïve scan to detect associations between 
Gag amino acid polymorphisms and lower viral loads and CD4+ counts at 12 months 
postinfection.  The mechanism of viral control by individuals carrying HLA-
B*57/B*5801 alleles remains unclear although targeting of the immunodominant epitopes 
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Leslie et al., 2004; Kiepiela et al., 2004).  The fitness cost incurred by the acquisition of 
escape mutations in these epitopes (especially for the T242N mutation) is thought to play 
a role in improving disease outcomes in HLA-B*57/B*5801 positive individuals.  To 
confirm that the T242N and A146X mutations contribute to lower viremia and higher 
CD4+ counts during acute infection, the nine T242N/A146X+ participants were grouped 
and their viral loads and CD4+ counts compared to the rest of the cohort (n = 12).  Viral 
load and CD4+ count dynamics up to 15 months postinfection in the nine individuals 
infected with T242N/A146X mutants were compared to those of the rest of the cohort 
(Figure 3.8A and B).   At all time-points the mean log viral load was lower and CD4+ 
count was higher in the individuals infected with the T242N/A146X mutants.  
Comparison of the viral load and CD4+ counts at 12 months revealed that the individuals 
with the transmitted escape variants had lower viral loads and higher CD4+ counts.  At 12 
months postinfection (median log VL 4.26 vs. 4.92, p = 0.0276 and median CD4+ count 
499.0 vs. 322.5, p = 0.0173), (Figure 3.9A and B). At three months, these participants 
also had significantly lower viral loads and higher CD4+ counts (median log VL 4.53 vs. 
5.09, p = 0.0077 and median CD4+ count 652.0 vs. 460.0, p = 0.0129), (Figure 3.9C and 
D).  This suggests that the possible protective effect of the HLA-B*57/B*5801 associated 
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Figure 3.8: Mean and standard error of A) log viral loads and B) CD4+ counts over a 15 month period for 
the 21 study participants. The T242N/A146X+ participants are shown in red and the T242N/A146X- 
participants are shown in blue. 
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Figure 3.9: Viral Load and CD4+ counts of study participants grouped according to the presence or 
absence of the T242N and/or A146X mutations at enrolment. The 21 B*57/B*5801 negative individuals 
were split into a group infected with viral strains carrying both the TW10 escape mutation and the ISW9 
processing escape mutations (n = 9) and a group infected with viruses that did not carry these mutations (n 
= 12). The viral load and CD4+ counts at 3 (A and B) and 12 months (C and D) postinfection were 
compared between these two groups. HLA-B*5801 positive individuals were excluded from the analysis.  
 
3.2.10 Reversion in the presence of compensatory mutations does not restore viral 
fitness 
 
Several studies have used in vitro assays to shown that the T242N mutation incurs a 
replicative fitness cost (Brockman et al., 2007; Crawford et al., 2009; Schneidewind et 
al., 2009; Boutwell et al., 2009).  Although associated with lower viral load in this study, 
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(Draenert et al., 2004).  However, recent studies suggest that the occurrence of this 
mutation in combination with other HLA-B*57B*5801 associated escape mutations 
contributes to reduced replication capacity (Crawford et al., 2009; Boutwell et al., 2009).  
The in vitro assays have also shown that compensatory mutations associated with the 
T242N mutation partially restore viral fitness.  In this study, the HLA-B*57/B*5801 
negative participants who were infected with T242N variants did not have increased viral 
loads following reversion of the mutation (Figure 3.4; Table 3.2).  To investigate the 
replicative fitness cost incurred by the HLA-B*57/B*5801 associated mutations, gag 
genes from two timepoints were cloned from one participant (CAP061).  The two 
sequences were identical except that the later sequence,  sampled at 29.7 months 
postinfection, had reverted to wild-type consensus states at three positions: 146 (146A), 
147 (147I) and 242 (242T) in the two epitopes, ISW9 and TW10.  Both of these 
sequences also carried the compensatory mutations H219Q, I223V, M228I and S252H 
(Figure 3.10A).    
 
To compare the effect in different genome backgrounds, gag genes were cloned into two 
different infectious molecular clones, pBR246-F10 (subtype C) and NL4-3 (subtype B) 
(Appendix F).  As a control, a subtype C consensus p24 fragment was cloned into the 
pBR246-F10 backbone.  To generate infectious viral stocks, HEK293T cells were 
transfected with the DNA constructs.  Viruses were harvested at 48 hr posttransfection for 
the NL4-3 chimeras and at 72 hr for the pBR246-F10 chimeras and quantified using p24 
ELISA.  For the pBR246-F10 variants, there was no significant difference in p24 
concentration for the two CAP061 variants and the pBR246-F10 wild-type, whereas the 
p24 concentration for the variant carrying the gag consensus p24 was higher, suggesting 
that it was the fittest of the variants (Figure 3.10B).  For NL4-3 chimeras, a similar trend 
was observed for the CAP061 variants whereas the NL4-3 wild-type had lower p24 
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Figure 3.10: Comparison of the chimeric gag variants constructed using either a subtype C or B genome 
backbone.  A) Sequence differences between the two CAP061 chimeric constructs obtained at 1.9 and 29.7 
months postinfection (CAP061_1.9 and CAP061_29.7, respectively) used for in vitro replication assays. 
The ISW9 and TW10 epitopes are highlighted in grey and the putative compensatory mutations are 
highlighted in yellow.  B) The concentration of p24 (ng.ml
-1
) obtained through p24 ELISA of the culture 
medum harvested 72 h after transfection of 293T cells with pBR246-F10 constructs. C) The concentration 
of p24 (ng/ml) obtained through p24 ELISA of the culture medium harvested 48 h after transfection of 
293T cells with NL4.3 constructs.  
 
To assess differences in the replicative capacity of variants carrying the two CAP061 
derived gag genes, PBMCs from four HIV negative donors were infected with 20 ng p24 
from each of the viral stocks and replication was monitored by using an ELISA assay to 
quantify p24 concentrations in the culture supernatant.  Although the clones in the 
subtype C backbone did not replicate as well as those in the subtype B backbone (Figure 
3.11), both sets of viruses displayed the same trend in replication kinetics.  For clones in 
the subtype C  backbone, that carrying  the T242N, A146P and I147L mutations 
(CAP061_1.9) replicated to higher titres than the one carrying the N242T reversion 
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subtype C consensus p24 replicated best (Figure 3.11A).  For the clones in the subtype B 
backbone, a similar trend was observed (Figure 3.11C-E) with the T242N escape mutant 
replicating to higher titres than the revertant.  This result was unexpected as  several 
studies have previously shown the T242 variant to be fitter than the N242 variant 
(Martinez-Picado et al., 2004; Brockman et al., 2007; Schneidewind et al., 2009).  It is 
possible that the H219Q, I223V, M228I and S242H compensatory mutations present in 
the CAP061 viruses might themselves have a context specific fitness cost that lowers the 
replicative value of T242 relative to N242 to the point where the T242 wild type in the 
presence of these compensatory mutations actually has less replicative value than the 
N242 escape mutant.  Alternatively, there may be other HLA-B*57/B*5801 associated 
mutations in other viral proteins which could be making the reverted variant (T242) fitter 
in vivo. Investigation of the impact of individual mutations or combinations of these four 
compensatory mutations in the presence of T242 and N242 on viral replication might 
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Figure 3.11: Replication kinetics of the viral constructs carrying the gag genes from CAP061 before 
(CAP061_1.9) and after (CAP061_29.7) reversion of the TW10 and ISW9 escape mutations. A) 
Representative growth curve of infection of PBMCs from donor 1625 with chimeric pBR246-F10 viruses 
carrying the CAP061 and p24 consensus gag genes.  B) Comparison of the slopes of viral spread between 
day-7 and day-14 for the chimeric pBR246-F10 viruses when four donor PBMCs were infected. C) 
Representative growth curve of infection of PBMCs from donor 1625 with chimeric NL4-3 viruses carrying 
the CAP061 gag genes. D) Growth curve for the combined donor PBMCs infected with NL4-3 chimeric 
constructs. E) Comparison of the slopes of viral spread between day-7 and day-14 for the chimeric NL4-3 
viruses when four donor PBMCs were infected. Twenty nanograms of p24 of viral stocks were used to 
infect 5.0x10
5
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3.3 Discussion 
 
This study presents an association of two Gag polymorphisms, A146X and T242N, with 
lower viral loads and higher CD4+ counts in a cohort of HIV-1 subtype C acutely 
infected females.  These two polymorphisms are well-known CTL escape mutations 
generally occurring in HLA-B*57/B*5801 positive individuals and within these 
individuals they have previously been indirectly associated with effective control of HIV-
1 (Kiepiela et. al., 2004; Crawford et al., 2009).  In this study individuals were 
investigated who were infected with viruses carrying these escape mutations during acute 
infection but who were, HLA-B*57/B*5801-negative.  These individuals had possibly 
acquired their viruses from HLA-B*57B*5801-positive donors.  Further evidence that 
these viruses were passaged through B*57/B*5801 positive individuals came from the 
finding that the viruses harboured additional HLA-B*57/B*5801 associated mutations in 
both Gag and Nef.  The finding that viruses with  CTL evasion and accessory 
compensatory mutations imprinted on their genomes within previous hosts might be 
easier to control following their transmission to HLA mismatched recipients has 
subsequently been supported by a Zambian study of transmission pairs (Goepfert et al., 
2008) 
 
The T242N mutation has a well established replicative fitness cost (Martinez-Picardo et. 
al., 2006) and rapidly reverts to wild type upon transmission to HLA-B*57B*5801-
negative (i.e. HLA-mismatched) recipients (Leslie et. al., 2004).  Here, reversions of 
transmitted T242N mutations were observed in 5/6 (83%) infected individuals in the 
absence of HLA-B*57B*5801 mediated selection.  The N242T reversion mutation often 
occurs via an N-S-T route.  In this study, the “S” reversion intermediate was observed in 
two participants (CAP088 and CAP225).  Although reversion of the T242N escape 
mutation was expected to restore viral replicative fitness and result in increased viral 
loads, this was not apparent within the individuals studied here.   In vitro replication 
assays of chimeric viruses carrying gag sequences from an infected individual that 
differed only in at positions 146, 147 and 242 showed that reversion, in the presence of 
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in vitro.  This may explain why an immediate increase in viral loads was not observed 
concomitant with the occurrence of the reversion mutations within the studied 
individuals.  However, further tests need to be carried out to asses the impact of the 
T242N-associated secondary mutations. 
 
The second mutation identified as being associated with higher CD4+ counts and lower 
viral loads, A146X, is a processing escape mutation flanking the ISW9 epitope on the N-
terminus of Gag (Draenert et. al., 2004).  Whereas the mutation on its own is not known 
to incur any replicative fitness costs in vitro (Draenert et al., 2004), its presence in 
combination with other B*57/B*5801 associated mutations has been shown to have a 
fitness cost (Crawford et al., 2009; Boutwell et al., 2009).  The delayed reversion of the 
A146X mutation may suggest that it probably incurs a fitness cost that is lower than that 
of the more rapidly reverting T242N mutation.  In this study, reversion was observed in 
only 2/9 (22%) of the infected individuals during the first 2 years of infection.  Out of the 
nine sampled viruses carrying the A146X mutation, six (67%) also carried the T242N 
mutation.   Conversely, all of the viruses carrying the T242N mutation also carried the 
A146X mutation. This supports the previously suggested existence of an epistatic 
association between the two mutations (Leslie et. al., 2004).  
 
The presence of A146X in the absence of T242N in the sampled virus sequences could 
suggest:  1) that the immediate donor was HLA B*57/B*5801 positive and the T242N 
mutation reverted before the individual was enrolled into the study or 2) the immediate 
transmitter was HLA-B*57B*5801 negative and the more unstable T242N escape 
mutation occurred in an earlier HLA-B*57B*5801 positive host and by passage through 
the immediate donor reverted before transmission to the current study participant. The 
immediate donors of viruses carrying T242N are more likely to have been HLA-
B*57B*5801 positive as this mutation reverts rapidly upon transmission as compared to 
A146X.  There was no reversion to consensus sequence observed in the three individuals 
with the A163X escape mutation in the KF11 epitope, despite the absence of the proposed 
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Compensatory mutations have been reported which partially recoup the negative fitness 
effects of the T242N mutation (Martinez-Picardo et. al., 2006; Brockman et al., 2007; 
Leslie et al., 2004).  Variation at positions 219, 223, 228, 248 and 252 has been 
reportedly associated with the T242N escape mutation.   Associations between previously 
described compensatory mutations and the T242N mutation were investigated. Of the six 
individuals infected with viruses carrying the T242N mutation, the H219Q compensatory 
mutation was found in only 1/6 of the HLA-B*57B*5801-negative individuals infected 
with the T242N variant.  This individual (CAP061) was infected with viruses that both 
had variation at three other sites (I223V, M228I, S252H/G) and experienced reversion of 
the T242N but not the H219Q mutations at 23.9 months postinfection,.  All the other 
participants except CAP225 had at least one previously described compensatory 
mutation.  The  presence of previously described compensatory mutations in all but one 
of the study participants infected with viruses carrying the T242N mutation supports the 
hypothesis that these viruses previously underwent HLA-B*57/B*5801 selection.  It is 
possible that these compensatory mutations themselves have a fitness cost in the absence 
of T242N as shown by the in vitro replication assays. 
 
This study demonstrates that, during the acute phase of infection at least, individuals who 
have received viruses carrying markers of previous selection in HLA-B*57/B*5801 
positive individuals experience both significantly lower viral loads and higher CD4+ 
counts than individuals infected with viruses without these markers.   While as yet 
unproven, these lower initial viral loads and higher CD4+ counts at the onset of infection 
may slow disease progression in these individuals.  Importantly, these findings are 
supported by another independent study following HLA-mismatched transmission pairs 
(Goepfert et al., 2008).  It has additionally been shown here, that contrary to expectations, 
reversion of the A146P and T242N mutations to wild-type is not invariably associated 
with increased viral replicative fitness. Furthermore, in vitro replication assays in fact 
demonstrated that the N242T reversion mutatants may in some cases at least be less 
replicationally fit than the T242N mutant. This suggests that the introduction of wild type 
T242 within the context of evolved gag sequences that have developed other stabilising 
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replicative capacity.  The possibility that an interacting network of viral attenuating 
mutations may be responsible for the lower viral loads experienced by the individuals 
studied here, should be investigated further as the existence of such networks could have 
important implications for the design of CTL based vaccines.  Further work is needed to 
investigate the role of compensatory mutations on replication fitness as these mutations 
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Abstract 
 
This study investigated both the dynamics of early CTL escape mutations in Gag and Nef 
in individuals carrying the HLA-B*5801 allele (n = 6), and the impact of these mutations 
on disease progression.  Escape was found to predominantly occur in two HLA-B*5801 
restricted epitopes, TW10 (n = 4) in Gag and KAF9 in Nef (n = 6).  Escape mutations in 
the TW10 epitope appeared within the first 3.75 months postinfection while those in 
KAF9 were detected within 6.25 months postinfection.  Although some rarer mutations 
preceded the emergence of the T242N mutation in TW10, most of these other mutations 
did not persist.  Furthermore, compensatory mutations located upstream of the TW10 
epitope were associated with escape in the TW10 epitope.  Importantly, both targeting of 
TW10 and the T242N mutation were associated with higher CD4+ counts at 12 months 
postinfection (p = 0.0231 and p = 0.0282, respectively) in HLA-B*5801 positive 
individuals.  The B*57/B*5801 associated escape mutations, A146X and T242X in Gag, 
were associated with higher CD4+ counts independent of the individuals’ HLA genotype 
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4.0 Introduction 
 
Several HLA class I alleles have been associated with improved disease outcome in HIV-
1 infected individuals including HLA-B*27, -B*57, B*5801 (Kiepiela et al., 2004; 
Kieiela et al., 2007; Frater et al., 2007; O’Brien et al., 2001).  Of these alleles, HLA-
B*57 and B*5801 are overrepresented in viral controllers (Kiepiela et al., 2007; Migueles 
et al., 2000; Pereyra et al., 2008; Miura et al., 2009).  The mechanisms through which 
individuals carrying these alleles control viremia are still not fully understood.  Several 
studies have reported that strong CTL responses which target several epitopes in the 
conserved p24 region of Gag contribute to viral control (Kiepiela et al., 2007; Altfeld et 
al., 2006; Scherer et al., 2004).  However, some studies have suggested that CTL driven 
selection of viral escape mutations that come with replicational fitness costs is a major 
contributing factor to better control of viremia in individuals carrying particular HLA 
alleles (Leslie et al., 2004; Martinez-Picardo et al., 2006; Brockman et al., 2007; 
Crawford et al., 2007).  One of the most extensively studied escape mutations associated 
with HLA-B*57/B*5801 alleles is the T242N mutation which occurs in the 
immunodominant TW10 epitope in the p24 region of Gag.  During acute infections this 
epitope is one of the first targeted by CTLs in HLA-B*57/B*5801 positive individuals 
(Goulder and Watkins, 2004; Brumme et al., 2008).  In vitro studies have directly shown 
that the T242N mutation incurs a replicational fitness cost.  However, secondary 
mutations upstream and downstream of the epitope have been reported to partially 
compensate for fitness lost to the T242N mutation (Brockman et al., 2007; Leslie et al., 
2004). 
 
 HLA-B*5801 has been associated with lower viral loads in subtype C chronic infection 
(Kielpela et al., 2007).  We were interested in whether this effect was seen within the first 
year of infection, and to explore the mechanism behind the observed viremic control in 
these individuals.   In this chapter we investigate the kinetics of CTL escape in HLA-
B*5801 positive individuals (n = 6) and the impact of CTL escape on disease progression.  
In the previous study (Chapter 3), it was shown that HLA-B*57/B*5801 negative 
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former hosts were better controllers of viral replication up to at least 12 months 
postinfection.  The study described here focuses on the analysis of early CTL escape 
associated viral evolution of Gag and Nef in HLA-B*5801 positive participants from 
enrolment to at least one year postinfection.   
 
4.1 Materials and Methods 
 
4.1.1 Study subjects 
 
Participants in this study are part of the CAPRISA 002 cohort investigating the role of 
viral and immunological factors in acute and early HIV-1 infections (van Loggerenberg et 
al., 2008; Chapters 2 and 3). A total of 36 individuals from the cohort who had reached 
12 months postinfection were included in this study, of which 24 were part of the study 
described in Chapter 3.  Of the 36 participants, six were HLA-B*5801 positive. 
 
4.1.2 RNA isolation, RT-PCR and viral sequencing 
 
Sequencing was carried out at enrolment, three and six months postinfection for all the 36 
study partiacipants who had reached 12 months postinfection at the time of this study. 
RNA isolation, RT-PCR and population sequencing were carried out as outlined in 
section 2.1.2.  Cloning was carried out for the HLA-B*5801 positive study participants 
for samples up to at least 12 months postinfection.  The PCR amplicons were cloned into 
the pGEM-T Easy cloning system according to the manufacturer’s instructions (Promega, 
USA).  Positive clones were sequenced in the same way as the PCR products. 
 
4.1.3 HLA typing 
 













Chapter 4: Early Escape in HLA-B*5801 Positive Study Participants Associated with 
High CD4+ Counts 
 
 
 - 96 - 
4.1.4 IFN-γ ELISpot assay 
 
The ELISpot assay was carried out to determine T cell responses in Gag and Nef in the 
six HLA-B*5801 positive study participants.  The assay was carried out as outlined in 
section 3.1.4 (data provided by C. Gray, NICD). 
 
4.1.5 Statistical Analyses 
 
Wilcoxon rank-sum tests were used to compare viral loads and CD4+ counts. The 





The CAPRISA 002 study follows high-risk HIV negative individuals who were enrolled 
into the acute infection cohort upon HIV infection.  At the time of this study,  36 enrolees 
had reached one year postinfection, of which 6 possessed the HLA-B*5801 allele that is 
associated with control of viral replication and long-term non-progression (Kiepiela et al., 
2007; Goulder et al., 1997).   
 
The study described here investigates the role of CTL escape in HLA-B*5801 positive 
individuals on disease progression using viral load and CD4+ counts at one year 
postinfection as a marker of disease progression.  CTL escape in Gag and Nef proteins 
was analysed.  A total of 437 gag sequences were generated from the six B*5801 positive 
individuals of which 11 sequences were representative of the viral population obtained 
through direct sequencing of PCR products, while a further 426 sequences were obtained 
from cloning (median = 10 sequences per sample; range 3 – 29).  For nef, the total 
number of sequences obtained was 387, of which 16 were generated from direct 
sequencing, and a further 371 sequences were generated through cloning (median = 23 
sequences per sample, range 21 -24).  The cloning of gag and nef genes was carried out to 
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4.2.1 Identification of putative CTL escape mutations in Gag and Nef in participants 
with HLA-B*5801 alleles 
 
CTL escape within the first year of infection was assessed in the six HLA-B*5801 
positive study subjects.  CTL escape mutations in epitopes restricted by this allele have 
been well described and include those in the TW10, ISW9 and KF11 epitopes in Gag; and 
HW9, YY8 and KAF9 epitopes in Nef.  Additional putative CTL epitopes associated with 
other HLA alleles of the host were identified by using the list of known HLA restricted 
epitopes (www.hiv.lanl.gov). Evidence of possible CTL escape was firstly inferred from 
the presence of amino acid substitutions within epitopes that were potentially restricted 
by any one of a participant’s HLA alleles.  Reversion has been associated with changes 
towards consensus (Li et al., 2007; Leslie et al., 2004), and conversely CTL escape 
mutations are often associated with changes from high to low amino acid frequency 
within HLA restricted epitopes (Liu et al., 2007).  Thus, sequences from the study 
participants were scanned for mutations yielding substitutions to low frequency amino 
acids relative to subtype C sequences in public sequence databases (www.hiv.lanl.gov).  
These changes from high to low frequency amino acid provided the second line of 
evidence of CTL escape.   A total of 413 Gag and 586 Nef amino acid sequences from the 
Los Alamos sequence database were used in the determination of amino acid frequency 
spectra.  One flanking amino acid residue on each end of known/predicted epitopes were 
included in the analysis as CTL escape has been previously reported to also occur in 
residues immediately adjacent to epitopes (Draenert et a., 2004).  The HLA data for the 
study participants is shown in Appendix A. 
 
Out of the 7 putative epitopes showing escape in Gag and Nef (Table 4.1), 4 (57%) were 
associated with HLA-B*5801 restriction.  Five of the epitopes (TW10; TSTLQEQIAW, 
KF9; KAAFDLSFF, QW9; QATQDVKNW, FL9; FPVRPQVPL and WI8; WPAVRERI) 
are bonafide optimal epitopes (www.hiv.lanl.gov) while two epitopes (YL9; 
YSKKRQEIL, YY9; YTPGPGVRY) have not been shown to be optimal epitopes.  
However, the fact that the mutating residues went from high to low frequency amino acid 
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participants developed escape mutations in the immunodominant TW10 epitope, with the 
T242N mutation in TW10 becoming fixed in all the 4 participants.  All 6 subjects also 
escaped in KAF9 epitope in Nef.  CTL escape was detected in at least 2 epitopes per 
participant with sequences from two participants showing escape in five epitopes 
(CAP217 and CAP274; Table 4.1). 
 
Table 4.1: Summary of putative CTL escape in the 6 HLA-B*5801 positive participants monitored for up 
to at least 14.5 months post infection.  Underlined (bold) are the residues where putative escape mutations 
occurred.  The timepoints where the mutations were first detected are shown. 
 
Epitope HLA Region CAP217 CAP229 CAP239 CAP268 CAP270 CAP274 
TTSTLQEQIAWM B*5801 p24 Gag 3.75 2.00 0.50   2.50 
EQATQDVKNWM B*5801 p24 Gag  23.00     
YKAAFDLSFFL B*5801 Nef 2.25 6.25 0.50 2.00 3.25 2.50 
IYSKKRQEILD Cw*0602/B*1503 Nef 2.25      
NYTPGPGVRYP B*5801 Nef 5.75      
GFPVRPQVPLR B*0705 Nef    6.00   
GWPAVRERIR B*0801 Nef     7.25  
 
 
4.2.2 Early evolution in p24 Gag is characterised by escape in the B*5801 restricted 
TW10 epitope 
 
Analysis of viruses infecting the HLA-B*5801 positive participants showed that escape 
mutations developed in the immunodominant TW10 epitope in 4 out of the 6 individuals 
within 3.75 months postinfection, with the earliest variation in the epitope being detected 
by 0.50 months postinfection (CAP239; Figure 4.1).  The emergence of the T242N 
mutation was often preceded by variation at other sites within the epitope.  Variation was 
detected at six sites within the epitope; positions 3, 4, 5, 7, 8, and 9 (T242, L243, Q244, 
Q246, I247, and A248, respectively).  In 4 participants (CAP217, CAP229, CAP268 and 
CAP270), the earliest sampled viruses had only the wild type TW10 sequence while in 
the remaining 2 individuals (CAP239 and CAP274) the baseline virus was a mixed 
population of wild-type and variants harbouring the escape mutations within the TW10 
epitope (Figure 4.1 and Figure 4.2).  The presence of variation at the earliest timepoint 
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were transmitted escape variants.  The predominant mutation within the TW10 epitope 
was T242N and once this mutation arose it became fixed in all virus sequences, 
suggesting that it provided the most optimal balance between escape and viral fitness.  In 
all four participants who harboured viruses carrying this mutation, the mutation became 
fixed within the virus population within 6.75 months of infection.    
 
IFN-γ responses, detected using the ELISpot assay, were available on the 6 participants 
(data provided by Clive Gray, NICD).  Three out of four of the participants whose virus 
escaped in the TW10 epitope had a reduction in ELIspot responses to peptides containing 
the TW10 epitope (Figure 4.1).  The fourth individual (CAP274) whose virus carried the 
T242N escape mutation did not have detectable responses to the TW10 epitope.  
However at 2.5 months post infection the escaped variant had already become the 
dominant virus, suggesting that a transient CTL response to TW10 may have already 
waned resulting in negative ELIspot assays.  The virus infecting CAP274 carried three 
mutations in the TW10 epitope at enrolment (2.5 months postinfection).  In the two 
individuals where CTL escape was not identified (CAP268 and CAP270), only one had 
ELIspot responses to TW10 (CAP268).  In CAP268, responses were 518 SFU.10
-6
 cells 
at 2.0 months which strengthened to 2523 SFU.10
-6
 cells at 6.0 months.  In the other 
individual whose virus did not escape in this epitope (CAP270), there were no responses 
detected to the TW10 epitope despite being infected by a virus carrying a wild type 
TW10 epitope.  It is unclear as to why this individual (CAP270) did not have immune 
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Figure 4.1: Sequence alignment of the TW10 epitope showing changes in the 6 HLA-B*5801 positive 
participants over time. The relative frequency of variants carrying the respective mutations are indicated 
along with the ELIspot responses.  Grey highlighting indicates different timepoints for each participant. 
 
 
PID  Variant  Mo. PI Frequency Elispot response 
         (SFU/10
6
 PBMC) 
  TSTLQEQIAW*  
 
CAP217  ..........   2.25      6/6
a
   218  
  ..........    3.00     3/3     2038  
  ..........    3.75     13/18  2008  
  ....P.....    3.75     4/18    
  ......E...    3.75     1/18    
  ..........    4.25     2/12  1360  
  ..N.......    4.25     6/12       
  ....P.....    4.25     4/12    
  ..N.......    4.75     12/12   485  
  ..........    5.75     1/9    195  
  ..N.......    5.75     7/9     
  ....T.....    5.75     1/9     
  ..N.......    6.75     10/10
a 
   
b
ND  
  ..N.......   15.00     14/14    ND  
 
CAP229  ..........    1.75     12/12
a
   1188  
  ..........    2.00     6/10   105  
  ........T.    2.00     2/10    
  ..N.....T.    2.00     2/10    
  ..N.....T.    2.25     6/6a       88  
  ..N.....T.    5.25     3/3     ND  
  ..N.....T.    6.25     23/23
a
     ND  
  ..N.....T.   20.00     15/15    ND  
  ..N.....T.   23.00     24/24    ND  
  ..N.....T.   26.25     15/15    ND  
  ..N.....T.   30.50     16/16    ND  
 
CAP239  .......V..    0.50     20/21
a
    ND  
  ...I...VT.    0.50     1/21    
  ..N....VT.    1.25     27/27   380  
  ..N....VT.    1.50     19/19
a
    80  
  ..N....V..    5.50     9/9a   113  
  ..N....V..   19.75     9/9     ND  
 
CAP268  ..........   2.00     6/6
a
     518 
  ..........   6.00     8/8
a
  2523 
  ..........  13.25      12/12
a
    ND 
  ..........  21.50     8/8     ND 
  ..........  34.25     10/10    ND 
 
CAP270  ..........    2.00     9/9      
c
NR  
  ..........    3.25     7/7       NR  
  ..........    7.25     9/9       ND  
  ..........   14.50     29/29      ND  
 
CAP274  ....H..VQ.    2.50     2/9     NR   
  ..N....VQ.    2.50     7/9      
  ..N....VQ.    5.50     7/7     ND  
  ..N....VQ.   15.00     19/19    ND  
 
a
Pop – population sequencing 
b
Not done  
c
No response 
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Figure 4.2: Kinetics of CTL escape in the TW10 epitope (TSTLQEQIAW) in the 4 participants whose 
viruses escaped in the epitope.    
 
4.2.3 Escape in the B*5801-restricted KAF9 epitope  
 
HLA- driven CTL escape in the Nef KAF9 epitope (KAAFDLSFF) has been previously 
described (Leslie et al., 2005; Moore et al., 2002).  All 6 of the B*5801 positive study 
participants showed ELIspot responses to Nef peptide YKAAFDLSFFLKEKG which 
overlaps with the KAF9 epitope (Figure 4.3).  The viruses infecting 2 of the 6 HLA-
B*5801 positive individuals were already carrying escape mutations at enrolment into the 
study whereas the other four individuals developed escape mutations within the epitope 
during the course of the study.  The most commonly reported B*5801 associated escape 
mutation in the KAF9 epitope is A83G (Leslie et al., 2005).  This mutation was detected 
in 4 participants (CAP229, CAP239, CAP268 and CAP274).  In one participant 
(CAP217), the dominant escape mutation was an A83E mutation and the A83G was only 
observed transiently as a minor variant (1/24 clones) at 5.75 months postinfection.  In 
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and was fixed by 14.5 months (Figure 4.3 and Figure 4.4).  In 2 individuals (CAP268 and 
CAP274), the viruses at enrolment (2.0 and 2.5 months postinfection, respectively) 
already carried the A83G and S88G mutations.  The virus infecting CAP274 also carried 
an F85V mutation in the KAF9 epitope at enrolment.  The presence of these mutations 
could have been a result of early escape.  However, it is possible that these individuals 
were recipients of transmitted escape mutants from a B*5801 positive donor. 
 
 
Figure 4.3: Sequence alignment of the Nef KAF9 epitope showing changes in the 6 HLA-B*5801 positive 
participants over time. The timing of appearance of viruses carrying escape mutations, their relative 





PID  Variant  Mo. PI Frequency Elispot response 
         (SFU/10
6
 PBMC) 
  KAAFDLSFF* 
   
CAP217  .........   2.25  20/24
a
   1238 
  ...V.....   2.25  2/24   
  -----....   2.25  1/24   
  .E.......   2.25  1/24   
  .........   5.75  10/24         0 
  .E.......   5.75  13/24
a
   
  .G.......   5.75  1/24   




CAP229  .........   1.75  23/23
a
   1078 
  .........   6.25  23/24
a
     352 
  R........   6.25  1/24      
  .G.......  20.00  24/24
a
       ND 
 
CAP239  ...V.....   0.50  24/24
a
       ND 
  ...V.....   1.25  23/23
a
     10 
  .G.V.....   5.50  22/23
a
       367 
  .........   5.50  1/23   
  .G.V.....  19.75  17/23
a
       ND 
  .G.......  19.75  6/23   
 
CAP268  .G....G..   2.00  
a
   2898 
.G....G..   3.75  
a
     ND 
.G....G..   6.00  
a




 .........   2.00  24/24
a
     ND 
  .........   3.25  23/24
a
     ND 
  ......G..   3.25  1/24
a
   
  ......G..  14.50  22/22
a
     ND 
 
CAP274  .G.V..G..   2.50  23/23
a
   1080 
  .G.V..G..   5.50  21/21
a
     ND 
  .G.V..G..  15.00  23/23
a
     ND 
 
a




A response of 245 SFU.10
-6
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Figure 4.4: Kinetics of CTL escape in the 6 HLA-B*5801 positive participants in the Nef KAF9 
(KAAFDLSFF) epitope.   
 
4.2.4 Putative CTL escape in other Gag and Nef epitopes in participants carrying 
the HLA-B*5801 allele  
 
In addition to escape in the Gag TW10 and Nef KAF9 epitopes, HLA-B*5801 positive 
individuals also harboured viruses that showed putative escape in other epitopes (Table 
4.2). The mutations were designated as CTL escape if they met the criteria used in 
Chapter 2 (section 2.1.5).  A total of 5 additional putative escape epitopes were identified.  
One of the epitopes was located in Gag while four were in Nef.  The epitope in Gag was 
restricted by HLA-B*5801 (CAP229; Table 4.2) and is a well-known HLA-B*5801 
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one epitope was restricted by HLA B*5801 (CAP217; Table 4.2).  The other two epitopes 
were restricted by HLA-B*0705 and HLA-B*0801 while one was potentially cross-
restricted by Cw*0602 and B*1503 (Table 4.2).   
 
Table 4.2: Additional epitopes showing putative escape in Gag and Nef in the six HLA-B*5801 positive 
individuals.  The top sequence represents the consensus subtype C sequence. 
PID Mo. PI Epitope/Region 
Restricting HLA/ 
Frequency Database Frequency (%) 
     
  IYSKKRQEILD (Nef) Cw*0602/B*1503 Y – 71.33; K - 83.45; R - 98.98 
CAP217 2.25 .H......... 23/24 H – 11.6 
 2.25 --......... 1/24  
 5.75 .H......... 16/24  
 5.75 .H.Q....... 7/24 Q - 8.36 
 5.75 .H.Q.G..... 1/24 G - 0.68 
 15 .H.E....... 17/22 E - 0.68 
 15 .H.Q....... 5/22   
     
  NYTPGPGVRYP (Nef) B*5801 V - 83.96 
 2.25 ........... 24/24  
 5.75 ........... 18/24  
 5.75 .......I... 6/24 I - 8.02 
  15 ........... 22/22   
     
  EQATQDVKNWM (p24) B*5801 T - 95.88; D - 71.91 
CAP229 1.75 ........... 12/12  
 2 ........... 10/10  
 2.25 ........... 6/6  
 5.25 ........... 3/3  
 6.25 ........... 23/23  
 20 ........... 15/15  
 23 ...S.E..... 24/24 S - 3.87; E - 27.6 
 26.25 ...S.E..... 14/15  
 26.25 ...S.G..... 1/15 G - 0.24 
 30.5 ...S.E..... 15/16  
  30.5 ........... 1/16   
     
CAP268  GFPVRPQVPLR (Nef) B*0705 R - 87.88 
 2 ........... Pop  
 3.75 ........... Pop  
  6 ....K...... Pop K - 8.53 
     
CAP270  GWPAVRERIR (Nef) B*0801 N - 5.8; R - 97.1; R - 93.17 
 2.00 ...N....M. 24/24  
 7.25 ...N....M. 11/24  
 7.25 ...D....M. 11/24 D - 7.51 
 7.25 ...N...GM. 1/24 G - 0.17 
 7.25 ...D.G..M. 1/24 G - 0.85 
 14.50 ...D...KM. 1/22 K - 3.41 
 14.50 ...D....M. 1/22  
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4.2.5 Disease progression in HLA-B*5801 positive individuals is influenced by 
immune targeting of TW10 and escape at T242 
 
Control of viral replication in HIV-1 infected individuals carrying the HLA-B*5801 allele 
is thought to be through targeting of various functionally constrained epitopes (Friedrich 
et al., 2004; Peyerl et al., 2003).  TW10 is one of the first immunodominant epitopes that 
are targeted following infection of HLA-B*5801 positive individuals (Leslie et al., 2004; 
Martinez-Picardo et al., 2006; Goulder et al., 1996).  CTL escape mutations in this 
epitope have an associated replicative fitness cost (Brockman et al., 2007; Martinez-
Picardo et al., 2006).  In this study, the viral load and CD4+ cell count trajectories of the 
six HLA-B*5801 positive study participants were analysed to determine the impact of: a) 
TW10 targeting and CTL escape through mutations at T242, b) TW10 targeting in the 
absence of CTL escape mutations at T242, and c) An absence of both TW10 targeting 
and CTL escape mutations at T242.   
 
Viral load trajectories for the six HLA-B*5801 positive individuals showed that 
participants who targeted the TW10 epitope and harboured viruses that escaped this 
response (CAP217, CAP229, CAP239, and CAP274) had moderate viral loads (black plot 
in Figure 4.5A).  CAP268 had ELISpot responses to the TW10 epitope but harboured 
viruses that did not carry the T242N mutation had the lowest viral load (blue plot in 
Figure 4.5A).  CAP270, the study participant who did not show any responses to the 
TW10 epitope and consequently did not introduce the escape mutation at T242, 
experienced persistently high viral loads, peaking at 1 680 000 RNA copies per mL at 
13.5 months postinfection (red plot in Figure 4.5A). 
 
CD4+ cell count trajectories showed that CAP270 also had the lowest CD4+ cells counts 
of any of the study participants (red plot in Figure 4.5B).  Based on the CAPRISA 
definition of rapid progression (CD4+ cell counts consistently below 350 by 12 months 
post infection) this individual was classified as a rapid progressor.  CAP268 the 
participant who responded to TW10 but whose infecting viruses did not develop the 
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individuals (CAP217, CAP229, CAP239, and CAP274) who responded to the epitope and 
harboured viruses that developed the T242N mutation had moderate to high CD4+ counts 
(black plot in Figure 4.5B).   
 
This suggests that targeting of TW10 epitope is associated with the preservation of CD4+ 




Figure 4.5:  Viral load and CD4+ count trajectories of the six HLA-B*5801 positive study participants 
including those infected with viruses that escaped an active TW10 targeted CTL response through 
introduction of the T242N mutation (black), the participant who harboured wild type virus and who did not 
have an immune response to the TW10 epitope (red); and the participant who responded to TW10 but 
whose infecting viruses did not accumulate escape mutations in the epitope (blue). 
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4.2.6 HLA-B*5801 immune responses targeting TW10 and T242N escape are 
associated with improved disease progression 
 
The previous study (Chapter 3; Chopera et al., 2008) showed that HLA-B*57/B*5801 
negative individuals infected with viruses carrying genetic traits indicative of their having 
been previously passaged through HLA-B*57B*5801 positive individuals, had lower 
viral loads and higher CD4+ counts, possibly due to the fitness cost of the escape 
mutations on the viruses. Specifically, the A146X (A = P or S) and T242N escape 
mutations identified in HLA-B*57/B*5801 restricted ISW9 and TW10 epitopes, 
respectively, were associated with better viral control.  To investigate the impact of T cell 
responses targeting the TW10 and escape in this epitope on disease progression we, 
therefore, excluded all HLA-B*57/B*5801 negative study participants who were infected 
with viruses carrying these mutations (A146X; X = I or S, T242X; X = N or S) (n = 13).  
A comparison of CD4+ counts and viral loads of the B*5801 positive (n = 6) and 
negative (n = 17) individuals at 12 months postinfection showed that there was no 
significant difference between the CD4+ counts and viral loads between these two groups 
(p = 0.1152 and p = 0.3471, respectively) (data not shown).   However, the B*5801 
positive individuals whose viruses developed the T242N mutation (n = 4) had 
significantly higher CD4+ counts compared to B*5801 negative participants whose 
viruses did not carry the A146X and T242X (X = N or S) mutations (p = 0.0282; Figure 
4.6A).  The viral loads were, however, not detectably different (p = 0.4465; Figure 4.6B).  
Comparison of CD4+ counts between the B*5801 positive participants who had 
responses to the TW10 epitope with the A146X and T242X variants showed that the 
B*5801 positive individuals had higher CD4+ counts though there was no difference in 
viral loads (Figure 4.6C and D).  These findings further point to the possibility that the 
targeting of the TW10 epitope and development of the T242N mutation may be 
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Figure 4.6: A) and B) CD4+ cell count and Viral Load comparison of HLA-B*5801 positive study 
participants who developed the T242N mutation (B*5801+/T242X+; n = 4) and the HLA-B*5801 negative 
who were not infected with viruses carrying B*57B*5801 associated A146X and T242X mutations 
(B*5801-/T242X-/A146X-; n = 17) at 12 months postinfection.  C) and D) CD4+ cell count and Viral Load 
comparison of HLA-B*5801 positive study participants who had ELISpot responses to the TW10 epitope 
(B*5801+/TW10+; n = 5) and the HLA-B*5801 negative who were not infected with viruses carrying 
B*57B*5801 associated A146X and T242X mutations (B*5801-/T242X-/A146X-; n = 17) at 12 months 
postinfection.  The 12 months postinfection viral loads and CD4+ counts refer to the closest sampled 
timepoint to 12 months. 
 
4.2.7 A146X and T242X mutations associated with higher CD4+ counts 
 
To determine the impact of the HLA-B*57/B*5801 associated mutations on viral load 
irrespective of the origin (transmitted or escaped) the CD4+ counts and viral loads of 
study participants whose viruses carried the A146X and T242X mutations (n = 17) 
relative to those of individuals whose viruses did not have these polymorphisms (n = 19) 
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mutants or who developed the mutations during follow-up were further grouped 
according to the mutations that the viruses carried (A146X, n = 5; T242X, n = 6; 
A146X/T242X, n = 6; Figure 4.7).  There was a general trend in CD4+ counts at 12 
months postinfection in participants whose viruses carried the escape mutations such that 
A146X < T242X < A146X/T242X (Figure 4.7).  This may suggest that the T242X 
mutation carries a higher fitness cost than the A146X mutations and both mutations have 
an additive fitness cost. Participants whose viruses had either or both polymorphisms had 
significantly higher CD4+ cell counts at 12 months postinfection than those whose 
viruses did not have the mutations (Non-Escape) (p = 0.0495).  The CD4+ counts of those 
participants infected with viruses carrying both mutations (A146X/T242X) were 
significantly higher than those participants infected with viruses carrying neither of the 




Figure 4.7: CD4+ counts at 12 months postinfection for study participants grouped according to the 
presence or absence of the A146X and/or T242X mutations.  Shown in red are the HLA-B*5801 positive 
study participants. 
 
4.2.8 Early escape may be facilitated by circulating compensatory mutations 
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Secondary mutations upstream and downstream of the TW10 epitope have been reported 
to partially restore viral fitness (Leslie et al., 2004; Brockman et al., 2007; Martinez-
Picado et al., 2006).  Analysis of Gag sequences from the six HLA-B*5801 positive 
individuals revealed that at enrolment, every individual already carried viral variants 
containing at least one mutation that is either known or strongly suspected to compensate 
for the replicative fitness costs of the T242N mutation  (Figure 4.8).  Previous reports 
have detected a high frequency of the compensatory mutation H219X in the absence of 
the T242N mutation, suggesting that the compensatory mutation does not readily revert 
following transmission to HLA-B*57/B*5801 negative individuals (Leslie et. al., 2004).  
All of the four study participants (CAP217, CAP229, CAP239, and CAP274) who 
developed the T242N mutation had at least one of the previously described compensatory 
mutations upstream of the epitope (Figure 4.8).  Interestingly, the one participant who 
showed ELISpot responses to the TW10 epitope but whose infecting viruses did not 
accumulate mutations within the epitope (CAP268) had no compensatory mutations 
upstream of the epitope at enrolment (2.0 months postinfection).  In this participant, the 
compensatory mutation at I223 developed at 13.25 months postinfection and was fixed by 
21.5 months postinfection (Figure 4.8).  However, the T242N mutation had still not been 
detected by 32.75 months postinfection.  In participant CAP239, an additional potentially 
compensatory mutation (M228L) was detected at 19.75 months postinfection (Figure 
4.8).  The high population-wide prevalence of these compensatory mutations may 
increase the rate at which viruses are able to escape TW10 targeted CTL responses 










Chapter 4: Early Escape in HLA-B*5801 Positive Study Participants Associated with 
High CD4+ Counts 
 
 
 - 111 - 
 
 
Figure 4.8: Alignment of sequences determined from clones sampled from the six HLA-B*5801 positive 
participants indicating the presence of previously described compensatory and escape mutations.  The 
compensatory sites are highlighted in yellow and the grey highlighting indicated minority variants.  The 
TW10 epitope is boxed and the Cyp A binding loop is underlined.  The sequences are aligned to the 
subtype C consensus p24 sequence and numbering is according to the HXB reference sequence. 
 
                        210       220       230       240       250       260           
PID          Mo.PI  |....|....|....|....|....|....|....|....|....|....|....|.. 
   INEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIAWMTSNPPIPVGDIY 
CAP217  2.25 ..........V.......V......D................................ 
  3.00 ..........V.......V......D................................ 
  3.75 ..........V.......V......D................................ 
  3.75 ..........V.......V......D.............P.................. 
  3.75 ..........V.......V......D...............E................ 
  4.25 ..........V.......V......D................................ 
  4.25 ..........V.......V......D...........N.................... 
  4.25 ..........V.......V......D.............P.................. 
  4.75 ..........V.......V......D...........N.................... 
  5.75 ..........V.......V......D...........N.................... 
  5.75 ..........V.......V......D.............T.................. 
  5.75 ..........V.......V......D................................ 
  5.75 ..........V.......V..................N.................... 
  6.75 ..........V.......V..................N.................... 
  6.75 ..........V.......V......D...........N.................... 
  15.00 ..........V.......V..................N.................... 
 
CAP229  1.75 ..........V............I.......................N.......... 
  2.00 ..........V............I.......................N.......... 
  2.00 ..........V............I...................T...N.......... 
  2.00 ..........V............I.......................N.......... 
  2.00 ..........V............I.............N.....T...N.......... 
  2.25 ..........V............I.............N.....T...N.......... 
  5.25 ..........V............I.............N.....T.............. 
  6.25 ..........V............I.............N.....T.............. 
  6.25 ..........V............I.............N.....T...N.......... 
  20.00 ..........V............I.............N.....T.............. 
  23.00 ..........V............I.............N.....T.............. 
  26.25 ..........V............I.............N.....T.............. 
  30.50 ..........V............I.............N.....T.............. 
 
CAP239  0.50 ..............Q...V.......................V........V...... 
  0.50 ..............Q...V...................I...VT.......V...... 
  1.25 ..............Q...V..................N....VT.......V...... 
  1.50 ..............Q...V..................N....VT.......V...... 
  5.50 ..............Q...V..................N....V........V...... 
  19.75 ..............Q...V..................N....V........V...... 
  19.75 ..............Q...V....L.............N....V........V...... 
 
CAP268  2.00 ..D..........................................I.G.......E.. 
6.00 ..D..........................................I.G.......E.. 
13.25 ..D..........................................I.G.......E.. 








CAP270  2.00 ..................V....................................... 
  3.25 ..................V....................................... 
  7.25 ..................V....................................... 
  14.50 ..................V....................................... 
 
CAP274  2.50 ..................V..................N....VQ...G...V...... 
  2.50 ..................V....................H..VQ...G...V...... 
  5.50 ..........V.......V..................N....VQ.............. 
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4.3 Discussion 
 
The B*5801 HLA allele is associated with better control of HIV-1 replication within 
chronically infected individuals (Kiepiela et.al, 2007; Goulder et al., 1997).  The 
favourable disease outcome associated with the HLA-B*5801 genotype has been 
attributed both to strong CTL responses targeting the functionally and structurally 
constrained p24 Gag protein, and to mutational escape in this region resulting in viral 
variants with reduced replicational fitness (Leslie et al., 2004; Crawford et al., 2007, 
Martinez-Picardo et al., 2006).  We were interested in determining whether this 
association was evident in early infection and to investigate viral determinants in order to 
explain possible mechanisms behind differential disease progression profiles in HLA-
B*5801 positive individuals.  We find that escape to B*5801 restricted TW10 and KAF9 
immunodominant epitopes is both rapid and frequent. While HLA-B*5801 alone is not 
predictive of control of replication in early infection, we find that targeting of the TW10 
and the T242N CTL escape mutation are associated with significantly higher CD4+ 
counts at 12 months postinfection. 
 
Escape in the immunodominant TW10 epitope located in the p24 Gag region occurred in 
four of the six HLA-B*5801 positive study participants (67%).   Escape was rapid, 
emerging as early as 2 weeks postinfection, suggesting strong selection pressures on the 
virus exerted by B*5801 CTLs.  The study described here had the advantage over most 
previous studies of monitoring infected participants very close to the time of infection, 
enabling the determination of mutational dynamics within immunodominant epitopes.  
The emergence of the T242N mutation was observed to be always preceded by another 
mutation within the epitope (Figure 4.1 and Figure 4.2).  This may suggest that; a) the 
route to escape has to occur through intermediate mutations, b) the other mutations may 
not provide a selective advantage to the virus while the T242N, being at the HLA binding 
site, provides the best escape option for the virus, or c) that the T242N mutation incurs a 
lower replicative fitness cost than the other mutations observed in the epitope.  The fact 
that all the variants detected prior to the emergence of the T242N in these viruses are 
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H244 – 0.24%; P244 – 0%; T244 – 0%; E246 – 0%; V247 – 7.26%; T248 – 10.65%; 
Q248 – 1.21%: www.hiv.lanl.gov) is consistent with the notion that they are escape 
intermediates and that, compared to the TW10 mutation, they provide inferior selective 
advantages with respect to balancing the demands of CTL escape and replicational 
fitness. 
 
In one individual (CAP268) viruses did not accumulate mutations in the TW10 epitope 
despite there being strong CTL responses targeting the epitope.  The virus infecting this 
individual, unlike the viruses infecting the four participants that developed escape 
mutations at T242, did not have any of the previously described compensatory mutations 
upstream of the epitope (Figure 4.8).  However, although mutations at one of the 
compensatory sites (I223V and I223N) emerged at 13.5 months postinfection, with the 
I223V mutation becoming fixed by 21.5 months postinfection, there were still no 
mutations detected within the TW10 epitope at 32.75 months postinfection (the last time-
point examined).  Together this data suggests that the presence of compensatory 
mutations upstream of the TW10 epitope may be facilitating early escape by reducing the 
over-all fitness defects incurred by subsequent TW10 mutations.  This is supported by the 
fact that the one individual who had immune responses targeting this epitope who did not 
escape also did not have the compensatory mutations upstream of the TW10 epitope.  As 
some of the compensatory mutations do not revert or take longer periods to revert 
following transmission to HLA-B*57/B*5801 negative individuals (Leslie et al., 2004), 
their accumulation to high frequencies in the population may slowly diminish the 
protective value of these HLA alleles.    
 
The other individual who did not show escape in the TW10 epitope (CAP270) did not 
show any detectable responses to the epitope.  This individual had a very high viral load 
and a low CD4+ count 12 months postinfection (1 680 000 RNA copies.mL
-1
 and 255 
cell.µL
-1
, respectively) and was classified as a rapid progressor.  This supports previous 
reports suggesting that control of viral replication by HLA-B*57/B*5801 positive 
individuals is primarily through immune targeting of the functionally and structurally 
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CTL escape in other HLA restricted epitopes besides TW10 and KAF9 was assessed.  
The data revealed that in four participants (CAP217, CAP229, CAP268 and CAP270), a 
total of five epitopes accumulated potential escape mutations during the follow-up period.  
One of these escape mutations was in Gag while four were in Nef. The mutations 
identified were from high frequency amino acid residues to low frequency residues, 
supporting the possibility that they were genuine CTL escape mutations.  Interestingly, 
two out of the five epitopes within which these mutations occurred were restricted by 
HLA-B*5801.  This data suggests that this allele may have a far more pervasive influence 
on HIV evolution than simply determining the population-wide frequencies of TW10 and 
KAF9 amino acid polymorphisms.    
 
HLA-B*5801 positive individuals who were infected by viruses with escape mutations in 
the TW10 epitope had higher CD4+ cell counts at 12 months postinfection but their viral 
loads were not significantly different from those of HLA-B*5801 negative individuals 
infected with viruses not carrying any B*57/B*5801 associated escape mutations.  The 
data suggests that by 12 months postinfection, the participants infected with T242N 
escape variants have better preservation of CD4+ cells but not necessarily lower viral 
loads.  This may nevertheless provide long-term advantages to infected individuals and 
may be a contributing factor to the better control of viral replication during chronic 
infection that is frequently seen in HLA-B*57/B*5801 positive individuals. 
 
These results are an example of the relationship between CTL escape in the Gag TW10 
epitope and HIV disease progression as defined by viral load. CAP270 illustrates the 
worst case scenario where TW10 CTL responses are absent resulting in high viral loads.  
Targeting the TW10 epitope without subsequent escape through introduction of T242N 
was most beneficial for the infected individual (CAP268) as viremia was controlled 
through immune clearance.  Once the virus escapes this immune response, the viral load 
increases but because of the fitness cost of the escape mutation, viremia remains fairly 
moderate.  However, a different pattern was observed when considering CD4+ counts.  
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counts at 12 months postinfection (CAP270; Figure 4.5B).  Targeting the TW10 without 
escape in the epitope was associated with moderate CD4+ counts (CAP268) while 
targeting TW10 with concomitant escape was associated with higher CD4+ counts.  
These findings point to the possibility that immune responses targeting TW10 are 
associated with better disease outcome.  Interestingly, the virus infecting the HLA-
B*5801 positive who did not show escape in the TW10 epitope carried a previously 
described HLA-B*5801 associated mutation (M250I; Martinez-Picardo et al., 2006).  
This mutation is reportedly associated with a lack of escape in TW10 (Martinez-Picardo 
et al., 2006).  It is possible that the lack of escape mutations in TW10 in the presence of 
the M250I mutation may be due to a fitness constraint on viral replication.  There may be 
other factors contributing to better viral control in the HLA-B*5801 positive participants 
which may include the contribution of other HLA alleles.  Noteworthy is the fact that two 
of the participants (CAP217 and CAP239) have the protective B*4201 allele (Kiepiela et 
al., 2004).  However, it is most likely that the observed viral control was largely due to 
the HLA-B*5801 allele as there were no other detectable immune responses in the p24 
Gag region which is associated with better disease outcome (Kiepiela et al., 2004).   
 
In an earlier study (Chapter 3; Chopera et al., 2008), it was revealed that two HLA-
B*57/B*5801 driven escape mutations (A146X and T242N) were associated with better 
control of viral replication and better preservation of CD4+ counts even in HLA-
B*57/B*5801 negative individuals.  Participants were grouped according to whether the 
infecting viruses carried or did not carry the A146X and/or T242X mutations irrespective 
of whether these variants were transmitted to HLA–B*5801 negative or arose in HLA-
B*5801 positive individuals.  The data revealed that CD4+ counts at 12 months 
postinfection were higher in participants who carried the escape mutations.  Amongst the 
individuals whose viruses carried the escape mutations, those infected with viruses 
carrying both mutations had higher CD4+ counts than those infected with viruses 
carrying either mutation alone.  This strongly suggests that a network of attenuating 
mutations, some of which are outside the regions looked at here, contribute to viral 
control observed in HLA-B*57/B*5801 positive individuals. This is an important 
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Chapter 5: Summary and Conclusions 
 
Paradoxically, avoidance of host CTL responses by HIV-1 through mutations can be both 
beneficial and disadvantageous to the host.  CTL escape can result from mutations that 
lead to alterations in antigen processing, failure of class I HLA molecules to bind HIV 
antigens, or antigens not being recognised by T cell receptors (reviewed by Sewell et al., 
2000).  In some cases, CTL escape can lead to reduced control of viral replication and 
rapid disease progression (Peyerl et al., 2004; Smith et al., 2004).  However, when the 
escape mutations result in alteration of structurally or functionally constrained regions of 
the virus proteome, they may incur replicative fitness costs that ultimately result in better 
disease outcomes (Miura et al., 2009; Schneidewind et al., 2009; Leslie et al., 2004; 
Wang et al., 2009).  HLA alleles that are associated with improved disease outcomes 
have been shown to illicit strong immune responses during the acute phase of infections 
(Altfeld et al., 2006).  These protective alleles have also been shown to drive CTL escape 
in functionally and/or structurally constrained regions of the virus proteome (Wang et al., 
2009).  Therefore, the timing and location of CTL escape mutations are important 
determinants of the course of HIV-1 disease progression.  
 
This study was aimed at the identification of CTL escape mutations in a cohort of 
recently infected women who were followed longitudinally.  Thus far, most studies have 
focused on the characterisation of acute infection in subtype B viruses.  As subtype C 
viruses account for about 50% of HIV-1 infections worldwide (Hemelaar et al., 2006) and 
are genetically distinct from subtype B viruses (Thomson et al., 2002), this study aimed 
to investigate the impact of CTL escape mutations on the pathogenesis of subtype C 
viruses.  This focus was important in that the few studies that have looked at CTL escape 
in subtype C acute infection (Crawford et al., 2009; Goepfert et al., 2007) have revealed 
that some of the observations made in subtype B infections are not necessarily 
generalisable to subtype C infections (Crawford et al., 2009; Goonetilleke et al., 2009).   
 
The frequency of escape from CTL pressures during the first 6 months of infection and 
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frequency within different infections of escape mutations arising in Gag and Nef was 
66%, suggesting that soon after infection CTLs exert considerable selection pressures on 
these immunodominant proteins.  There was, however, no detected association between 
CTL escape and disease progression.  Nevertheless, the high frequency of Nef and Gag 
escape mutations during the acute/early phase of infection suggests that T cell responses 
and, possibly, CTL escape make a substantial contribution to the control of peak viremia 
during acute infection.  A potentially key finding was that reversion mutations outnumber 
escape mutations within the Gag p24 region.  Probable reversion mutations in p24 
occurred predominantly at more evolutionarily conserved sites while probable escape 
mutations occurred at less conserved sites.  This data supports the hypothesis that the 
replicative fitness costs of many mutations in conserved genomic regions substantially 
decrease the fitness benefits of some of these mutations that would otherwise provide 
easy escape from host T cell responses (Smith, 2004). 
 
Characterisation of transmitted viruses was carried out to identify genetic markers in the 
Gag and Nef regions that were associated with either increased viral replication or better 
viral control at 12 months postinfection.  This analysis identified two polymorphic sites 
(A146 and T242 in the ISW9 and TW10 epitopes, respectively) within the Gag p24 
protein that were associated with lower viral loads and higher CD4+ counts.  These 
polymorphisms were located in well-known immunodominant epitopes restricted by 
HLA-B*57/B*5801 alleles and were detected in viruses infecting 9 of the 21 participants 
who had reached 12 months postinfection at the time of the study.  Those individuals 
carrying B*57/B*5801 alleles were excluded from this analysis as they are well-known 
controllers of viral replication and their inclusion would, therefore, have biased the 
analysis.  Identification of the HLA-B*57/B*5801 associated mutations in the HLA-
B*57/B*5801 negative individuals suggested that these study participants were infected 
with viruses that had previously been passaged through individuals carrying these alleles.  
Analysis of the viruses which carried the A146X and T242N mutations indicated that 
they carried more HLA-B*57/B*5801 associated genetic footprints as compared to those 
that did not have the mutations.  These results suggest a dependency between the rate of 
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whom the virus was acquired.  The T242N mutation was found to revert to consensus in 
5/6 individuals.  Interestingly, upon reversion of the T242N mutation, no increase in viral 
loads was observed suggesting that a network of viral attenuating mutations could be 
responsible for the better control observed in vivo.  This was supported by in vitro 
replication assays which showed that chimeric viruses carrying gag sequences from one 
of the participants actually had a lower replicative capacity following reversion of the 
T242N and A146X mutations in the presence of T242N-associated compensatory 
mutations. 
 
As is mentioned above, HLA alleles such as B*5801 have been associated with control of 
disease progression (Goulder et al., 1996; Kiepiela et al., 2004; Kiepiela et al. 2007).  
However the mechanism whereby this occurs is not fully understood.  It was of interest to 
determine firstly, whether the viral control observed in HLA-B*5801 positive individuals 
could be detected within the first year of infection and, secondly, what the mechanisms 
were behind the differential disease progression in these individuals.  This study therefore 
determined the kinetics of CTL escape in HLA-B*5801 positive individuals (n = 6) and 
then tested for an association between CTL escape and disease progression.  Escape was 
found to predominantly occur in the HLA-B*5801 restricted epitopes, TW10 (n = 4) in 
Gag and KAF9 in Nef (n = 6).  The emergence of the T242N in TW10 was always 
preceded by at least one mutation within the epitope, suggesting either that CTL escape 
via the T242N mutation predominantly occurs through intermediates, or that the T242N 
mutation provides a better selective advantage to the virus than the other mutations.  Both 
targeting of the TW10 epitope and the presence of the T242N mutation were associated 
with higher CD4+ counts at 12 months post-infection in HLA-B*5801 positive 
individuals compared to those that did not carry this allele.  Moreover, the B*57/B*5801 
associated escape mutations, A146X and T242X in Gag, were associated with higher 
CD4+ counts irrespective of an individuals’ HLA genotype (p = 0.0387).  The occurrence 
of compensatory mutations located upstream of the TW10 epitope was found to be 
associated with escape mutations arising in the TW10 epitope within the first four months 
of infection.  Conversely, it was found that an absence of T cell responses to the TW10 
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further insights into the mechanisms associated with the differential disease outcomes of 
individuals carrying the HLA-B*5801 allele.  It is, however, intriguing that in B*5801 
positive individuals, the viral load was the same as in B*5801 negative individuals.  The 
reason for this observation remains unclear although it is likely that HLA-B*5801 T cell 
responses may be associated with preservation of CD4+ T cells (Streeck et al., 2009). 
 
In conclusion, these findings suggest that CTL escape plays an important role in viral 
evolution and, more importantly, in HIV-1 pathogenesis.  The observations that escape 
mutations arising within the first six months of an infection were not obviously associated 
with accelerated disease progression, and that HLA-B*5801 driven escape mutations 
arising in the Gag p24 region were associated with improved viral control both support 
the prevailing hypothesis that replicationally deleterious escape mutations within 
functionally constrained epitopes contributes substantially to the high degrees of viral 
control observed in individuals carrying protective HLA alleles.  This underscores the 
recent findings by Wang et al., (2009), who found that during acute infection protective 
HLA alleles were associated with escape mutations arising at evolutionarily constrained 
sites.  The occurence of the A146X and T242X escape mutations irrespective of the 
presence or absence of the HLA alleles that drive their selection was associated with 
better viral control.  The implications of this from a vaccine design perspective is that 
vaccines targeting these conserved regions in such a way as to drive the accumulation of 
‘attenuating’ mutations could have an important population-scale influence on HIV 
evolution.  By globally diverting HIV evolution to reduced virulence such a vaccine 
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Appendix A: HLA data, viral loads and CD4+ counts at 12 months postinfection 
 
Appendix A1: HLA data for the 36 study participants 
 
PID HLA 
  A B C 
8 A2301 A2301 B0801 B1510 Cw0701 Cw1601 
30 A0201 A3402 B4403 B4501 Cw0401 Cw1601 
37 A2301 A2402 B0702 B5301 Cw1701 Cw1701 
40 A3001 A3002 B1510 B4201 Cw0304 Cw1701 
45 A2301 A2902 B1510 B4501 Cw0602 Cw1601 
61 A6602 A6802 B1401 B4201 Cw0802 Cw1701 
65 A2301 A6802 B1510 B5802 Cw0511 Cw0611 
69 A0301 A2301 B1503 B5802 Cw0210 Cw0602 
84 A2902 A7401 B1503 B4407 Cw0210 Cw0701 
85 A3002 A3002 B0801 B4501 Cw0701 Cw1601 
88 A2902 A6601 B4501 B5802 Cw0602 Cw0602 
129 A2601 A8001 B1801 B8101 Cw0202 Cw0401 
136 A3004 A7401 B4201 B4201 Cw1701 Cw1701 
137 A2902 A6801 B4101 B5802 Cw0602 Cw1701 
174 A0301 A7401 B4901 B5802 Cw0602 Cw0701 
177 A0301 A3002 B1510 B4501 Cw0401 Cw1601 
200 A0205 A4301 B1510 B4101 Cw0401 Cw1701 
206 A3204 A7412 B0702 B4403 Cw0210 Cw0702 
210 A6802 A6802 B1510 B1510 Cw0304 Cw0304 
217 A0202 A2901 B1503 B5801 Cw0210 Cw0602 
222 A3001 A3303 B5301 B8101 Cw0401 Cw0401 
225 A0101 A3001 B4202 B8101 Cw1801 Cw1701 
228 A2301 A2601 B4403 B5101 Cw0303 Cw0701 
229 A0101 A0101 B5801 B5801 Cw0602 Cw0602 
239 A0101 A2902 B4201 B5801 Cw0602 Cw1701 
244 A2301 A3004 B4403 B5802 Cw0401 Cw0602 
248 A0205 A2902 B1401 B1503 Cw0210 Cw0804 
255 A0301 A8001 B0801 B1807 Cw0202 Cw0702 
256 A2902 A6601 B1503 B5802 Cw0401 Cw0602 
257 A2902 A2301 B4202 B4403 Cw1701 Cw1701 
258 A2902 A2301 B4101 B4201 Cw1701 Cw1701 
262 A0101 A6602 B4201 B8101 Cw0609 Cw1701 
264 A3601 A6802 B1510 B5301 Cw0802 Cw0401 
268 A0205 A2601 B0705 B5801 Cw0701 Cw0702  
270 A0301 A3002 B0801 B5801 Cw0701 Cw0701 
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8 39,300 4.59 332 
30 204,000 5.31 573 
40 11,000 4.04 321 
45 556 2.75 1030 
61 418 2.62 412 
65 71,300 4.85 241 
69 1,230,000 6.09 202 
85 400 2.60 682 
88 38,700 4.59 499 
129 145,000 5.16 634 
136 400 2.60 695 
174 33,600 4.53 303 
177 42,100 4.62 370 
200 72,100 4.86 367 
206 315,000 5.50 337 
210 376,000 5.58 344 
217 42,500 4.63 533 
222 448 2.65 654 
225 21,500 4.33 624 
228 1,520 3.18 642 
229 22,500 4.35 680 
239 156,000 5.19 793 
244 14,500 4.16 303 
248 64,600 4.81 313 
255 18,200 4.26 397 
257 10,000 4.00 470 
258 108,000 5.03 228 
262 3,560 3.55 432 
264 25,300 4.40 410 
268 12,400 4.09 474 
270 1,680,000 6.23 255 
274 373,000 5.57 452 
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Appendix B: Standard DNA and RNA Techniques 
 
B1. Extraction of viral RNA 
 
RNA was extracted both manually or using the automated method.  For automatic extraction 
using 200µL of plasma, the Magna Pure Compact machine was used (Roche, Mannheim, 
Germany).  RNA was extracted manually extracted using the QIAamp® Viral RNA Mini Kit 
for the purification of viral RNA from plasma (Qiagen, Valencia, CA).  A 140-280µL sample 
aliquot was added to 560µl prepared Buffer AVL containing carrier RNA in a 1.5mL micro-
centrifuge tube, mixed by pulse-vortexing for 15 seconds, incubated at room temperature (15 
-25°C) for 10- minutes and briefly centrifuged to remove drops from the inside of the lid. 
Ethanol (560µL;96-100%) was added and mixed by pulse vortexing for 15 seconds, and 
briefly centrifuged to remove drops form the inside of the lid and the solution was carefully 
applied to the QIAmp spin columns and centrifuged at 6000x g (8 000rpm) for 1 minute.  The 
column was placed in a clean 2mL collection tube and the tube containing the filtrate was 
discarded. Next 500 µL Buffer AW1 was added and centrifuged at 6000x g (8 000rpm) for 1 
minute, the column placed in a clean collection tube and the tube containing the filtrate was 
discarded. Next 500µl Buffer AW2 was added and centrifuged at 20 000x g (14 000rpm) for 
3 minutes and the tube containing the filtrate was discarded. The column was then placed in a 
clean 2mL collection tube and centrifuged for an additional 1 minute at full speed. The 
sample was then eluted after a one minute incubation step with 60µL AVE buffer, aliquoted 
to 10µL l-20µL and either used directly in the cDNA synthesis or stored at –80°C. 
 
B2. PCR Purification 
PCR products were purified by the QIAquick Spin Kit (Qiagen, Valencia, CA) according to 
the manufacturer’s instructions. Briefly PB buffer (5x volume of PCR product) was mixed 
with the PCR product and loaded on the spin column and centrifuged for a minute at 
13000rpm. PE buffer (750µL) was used to wash by centrifugation at 13000rpm for one 
minute. Clean PCR product was eluted by centrifugation at 13000rpm using buffer EB 
(50µL). 
 
B3. Transformation  
 
Preparation of competent cells 
Both commercial available competent cells (cells supplied with the kits) and E. coli 
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Miller, 1988) were used for transformation.  A 5mL volume of 2YT broth was inoculated 
and incubated overnight at 37°C on a shaker. A dilution of 1/100 was made from the 
culture into 100mL 2YT broth in a litre culture flask and grown on the shaker to early log 
phase (OD600 0.2 to 0.4). The cells were then harvested by centrifugation at 5000 rpm for 
5 min at 4°C in a Beckman J2-21 centrifuge.  The pellet was resuspended in ice cold TSB 
buffer (Appendix C) and placed on ice for 10 min.  Sterile glycerol was added to a final 




Frozen cells were defrosted on ice and the 3µL ligation mix was then mixed with the cells 
and left on ice between 10 to 20 min. The cells were heat shocked at 42 °C for 0.5 min. One 
milliliter of 2YT medium was added and the cells were incubated for 30 to 45 min at 37°C. A 
volume of 50µL to 100µL was plated on selective plates containing either ampicillin or 
kanamycin (Appendix B). Blue/White screening was done with pGEM®-T Easy vector by 
the addition of Xgal (5-bromo-4-chloro-3-indolyl-β-D-galactosidase) and IPTG (isopropyl-β-
D-thio-galactopyranoside) to plates. The plates were then incubate at 37°C and single 
colonies were either inoculated into 2 mL 2YT broth for minipreparations or for colony PCR 
screening.   
 
B4. Colony Screening 
 
Following transformation colonies were screened by colony PCR as described by (Lee and 
Cooper, 1995). The colonies were picked using a plastic pipette tip, replicated on another 
plate for future reference and inserted into a 25µL to 50µL PCR master mix as described in 
chapter 2 (2.3.6). The PCR conditions and master mixes were prepared the same way as in 
second round PCRs and 5µL of the PCR product was run on a gel to confirm the presence of 
the insert. Posive PCR fragments were cleaned up for sequencing. 
 
B5. Agarose gel electrophoresis 
 
Fragments were visualized in 2% agarose gels. Agarose gel electrophoresis was performed 
using horizontal gel apparatus (Stratagene, La Jolla, USA).  The agarose gel was prepared by 
melting the appropriate weight per volume agarose (Agarose Di LE, Hispanagar, Burgos, 
Spain) in 1X TBE (Appendix C1).  Once melted 10mg/mL ethidium bromide stock solution 
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setting trays and cooled down to room temperature to allow setting and then placed in a gel 
apparatus submerged in 1X TBE.  Before loading, 1-5µl PCR product was mixed with 2µl of 
6X agarose gel electrophoresis loading dye.  In order to determine the size of the amplicons a 
DNA molecular weight marker VI (Roche, GmbH, Mannheim, Germany) was included in the 
first lane of all gels.  The gel was electrophoresed at 100 to 120V according to gel size for 60 
minutes or until sufficient separation of bands.  The DNA fragments were then visualized on 
a UVP transilluminator (UVP, San Gabriel, California, USA) at 256nm wavelength and 
photographed with a Kodak ds 1D, Electrophoresis Documentation and Analysis System 120, 
V 2.0.3. computerized gel imager (Kodak ds 1D digital science, version 2.03).   
 
Appendix C: Standard Buffers and Solutions 
 
C1. 10X TBE (Tris-Boric acid EDTA) buffer:  
108g Tris-HCl, 55g Boric acid 20mL 1,5M EDTA, made up to one litre with dH2O. 
C2. 6X Agarose Gel Electrophoresis Loading Dye: 
0,25% bromophenol blue, 0,25% xylene cyanol FF 30% glycerol (In deionised water) 
C3. X-Gal, IPTG, Ampicillin LB agar plates: 
Per litre: 10g tryptone, 5g yeast extract, 10g NaCl, 15g agar after agar has been 
sterilised by autoclavation and allowed to cool down to ~ 50°C the following 
selective regents were added: 15µg/mL tetracycline, 100µg/mL ampicillin, 80µg/mL 
X-gal, 0,5mM IPTG. 
C4. LB Broth: 
10g NaCl, 5g Yeast extract, 10g Tryptone, up to 1lµL with deionised water 
C5. TSB: 
1.6g peptone, 1.0g yeast extract, 0.5g NaCl, 10g polyethylene glycol (PEG) 3350-
4000, 5mL DMSO, 1mL 1MgCl2, 1mL 1M Mg SO4 plus water to 100mL. Store in 
10mL aliquots. 
C6. 2YT (yeast-tryptone) liquid medium (pH7.0): 
 16g tryptone, 10g yeast extract, 5g NaCl 
C7. 2YT plates: 
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C8. Antibiotic and Xgal/IPTG selection: 
Ampicillin (Sigma, MO, USA) 100µg/mL was added to liquid media and plates, 
kanamycin (Km; Nova Nordisk, Johannesburg, R.S.A) at a concentration of 15 
µg/mL. Xgal (Biosolve, Netharlands) 20 mg/mL stock of 0.4g dissolved in 5mL 
DMSO and made up to 10mL and IPTG (Roche, Germany) 200mg/mL stock were 
both added to plates at a final concentration of 0.1 mg/mL. 
C9. 1X Electrophoresis Buffer  
(Dilute from 10X TBE Gel Electrophoresis Buffer above) 
Dilute 1/10 to a final concentration of 89 mM Tris-borate, pH 8.0, 89 mM Boric 
Acid 2 mM EDTA in deionised water. 108g Tris-HCl, 55g Boric acid 20mL 1,5M 
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Appendix D: CTL escape in Gag and Nef 
 
Appendix D1: Detailed CTL escape summary for Gag in the first 6 months postinfection.  The 
sequence at the top represents the subtype C consensus sequence.  The frequency of the escaping 
site with respect to the HIV subtype C database is also shown. 
PID Mo. PI Epitope Restricting HLA Frequency 
     
  KHY mL KHLVWA A*2301 M - 80.15% 
8 0.5 .Q.........   
 0.75 .Q.........   
 1.5 .Q.........   
 2.5 .Q.........   
 3.25 .Q.K.......  K - 5.08% 
  6.25 .Q.K.......     
     
  IRLRPGGKKHYM B*4201 M - 80.15% 
40 1.0 ............   
 3.0 ...........R   
 5.5 ...........R  R - 11.38% 
     
  IRLRPGGKKHYM B*4201 T - 3.39% 
61 2.0 .S.......T..   
 2.75 .S.......T..   
  6.25 .S.......K..  K - 5.08% 
     
  DYVDRFFKTLR B*1503 R - 100% 
69 1.25 ...........   
 2.5 ...........   
  6.0 ....W......   W - 0% 
     
  ISPRTLNAWVKVI B*8101 I - 70.94% 
129 4 .............   
 11 .............   
  23 M............   M - 0.97% 





 K - 35.11% 
174 1.0 ......K..D....   
 2.25 ......K..D....   
 3.25 ......K..D....   
  6.0 ......KR.D....  R - 16.46% 
     
  TTSTLQEQIAWM B*5801 T - 84.75%; Q - 98.06%; Q - 100% 
217 2.25 ............   
 3.0 ............   
 3.75 ............   
 3.75 .....P......  P - 0% 
 3.75 .......E....  E - 0% 
 4.25 ............   
 4.25 ...N........  N - 10.41% 
 4.25 .....P......   
 4.75 ...N........   
 5.75 ...N........   
 5.75 .....T......  T - 0% 
 5.75 ............   
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  TTSTLQEQIAWM B*5801 T - 84.75%; A - 82.57% 
229 1.75 ............   
 2.0 ............   
 2.0 .........T..  T - 10.65% 
 2.0 ...N.....T..  N - 10.41% 
 2.25 ...N.....T..   
 5.25 ...N.....T..   
  6.25 ...N.....T..     
     
  TTSTLQEQIAWM B*5801 T - 84.75%; L - 98.79; A - 82.57% 
239 0.5 ........V...   
 0.5 ....I...VT..  I - 0% ; T - 10.65% 
 1.25 ...N....VT..  N - 10.41% 
 1.5 ...N....VT..   
 2.75 ...N....V...   
 5.5 ...N....V...   
     
  KHYMLKHLVWA A*2301 L - 69.01% 
244 2.0 .R.RI......   
 3.0 RR.RI......   
  7.0 .R..I..I...   I - 30.27% 
     
  QIIKQLQPALQ A*2902 K - 53.75%; L - 97.34% 
248 2.25 ..M...K...H   
 3.0 ..ME.IK...H  E - 2.18%; I - 1.94% 
  5.5 ..ME.IK...H     
     
     
  TTSTLQEQIAWM B*5801  
274 10 .....H..VQ..  (T - 84.75%; H - 0.24%) 
 10 ...N....VQ..  (N - 10.41%) 
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Appendix D2: Detailed CTL escape summary for Nef in the first 6 months postinfection. The 
sequence at the top represents the subtype C consensus sequence.  The frequency of the escaping 
site with respect to the HIV subtype C database is also shown. 
PID Mo. PI Epitope Restricting HLA Frequency 
     
  FFLKEKGGLEG B*0801 E - 61.77% 
8 0.5 ...........   
 0.75 ...........   
 1.5 ...........   
 2.5 .........D.  D - 37.71% 
 3.25 .........D.   
 6.25 .........D.   
     
  IYSKKRQEILDLWVYH Cw*0701 Y - 71.33%; K - 83.45%; 82.94% 
 0.5 ................   
 0.75 ................   
 1.5 ................   
 2.5 ................   
 3.25 .H.Q............  H - 11.6%; Q - 8.36% 
 6.25 .H.Q............   
     
  EEEVGFPVRPQVP B*4501 E - 68.6% 
30 1.25 G.D.....K....   
 2.75 GD......K....  D - 6.83% 
  7.25 GD...........     
     
  VLKWKFDSHLA Cw*0601 W - 99.83% 
45 0.5 ........S..   
 1.25 ........S..   
  3 ...R....S..   R – 0%) 
     
   ATNNADCAWLEA B*1401/Cw*0802 A - 90.1% 
61 2 .ST...M....G   
 2.75 .ST...V....G   
 8.25 .ST.T.V....G  T - 0.51% 
     
  EEEVGFPVRPQVP B*4501 K - 0.34% 
88 1.25 .K...........   
 3.25 .K...........   
  6.5 .D...........   D - 6.83% 
     
  KKRQEILDLWVYH B*1801 E - 59.56% 
129 1.25 ...........H.   
 1.25 .............   
 2.75 .............   
  5.75 ....D........   D - 39.93% 
     
  KKRQEILDLWVYH Cw*0701 K - 82.94%; Y - 98.29% 
174 0.5 ...RD.......N   
 1 .E.RD.......N  E - 0.17% 
 2.25 ...RD.......N   
 2.75 ...RD.......N   
 3.25 ...RD......HN  H - 1.37% 
 4.25 ...RD......HN   
  6 .N.RD......HN   N - 0.51% 
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  YKAAFDLSFFL B*5801 A - 47.61%; F - 84.64% 
217 2.25 ...........   
 2.25 ....V......  V - 10.75% 
 2.25 ------.....   
 2.25 ..E........  E - 1.88% 
 5.75 ...........   
 5.75 ..E........   
  5.75 ..G........   G - 46.76% 
     
  IYSKKRQEILD Cw*0602/B*1503 K - 83.45%; R - 98.98% 
 2.25 .H.........   
 2.25 --.........   
 5.75 .H.........   
 5.75 .H.Q.......  Q - 8.36% 
 5.75 .H.Q.G.....  G - 0.68% 
     
  NYTPGPGVRYP B*5801 V - 83.96% 
 2.25 ...........   
 5.75 ...........   
  5.75 .......I...   I - 8.02% 
     
  YKAAFDLSFFL B*5801 K - 97.95%; A - 47.61% 
229 1.75 ...........   
 3.00 ...........   
 6.25 ...........   
  6.25 .R.........   R - 0.51% 
     
  YKAAFDLSFFL B*5801 A - 47.61%; V - 10.75% 
239 0.5 ....V......   
 1.25 ....V......   
 2.75 ....V......   
 5.5 ..G.V......  G - 46.76% 
  5.5 ...........   F - 84.64% 
     
  KKRQEILDLWVYH B*4403 E - 59.56% 
244 2 .............   
 3 ....D........  D - 39.93% 
  7 ....D........     
     
  KKRQEILDLWVYH B*1801 Q - 95.9%; E - 59.56%; H - 1.37% 
255 2 ...........HN   
 3.25 ...R........N  R - 0.34%; Y - 98.29% 
  5.75 ...RD.......N   D - 39.93% 
     
  KKRQEILDLWVYH B*4403 E - 59.56% 
257 1.75 ............N   
 3.5 ............N   
 7.5 ....D.......N  D - 39.93% 
     
258  VRYPLTFGWCFK A*2301 F - 97.27% 
 1.75 T...........   
 3.75 T...........   
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  VRPQVPLRPMT B*8101 R - 87.88% 
262 1.75 ...........   
 3 ...........   
 4 .K.........  K - 8.53% 
  6.5 .K.........     
     
268  GFPVRPQVPLR B*0705 R - 87.88% 
 2 ...........   
 3.75 ...........   
  6 ....K......   K - 8.53% 
     
  GWPAVRERIR B*0801 N - 5.8%; R - 97.1%; R - 93.17% 
270 2 ...N....M.   
 7.25 ...N....M.   
 7.25 ...D....M.  D - 7.51% 
 7.25 ...N...GM.  G - 0.17% 
 7.25 ...D.G..M.  G - 0.85% 
     
  YKAAFDLSFFL B*5801 S - 76.28% 
 2 F..........   
 7.25 F..........   
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Appendix E: Epitopes in p24 Gag  
 
Appendix E1: Epitope map of p24 Gag showing all known epitopes in the region with respect to 
subtype C consensus p24.  Highlighted in grey are the sites where deviation from consensus was 
detected at the earliest sequenced timepoints in the 32 individuals who were infected with viruses 
whose sequences clustered together.  The numbering at the top denotes the amino acid position with 
respect to the HXB2 reference sequence (www.hiv.lanl.gov). 
 
                135       140       150       160       170       180       190            
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CONSENSUS_C  --PIVQNLQGQMVHQAISPRTLNAWVKVIEEKAFSPEVIPMFTALSEGATPQDLNTMLNTVGGHQAAMQM  
1            NYPIVQNL                                                                
1            ----VQNLQGQMV                                                           
1            ---------GQMVHQAISP                                                     
1            ---------GQMVHQAISPRTL                                                  
1            ---------GQMVHQAISPRTLN                                                 
1            ----------QMVHQAISPR                                                    
1            ------------VHQAISPRTL                                                  
1            --------------QAISPRTL                                                  
1            --------------QAISPRTLNAW                                               
1            --------------QAISPRTLNAV                                               
1            ---------------AISPRTLNAW                                               
1            ----------------ISPRTLNAW                                               
1            ----------------LSPRTLNAW                                               
1            -------------------RTLNAWVKV                                            
1            --------------------TLNAWVKVI                                           
1            -------------------------VKVIEEKAF                                      
1            ----------------------------IEEKAFSPEV                                  
1            ----------------------------IEEKAFSPEVI                                 
1            -----------------------------EEKAFSPEV                                  
1            ------------------------------EKAFSPEV                                  
1            -------------------------------KAFSPEVIPMF                              
1            ----------------------------------SPEVIPMF                              
1            ------------------------------------EVIPMFTAL                           
1            -------------------------------------VIPMFTAL                           
1            --------------------------------------------LSEGATPQDL                  
1            ---------------------------------------------SEGATPQDL                  
1            ------------------------------------------------ATPQDLNTM               
1            ------------------------------------------------ATPQDLNMML              
1            ------------------------------------------------ATPQDLNTMLNT            
1            -------------------------------------------------TPQDLNTM               
1            -------------------------------------------------TPQDLNTML              
1            -------------------------------------------------TPQDLNMMLN             
1            -------------------------------------------------TPQDLNQMLNTV           
1            --------------------------------------------------PQDLNTMLN             
1            ----------------------------------------------------DLNMMLNIV           
1            ----------------------------------------------------DLNTMLNTV           
1            ----------------------------------------------------DLNTMLNTVG          
1            --------------------------------------------------------------GHQAAMQM  
1            --------------------------------------------------------------GHQAAMQM  
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                200       210       220       230       240       250       260 
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CONSENSUS_C  LKDTINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIAWMTSNPPIPVGDIYKRWIILGL  
             L                                                                       
1            LKD                                                                     
1            LK                                                                      
1            -KDTINEEAA                                                              
1            --DTINEEAAEW                                                            
1            ------EEAAEWDRL                                                         
1            ---------AEWDRLHPV                                                      
1            --------------LHPVHAGPIA                                                
1            ---------------HPVHAGPI                                                 
1            ---------------HPVHAGPIA                                                
1            --------------------GPIAPGQM                                            
1            -------------------------GQMREPRGSDI                                    
1            ---------------------------------------TSTLQEQIAW                       
1            ----------------------------------------STLQEQIGW                       
1            ----------------------------------------STLQEQIGWM                      
1            ------------------------------------------------WMTSNPPIPV              
1            -------------------------------------------------MTSNPPIPV              
1            -----------------------------------------------------PPIPVGDIY          
1            ----------------------------------------------------------GDIYKRWIIL    
1            -----------------------------------------------------------DIYKRWIIL    
1            --------------------------------------------------------------KRWIILGL  
1            -----------------------------------------------------------------IILGL  
1            -----------------------------------------------------------------IILGL  
1            ------------------------------------------------------------------ILGL  
1            ------------------------------------------------------------------ILGL  
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                270       280       290       300       310       320       330       
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CONSENSUS_C  NKIVRMYSPVSILDIKQGPKEPFRDYVDRFFKTLRAEQATQDVKNWMTDTLLVQNANPDCKTILRALGPG  
1            NK                                                                      
1            NKIV                                                                    
1            NKIVR                                                                   
1            NKIV                                                                    
1            NKIVRMY                                                                 
1            NKIVRMY                                                                 
1            ----------SILDIRQGPK                                                    
1            -------------DIRQGPKEPFR                                                
1            --------------------EPFRDYVDRF                                          
1            --------------------EPFRDYVDRFF                                         
1            ---------------------PFRDYVDRFF                                         
1            ----------------------FRDYVDRFF                                         
1            ----------------------FRDYVDRFFK                                        
1            ----------------------FRDYVDRFFKTLRA                                    
1            -----------------------RDYVDRFFKTL                                      
1            ------------------------DYVDRFFKT                                       
1            ------------------------DYVDRFFKTL                                      
1            -------------------------YVDRFFKTL                                      
1            ---------------------------DRFFKTLRA                                    
1            --------------------------------TLRAEQATQD                              
1            ----------------------------------RAEQATQDV                             
1            ----------------------------------RAEQATQDVK                            
1            -----------------------------------AEQATQDVKNW                          
1            -----------------------------------AEQATQDVKNWM                         
1            -------------------------------------QATQDVKNW                          
1            ------------------------------------------VKNWMTDTLL                    
1            ------------------------------------------VKNWMTDTLLV                   
1            ---------------------------------------------------LVQNANPDCK           
1            ----------------------------------------------------VQNANPDCK           
1            ------------------------------------------------------NANPDCKTI         
1            ------------------------------------------------------NANPDCKTI         
1            -------------------------------------------------------ANPDCKTIL        
1            --------------------------------------------------------NPDCKTIL        
1            --------------------------------------------------------NPDCKTILRAL     
1            ----------------------------------------------------------DCKTILRAL     
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                340       350  
             ....|....|....|....|.... 
CONSENSUS_C  ATLEEMMTACQGVGGPSHKARVL   
1            ATLEEM                    
1            ATLEEMMTA                 
1            ----EMMTACQGV             
1            --------ACQGVGGPSHK       
1            ------------VGGPSHKARVL   
1            --------------GPSHKARVL   
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Appendix E2: List of known epitopes in p24 Gag (www.hiv.lanl.gov) where variation was detected 
in the earliest sampled viruses. In red font are the amino acid residues where deviation from 
consensus was detected in the baseline virus (earliest sequenced sample). 
 
Epitope Restricting HLA 
NYPIVQNL A*2402 
VQNLQGQMV B13 
GQMVHQAISP B*5802, B57 
GQMVHQAISPRTL Cw3 
GQMVHQAISPRTLN A03, A32, B08, B62, Cw3 
QMVHQAISPR A3 supertype 
VHQAISPRTL B*1510 
QAISPRTL Cw3 
QAISPRTLNAW A*2501, A25 
QAISPRTLNAV A25 
AISPRTLNAW B57, B63 
ISPRTLNAW 
 
A*310102, A*6603, B*440302, B*5701, B*5703, B*58, B*5801, 
B57, B58, B63, Cw*040101, Cw*0602, Cw*07 
LSPRTLNAW B*5703, B*5801, B57, B58 
RTLNAWVKV A2 








A*310102, A*6603, B*440302, B*5701, B*5703, B*5801, B57, B58, 
B63, B8, Cw*040101, Cw*07 
SPEVIPMF B35 
EVIPMFSAL A*2601, A*2603, A26 
VIPMFSAL Cw*0102, Cw1, Cw2 
LSEGATPQDL B*4403, B42, B44 







B*0702, B*3910, B*4201, B*5301, B*8101, B07, B39, B42, B53, 
B7, B81, Cw*0802, Cw8 
TPQDLNMML B*4202, B*5301, B53 
TPQDLNQML B53, B81 
TPQDLNTMLN B14, B7 
TPQDLNQMLNTV B58 
PQDLNTMLN B14, Cw8 
DLNMMLNIV B14 
DLNTMLNTV B*1402, B14, Cw8 
DLNTMLNTVG A2, B14 
GHQAAMQML B*1510, B*3901, B38, B39 
GHQAAMQMLKE A2 
HQAAMQMLK A11, B52 
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DTINEEAAEW A*25, A*2501, A25, B*5301, B53, B58, B*5801 
EEAAEWDRV B40 
AEWDRLHPV A2, B*04, B*4006, Cw*0602, B*4002, B40 
VHPVHAGPIA B55 
HPVHAGPI B35 





A*310102, A*6603, B*440302, B*5701, B*5703, B*58, B*5801, 




PPIPVGDIY B*3501, B*3502, B35, B53, B7 supertype 
GDIYKRWIIL B*0801 
DIYKRWIIL A*2402, A2, A24 
KRWIILGLNK A2, B*2705, B27, B2705, B35, B57 
IILGLNKIV A2 
IILGLNKIVR A11, A3, A33 
ILGLNKIV A*0201, A2, A3, B27 




EPFRDYVDRF A*0201, H-2<sup>d</sup>, H-2L<sup>d</sup> 
EPFRDYVDRFF B81 
FRDYVDRFF Cw*1801, Cw18 
FRDYVDRFFK B*1801, B18, B27 





A*0207, A2, B70, A*2601, A26, B*1503, B*1510, B15, B70, 
Cw*0303, Cw*0304 
DRFFKTLRA B*1401, B*1402, B*1403, B14 
TLRAEQATQD Cw*0304 
RAEQATQDV Cw*0802, Cw08, Cw8 
AEQATQDVKNW B*4402, B44 
AEQATQDVKNWM Cw5 
QATQDVKNW B*5301, B*5701, B*5801, B53, B57, B58, Cw04, Cw4 
VKNWMTDTLL B8 
VKNWMTDTLLV B*27 motif 
LVQNSNPDCK A11 
NANPDCKTI B*5101, B51, B8 
ANPDCKTIL B7 
NPDCKTIL B*0801, B35 
NPDCKTILRAL B*3910 
DCKTILRAL B*0801, B8 
GPGATLEEM B*0702, B*5801, B*8101 
ATLEEMMTA A*0206, A2 
EMMTACQGV A*0201, A2 
ACQGVGGPSHK A*11, A*1101, A*1103, A11 
VGGPSHKARVL B7 
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Appendix F: Restriction maps of the modified pBR246-F10 (subtype C) and NL4-3 
(subtype C) backbones 
 
Appendix F1:  Restriction map of the modified pBR246-F10 backbone. The BssHII and XhoI sites 
were introduced at gag codons 2 and 3 and ~60 nucleotides after the gag stop codon, respectively, 
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Appendix F2: Restriction map of the modified NL4-3 backbone. The BssHII was already present in 
the NL4-3 5΄ LTR (~80 nucleotides upstream of the gag start codon). The XhoI site was introduced at 
~60 nucleotides after the gag stop codon using site directed mutagenesis.  The XhoI site which was 
present in the unmodified backbone (light blue highlighting) was deleted using site-directed 
mutagenesis. 
 
 
 
 
NL4-3
14824 bp
XhoI
BssHII
XhoI
SbfI
BamHI
NcoI
Gag
BamHI
Eco RI
Nco I
Pst I
Pst I
Pst I
Pst I
Ava I
Ava I
Ava I
Ava I
Ava I
HindIII
HindIII
HindIII
HindIII
HindIII
ApaLI
ApaLI
ApaLI
ApaLI
ApaLI
ApaLI
ApaLI
Un
ive
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ty 
of 
Ca
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